

EP 2 575 835
THE UNIVERSITY OF TOKYO

197 780 m10
December 2018

Auxiliary Request ~~10~~ 2

1. A composition for use in a method of treating or preventing a disease selected from infectious disease or allergic disease in an individual by inducing proliferation or accumulation of transcription factor Foxp3-positive regulatory T cells, the composition comprising, as an active ingredient, bacteria belonging to the genus Clostridium comprising spore-forming bacteria belonging to Clostridium clusters IV and XIVa in combination, which combination induces said proliferation or accumulation of transcription factor Foxp3-positive regulatory T cells in said individual.
2. The composition for use according to any one of the preceding claims wherein the bacteria belonging to Clostridium clusters IV and XIVa in combination comprise multiple strains of bacteria belonging to Clostridium cluster XIVa or cluster IV in combination as an active ingredient.
3. The composition for use according to any one of the preceding claims, wherein the composition further comprises, as an active ingredient, one or more strains of bacteria belonging to the genus Clostridium belonging to a Clostridium cluster other than Clostridium cluster XIVa or cluster IV.
4. The composition for use according to any one of the preceding claims, wherein the composition is a pharmaceutical composition.
5. The composition for use according to claim 1 wherein said composition is used in combination with an additional therapeutic composition selected from: corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-IgE antibodies, and combinations thereof.
6. The composition for use according to any one of the preceding claims wherein said bacteria belonging to Clostridium clusters IV and XIVa are in the form of spores.

7. The composition for use according to any one of the preceding claims wherein said bacteria are obtained from a spore-forming fraction of a fecal sample obtained from a human.

8. The composition for use according to claim 7 wherein said spore-forming fraction is a chloroform-resistant fraction of said fecal sample.

Description

[Technical Field]

~~[0001] Described herein is a composition which has an effect of inducing proliferation or accumulation of regulatory T cells, and which comprises, as an active ingredient, bacteria belonging to the genus Clostridium, a physiologically active substance derived from the bacteria, bacterial spores, or the like. The present invention relates to compositions for use in a method of treating or preventing a disease selected from infectious disease, autoimmune disease or allergic disease in an individual, the composition comprising, as an active ingredient, bacteria comprising spore-forming bacteria belonging to Clostridium clusters IV and XIVa in combination, which combination induces proliferation or accumulation of transcription factor Foxp3-positive regulatory T cells in said individual.~~

[Background Art]

[0002] Hundreds of species of commensal microorganisms are harbored in gastrointestinal tracts of mammals, and intimately interact with the host immune systems. Results of researches using germ-free (GF) animals have shown that the commensal microorganisms exert great influences on the development of mucosal immune systems such as histogenesis of Peyer's patches (PPs) and isolated lymphoid follicles (ILFs), secretion of antimicrobial peptides from epithelium, and accumulation of unique lymphocytes in mucosal tissues, the unique lymphocytes including immunoglobulin A-producing plasma cells, intraepithelial lymphocytes, IL-17-producing CD4-positive T cells (Th 17), and IL-22-producing NK-like cells (Non-Patent Documents 1 to 7). Consequently, the presence of intestinal bacteria enhances protective functions of the mucous membranes, providing the hosts with robust immune responses against pathogenic microbes invading the bodies. On the other hand, the mucosal immune systems maintain unresponsiveness to dietary antigens and harmless microbes (Non-Patent Document 3). For this reason, abnormality in the regulation of cross-talk between commensal bacteria and an immune system (intestinal dysbiosis) may lead to overly robust immune response to environmental antigens, so that inflammatory bowel disease (IBD) is caused (Non-Patent Documents 8 to 10).

[0003] Results of Recent studies have shown that individual commensal bacteria control differentiation of their specific immune cells in the mucosal immune system. For example, Bacteroides fragilis, which is a commensal bacterium in humans, specifically induces a systemic Th1 cell response and a mucosal IL-10-producing T cell response in mice, and plays a role in protecting the host from colitis, which would otherwise be caused by a pathogen (Non-Patent Document 3). Segmented filamentous bacteria, which are intestinal commensal bacteria in mice, are shown to induce mucosal Th17 cell response and thereby to enhance resistance against infection of gastrointestinal tracts of the host with a pathogen (Non-Patent Documents 11 to 13). In addition, short-chain fatty acids derived from several commensal bacteria are known to suppress intestinal inflammation (Non-Patent Document 14). Moreover, it is presumed that the presence of some species of intestinal microbiota exerts a great influence on the differentiation of regulatory T cells (hereafter referred to as "Treg cells") which maintain homeostasis of the immune system.

[0004] Meanwhile, regulatory T cells which have been identified as a subset suppressing immunity are CD4⁺ T cells in which a transcription factor Foxp3 is expressed, and are known to play an important role in maintaining immunological homeostasis (Non-Patent Documents 8, 9, 15, and 16). Moreover, it has been known that the Foxp3-expressing cells are present in a large number especially in the colon, and only Treg cells present locally in the colon constantly expresses IL-10, which is an immunosuppressive cytokine, at a high level (Non-Patent Document 17). It is also known that animals having CD4⁺ Foxp3⁺ cells from which IL-10 is specifically removed develop inflammatory bowel disease (Non-Patent Document 18).

[0005] Accordingly, if the mechanism of the induction of Treg cells which produce IL-10 in the colon at a high level is elucidated, immunosuppression can be enhanced, which in turn can be applied to treatment of autoimmune diseases such as inflammatory bowel disease, as well as to organ transplantation.

[0006] However, mechanisms of how a large number of Treg cells come to be present in the colon and how the Treg cells produce IL-10 in the colon at a high level are still unclear. Moreover, it is also still unclear what species of bacteria constituting the intestinal commensal bacterial flora exerts the influence on the induction of regulatory T cells.

[Citation List]

[Non Patent Literature]

[0007]

[NPL 1] J. J. Cebra, "Am J Clin Nutr", May, 1999, 69, 1046S

[NPL 2] A. J. Macpherson, N. L. Harris, "Nat Rev Immunol", June 2004, 4, 478

Amended paragraph [0001]

20.2.2019

J. Cebra
OGIE, JAMES

EP 2 575 835 B1

Description

[Technical Field]

by inducing proliferation or accumulation of transcription factor Foxp3-positive regulatory T cells

5 [0001] Described herein is a composition which has an effect of inducing proliferation or accumulation of regulatory T cells, and which comprises, as an active ingredient, bacteria belonging to the genus Clostridium, a physiologically active substance derived from the bacteria, bacterial spores, or the like. The present invention relates to compositions for use in a method of treating or preventing a disease selected from infectious disease, autoimmune disease, or allergic disease in an individual, the composition comprising, as an active ingredient, bacteria comprising spore-forming bacteria belonging to Clostridium clusters IV and XIVa in combination, which combination induces proliferation or accumulation of transcription factor Foxp3-positive regulatory T cells in said individual.

[Background Art]

15 [0002] Hundreds of species of commensal microorganisms are harbored in gastrointestinal tracts of mammals, and intimately interact with the host immune systems. Results of researches using germ-free (GF) animals have shown that the commensal microorganisms exert great influences on the development of mucosal immune systems such as histogenesis of Peyer's patches (PPs) and isolated lymphoid follicles (ILFs), secretion of antimicrobial peptides from epithelium, and accumulation of unique lymphocytes in mucosal tissues, the unique lymphocytes including immunoglobulin A-producing plasma cells, intraepithelial lymphocytes, IL-17-producing CD4-positive T cells (Th 17), and IL-22-producing NK-like cells (Non-Patent Documents 1 to 7). Consequently, the presence of intestinal bacteria enhances protective functions of the mucous membranes, providing the hosts with robust immune responses against pathogenic microbes invading the bodies. On the other hand, the mucosal immune systems maintain unresponsiveness to dietary antigens and harmless microbes (Non-Patent Document 3). For this reason, abnormality in the regulation of cross-talk between commensal bacteria and an immune system (intestinal dysbiosis) may lead to overly robust immune response to environmental antigens, so that inflammatory bowel disease (IBD) is caused (Non-Patent Documents 8 to 10).

20 [0003] Results of Recent studies have shown that individual commensal bacteria control differentiation of their specific immune cells in the mucosal immune system. For example, Bacteroides fragilis, which is a commensal bacterium in humans, specifically induces a systemic Th1 cell response and a mucosal IL-10-producing T cell response in mice, and plays a role in protecting the host from colitis, which would otherwise be caused by a pathogen (Non-Patent Document 3). Segmented filamentous bacteria, which are intestinal commensal bacteria in mice, are shown to induce mucosal Th17 cell response and thereby to enhance resistance against infection of gastrointestinal tracts of the host with a pathogen (Non-Patent Documents 11 to 13). In addition, short-chain fatty acids derived from several commensal bacteria are known to suppress intestinal inflammation (Non-Patent Document 14). Moreover, it is presumed that the presence of some species of intestinal microbiota exerts a great influence on the differentiation of regulatory T cells (hereafter referred to as "Treg cells") which maintain homeostasis of the immune system.

25 [0004] Meanwhile, regulatory T cells which have been identified as a subset suppressing immunity are CD4⁺ T cells in which a transcription factor Foxp3 is expressed, and are known to play an important role in maintaining immunological homeostasis (Non-Patent Documents 8, 9, 15, and 16). Moreover, it has been known that the Foxp3-expressing cells are present in a large number especially in the colon, and only Treg cells present locally in the colon constantly expresses IL-10, which is an immunosuppressive cytokine, at a high level (Non-Patent Document 17). It is also known that animals having CD4⁺ Foxp3⁺ cells from which IL-10 is specifically removed develop inflammatory bowel disease (Non-Patent Document 18).

30 [0005] Accordingly, if the mechanism of the induction of Treg cells which produce IL-10 in the colon at a high level is elucidated, immunosuppression can be enhanced, which in turn can be applied to treatment of autoimmune diseases such as inflammatory bowel disease, as well as to organ transplantation.

35 [0006] However, mechanisms of how a large number of Treg cells come to be present in the colon and how the Treg cells produce IL-10 in the colon at a high level are still unclear. Moreover, it is also still unclear what species of bacteria constituting the intestinal commensal bacterial flora exerts the influence on the induction of regulatory T cells.

[Citation List]

[Non Patent Literature]

55 [0007]

[NPL 1] J. J. Cebra, "Am J Clin Nutr", May, 1999, 69, 1046S

[NPL 2] A. J. Macpherson, N. L. Harris, "Nat Rev Immunol", June 2004, 4, 478

4 (paragraphs [0002]-[0007] unamended)

- [NPL 3] J. L. Round, S. K. Mazmanian, "Nat Rev Immunol", May 2009, 9, 313
 [NPL 4] D. Bouskra et al., "Nature", November 27, 2008, 456, 507
 [NPL 5] K. Atarashi et al., "Nature", October 9, 2008, 455, 808
 [NPL 6] Ivanov, II et al., "Cell Host Microbe", October 16, 2008, 4, 337
 5 [NPL 7] S. L. Sanos et al., "Nat Immunol", January 2009, 10, 83
 [NPL 8] M. A. Curotto de Lafaille, J. J. Lafaille, "Immunity", May 2009, 30, 626
 [NPL 9] M. J. Barnes, F. Powrie, "Immunity", September 18, 2009, 31, 401
 [NPL 10] W. S. Garrett et al., "Cell", October 5, 2007, 131, 33
 [NPL 11] Ivanov, II et al., "Cell", October 30, 2009, 139, 485.
 10 [NPL 12] V. Gaboriau-Routhiau et al., "Immunity", October 16, 2009, 31, 677
 [NPL 13] N. H. Salzman et al., "Nat Immunol", 11, 76.
 [NPL 14] K. M. Maslowski et al., "Nature", October 29, 2009, 461, 1282
 [NPL 15] L. F. Lu, A. Rudensky, "Genes Dev", June 1, 2009, 23, 1270
 [NPL 16] S. Sakaguchi, T. Yamaguchi, T. Nomura, M. Ono, "Cell", May 30, 2008, 133, 775
 15 [NPL 17] C. L. Maynard et al., "Nat Immunol", September 2007, 8, 931
 [NPL 18] Y. P. Rubtsov et al., "Immunity", April 2008, 28, 546

[0008] V. Gaboriau-Routhiau et al., "Immunity", October 16, 2009, 31, 677 describes Segmented-Filamentous Bacteria (SFBs) which do not belong to the genus Clostridium, and indeed are phylogenetically remote therefrom.

20 [0009] SOKOL HARRY ET AL: "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, WASHINGTON, DC; US, vol. 105, no. 43, 28 October 2008 (2008-10-28), pages 16731-16736, proposes *Faecalibacterium prausnitzii* (belonging to Clostridium cluster IV) as candidate probiotic agent in the treatment of Crohn's disease (CD).

25 [0010] DE 10 2006 062250 A1 (SAUR-BROSCH ROLAND [DE]) discloses the use of a composition comprising minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment or prevention of abdominal discomfort which are accompanied by a reduced reductively acetogenic metabolic activity.

[0011] ITOH K ET AL: "Characterization of clostridia isolated from faeces of limited flora mice and their effect on caecal size when associated with germ-free mice." LABORATORY ANIMALS APR 1985 vol. 19, no. 2, April 1985 (1985-04),
 30 pages 111-118 discloses the characterization of 115 strains of clostridia accumulated from 3 separate isolations from the faeces of 1 limited flora (LF) mouse produced by inoculation of germ-free mice with chloroform-treated faeces of conventional mice, and the effect on caecal size when associated with germ-free mice was studied.

[Summary of Invention]

35 [Technical Problem]

[Solution to Problem]

40 [0012] The present inventors have found that a chloroform-treated fraction and a spore-forming fraction of a fecal sample obtained from a mammal induces accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors have found that bacteria belonging to the genus Clostridium induce proliferation or accumulation of regulatory T cells in the colon. The present inventors have also found that the regulatory T cells induced by these bacteria suppress proliferation of effector T cells. Furthermore, the present inventors have also found that colonization of bacteria
 45 belonging to the genus Clostridium and resultant proliferation or accumulation of Treg cells regulate local and systemic immune responses.

[0013] From these findings, the present inventors have found that the use of bacteria belonging to the genus Clostridium, spores thereof, or a physiologically active substance derived therefrom makes it possible to induce the proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.

50 ~~[0014] In one aspect, the present invention provides a composition for use in a method of treating or preventing a disease selected from infectious disease, autoimmune disease or allergic disease in an individual, the composition comprising, as an active ingredient, bacteria comprising spore-forming bacteria belonging to Clostridium clusters IV and XIVa in combination, which combination induces proliferation or accumulation of transcription factor Foxp3-positive regulatory T cells in said individual.~~

55 [0015] Other aspects of the invention are as defined in the claims appended hereto.

Amended paragraph [0014]

D. GLE
OGLE, JAMES
(paragraphs [0004]-[0013]
and [0015]
unamended)

EP 2 575 835 B1

[NPL 3] J. L. Round, S. K. Mazmanian, "Nat Rev Immunol", May 2009, 9, 313
[NPL 4] D. Bouskra et al., "Nature", November 27, 2008, 456, 507
[NPL 5] K. Atarashi et al., "Nature", October 9, 2008, 455, 808
[NPL 6] Ivanov, II et al., "Cell Host Microbe", October 16, 2008, 4, 337
[NPL 7] S. L. Sanos et al., "Nat Immunol", January 2009, 10, 83
[NPL 8] M. A. Curotto de Lafaille, J. J. Lafaille, "Immunity", May 2009, 30, 626
[NPL 9] M. J. Barnes, F. Powrie, "Immunity", September 18, 2009, 31, 401
[NPL 10] W. S. Garrett et al., "Cell", October 5, 2007, 131, 33
[NPL 11] Ivanov, II et al., "Cell", October 30, 2009, 139, 485.
[NPL 12] V. Gaboriau-Routhiau et al., "Immunity", October 16, 2009, 31, 677
[NPL 13] N. H. Salzman et al., "Nat Immunol", 11, 76.
[NPL 14] K. M. Maslowski et al., "Nature", October 29, 2009, 461, 1282
[NPL 15] L. F. Lu, A. Rudensky, "Genes Dev", June 1, 2009, 23, 1270
[NPL 16] S. Sakaguchi, T. Yamaguchi, T. Nomura, M. Ono, "Cell", May 30, 2008, 133, 775
[NPL 17] C. L. Maynard et al., "Nat Immunol", September 2007, 8, 931
[NPL 18] Y. P. Rubtsov et al., "Immunity", April 2008, 28, 546

[0008] V. Gaboriau-Routhiau et al., "Immunity", October 16, 2009, 31, 677 describes Segmented-Filamentous Bacteria (SFBs) which do not belong to the genus *Clostridium*, and indeed are phylogenetically remote therefrom.

[0009] SOKOL HARRY ET AL: "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, WASHINGTON, DC; US, vol. 105, no. 43, 28 October 2008 (2008-10-28), pages 16731-16736, proposes *Faecalibacterium prausnitzii* (belonging to *Clostridium* cluster IV) as candidate probiotic agent in the treatment of Crohn's disease (CD).

[0010] DE 10 2006 062250 A1 (SAUR-BROSCH ROLAND [DE]) discloses the use of a composition comprising minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment or prevention of abdominal discomfort which are accompanied by a reduced reductively acetogenic metabolic activity.

[0011] ITOH K ET AL: "Characterization of clostridia isolated from faeces of limited flora mice and their effect on caecal size when associated with germ-free mice." LABORATORY ANIMALS APR 1985 vol. 19, no. 2, April 1985 (1985-04), pages 111-118 discloses the characterization of 115 strains of clostridia accumulated from 3 separate isolations from the faeces of 1 limited flora (LF) mouse produced by inoculation of germ-free mice with chloroform-treated faeces of conventional mice, and the effect on caecal size when associated with germ-free mice was studied.

[Summary of Invention]

[Technical Problem]

[Solution to Problem]

[0012] The present inventors have found that a chloroform-treated fraction and a spore-forming fraction of a fecal sample obtained from a mammal induces accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors have found that bacteria belonging to the genus *Clostridium* induce proliferation or accumulation of regulatory T cells in the colon. The present inventors have also found that the regulatory T cells induced by these bacteria suppress proliferation of effector T cells. Furthermore, the present inventors have also found that colonization of bacteria belonging to the genus *Clostridium* and resultant proliferation or accumulation of Treg cells regulate local and systemic immune responses.

[0013] From these findings, the present inventors have found that the use of bacteria belonging to the genus *Clostridium*, spores thereof, or a physiologically active substance derived therefrom makes it possible to induce the proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.

[0014] In one aspect, the present invention provides a composition for use in a method of treating or preventing a disease selected from infectious disease, autoimmune disease or allergic disease in an individual, the composition comprising, as an active ingredient, bacteria comprising spore-forming bacteria belonging to *Clostridium* clusters IV and XIVa in combination, which combination induces proliferation or accumulation of transcription factor Foxp3-positive regulatory T cells in said individual. said

[0015] Other aspects of the invention are as defined in the claims appended hereto.

belonging to the genus *Clostridium*
by inducing proliferation or accumulation of transcription factor Foxp3-
positive regulatory T cells

[Advantageous Effects]

[0016] The compositions described herein serve as an excellent composition for inducing the proliferation or accumulation of regulatory T cells (Treg cells). Immunity in a living organism can be suppressed through administration of the composition herein described as a pharmaceutical product or ingestion of the composition as a food or beverage. Accordingly, the composition described herein can be used, for example, to prevent or treat autoimmune diseases or allergic diseases, as well as to suppress immunological rejection in organ transplantation or the like. In addition, if a food or beverage such as a health food comprises the composition of the present invention, healthy individuals can ingest the composition easily and routinely. As a result, it is possible to induce the proliferation or accumulation of regulatory T cells and thereby to improve immune functions.

[Brief Description of Drawings]

[0017]

[Fig. 1] Fig. 1 is a schematic diagram showing a method of producing $Il10^{venus}$ mouse.

[Fig. 2] Fig. 2 is a diagram showing results of Southern blotting performed for analysis as to whether or not the $Il10^{venus}$ mice have an $Il10^{venus}$ allele.

[Fig. 3] Fig. 3 is a FACS dot-plot diagram showing results obtained when Venus-positive cells and Venus-negative cells from the $Il10^{venus}$ mice were sorted.

[Fig. 4] Fig. 4 is a graph showing the results obtained when the amounts of IL-10 mRNA expressed in Venus positive-cells and Venus-negative cells of the $Il10^{venus}$ mice were analyzed by real-time RT-PCR.

[Fig. 5] Fig. 5 is a graph showing change in the ratio of Foxp3⁺ cells in CD4⁺ lymphocytes of SPF mice.

[Fig. 6] Fig. 6 shows FACS dot-plot diagrams showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the small intestine, the colon, and the peripheral lymph nodes of GF mice and SPF mice.

[Fig. 7] Fig. 7 is a graph showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the small intestine, the colon, and the peripheral lymph nodes of GF mice and SPF mice.

[Fig. 8] Fig. 8 shows graphs showing analysis results of the numbers of CD4⁺ Foxp3⁺ cells isolated from the small intestine, the colon, and the peripheral lymph nodes of GF mice and SPF mice.

[Fig. 9] Fig. 9 is a plot diagram showing analysis results of the ratios of Venus⁺ cells in CD4⁺ cells in various tissues of SPF mice treated with antibiotics.

[Fig. 10] Fig. 10 shows FACS dot-plot diagrams showing analysis results of the ratio of Foxp3⁺ cell in CD4⁺ lymphocytes isolated from the colonic lamina propria of GF mice to which a fecal suspension of SPF mice was administered.

[Fig. 11] Fig. 11 is a graph showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the lamina propria of the colon and the lamina propria of the small intestine of GF mice to which a fecal suspension of SPF mice was administered.

[Fig. 12] Fig. 12 is a graph showing analysis results of the ratio of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the lamina propria of mice deficient in ILFs, PPs, and colonic-patches.

[Fig. 13] Fig. 13 shows FACS dot-plot diagrams showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the colonic lamina propria of GF mice to which specific commensal bacteria were administered.

[Fig. 14] Fig. 14 shows graphs showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the colonic lamina propria of GF mice to which specific commensal bacteria were administered.

[Fig. 15] Fig. 15 is a graph showing analysis results of the ratios of IFN- γ ⁺ cells in CD4⁺ lymphocytes isolated from the colonic lamina propria of mice in which specific commensal bacteria were colonized.

[Fig. 16] Fig. 16 is a graph showing analysis results of the ratios of IL-17⁺ cells in CD4⁺ lymphocytes isolated from the colonic lamina propria of mice in which specific commensal bacteria were colonized.

[Fig. 17] Fig. 17 is a graph showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the colon of kinds of SPF mice each being deficient in a pathogen-associated molecular pattern recognition receptor-associated factor.

[Fig. 18] Fig. 18 is a graph showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the colonic lamina propria of Myd88^{-/-} mice in which the Clostridium was colonized.

[Fig. 19] Fig. 19 shows FACS dot-plot diagrams showing analysis results of the ratios of Venus⁺ cells in lymphocytes isolated from various tissues of $Il10^{venus}$ mice.

[Fig. 20] Fig. 20 is a FACS dot-plot diagram showing analysis results of the expression of a T cell receptor β chain on cell surfaces of lymphocytes isolated from the colonic lamina propria of $Il10^{venus}$ mice.

[Fig. 21] Fig. 21 shows FACS dot-plot diagrams showing analysis results of the expression of IL-17, IL-4, and IFN-

[Advantageous Effects]

[0016] The compositions described herein serve as an excellent composition for inducing the proliferation or accumulation of regulatory T cells (Treg cells). Immunity in a living organism can be suppressed through administration of the composition herein described as a pharmaceutical product or ingestion of the composition as a food or beverage. Accordingly, the composition described herein can be used, for example, to prevent or treat ~~(autoimmune diseases or)~~ allergic diseases ~~(as well as to suppress immunological rejection in organ transplantation or the like)~~. In addition, if a food or beverage such as a health food comprises the composition of the present invention, healthy individuals can ingest the composition easily and routinely. As a result, it is possible to induce the proliferation or accumulation of regulatory T cells and thereby to improve immune functions.

~~[Brief Description of Drawings]~~

[0017]

[Fig. 1] Fig. 1 is a schematic diagram showing a method of producing $Il10^{venus}$ mouse.

[Fig. 2] Fig. 2 is a diagram showing results of Southern blotting performed for analysis as to whether or not the $Il10^{venus}$ mice have an $Il10^{venus}$ allele.

[Fig. 3] Fig. 3 is a FACS dot-plot diagram showing results obtained when Venus-positive cells and Venus-negative cells from the $Il10^{venus}$ mice were sorted.

[Fig. 4] Fig. 4 is a graph showing the results obtained when the amounts of IL-10 mRNA expressed in Venus positive-cells and Venus-negative cells of the $Il10^{venus}$ mice were analyzed by real-time RT-PCR.

[Fig. 5] Fig. 5 is a graph showing change in the ratio of Foxp3⁺ cells in CD4⁺ lymphocytes of SPF mice.

[Fig. 6] Fig. 6 shows FACS dot-plot diagrams showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the small intestine, the colon, and the peripheral lymph nodes of GF mice and SPF mice.

[Fig. 7] Fig. 7 is a graph showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the small intestine, the colon, and the peripheral lymph nodes of GF mice and SPF mice.

[Fig. 8] Fig. 8 shows graphs showing analysis results of the numbers of CD4⁺ Foxp3⁺ cells isolated from the small intestine, the colon, and the peripheral lymph nodes of GF mice and SPF mice.

[Fig. 9] Fig. 9 is a plot diagram showing analysis results of the ratios of Venus⁺ cells in CD4⁺ cells in various tissues of SPF mice treated with antibiotics.

[Fig. 10] Fig. 10 shows FACS dot-plot diagrams showing analysis results of the ratio of Foxp3⁺ cell in CD4⁺ lymphocytes isolated from the colonic lamina propria of GF mice to which a fecal suspension of SPF mice was administered.

[Fig. 11] Fig. 11 is a graph showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the lamina propria of the colon and the lamina propria of the small intestine of GF mice to which a fecal suspension of SPF mice was administered.

[Fig. 12] Fig. 12 is a graph showing analysis results of the ratio of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the lamina propria of mice deficient in ILFs, PPs, and colonic-patches.

[Fig. 13] Fig. 13 shows FACS dot-plot diagrams showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the colonic lamina propria of GF mice to which specific commensal bacteria were administered.

[Fig. 14] Fig. 14 shows graphs showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the colonic lamina propria of GF mice to which specific commensal bacteria were administered.

[Fig. 15] Fig. 15 is a graph showing analysis results of the ratios of IFN- γ cells in CD4⁺ lymphocytes isolated from the colonic lamina propria of mice in which specific commensal bacteria were colonized.

[Fig. 16] Fig. 16 is a graph showing analysis results of the ratios of IL-17⁺ cells in CD4⁺ lymphocytes isolated from the colonic lamina propria of mice in which specific commensal bacteria were colonized.

[Fig. 17] Fig. 17 is a graph showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the colon of kinds of SPF mice each being deficient in a pathogen-associated molecular pattern recognition receptor-associated factor.

[Fig. 18] Fig. 18 is a graph showing analysis results of the ratios of Foxp3⁺ cells in CD4⁺ lymphocytes isolated from the colonic lamina propria of Myd88^{-/-} mice in which the Clostridium was colonized.

[Fig. 19] Fig. 19 shows FACS dot-plot diagrams showing analysis results of the ratios of Venus⁺ cells in lymphocytes isolated from various tissues of $Il10^{venus}$ mice.

[Fig. 20] Fig. 20 is a FACS dot-plot diagram showing analysis results of the expression of a T cell receptor β chain on cell surfaces of lymphocytes isolated from the colonic lamina propria of $Il10^{venus}$ mice.

~~[Fig. 21] Fig. 21 shows FACS dot-plot diagrams showing analysis results of the expression of IL-17, IL-4, and IFN-~~

γ in lymphocytes isolated from the colonic lamina propria of $Il10^{venus}$ mice.

[Fig. 22] Fig. 22 shows graphs showing analysis results of the amounts of mRNAs of IL-10, CTLA4, Foxp3, and GITR expressed in spleen Foxp3-CD4⁺ cells, spleen Foxp3⁺ CD4⁺ cells, colonic lamina propria Venus⁺ cells, and small intestinal lamina propria Venus⁺ cells.

[Fig. 23] Fig. 23 shows FACS dot-plot diagrams showing analysis results of the expression of CD4, Foxp3, and Venus in the lamina propria of the small intestine and the lamina propria of the colon of GF $Il10^{venus}$ mice and SPF $Il10^{venus}$ mice.

[Fig. 24] Fig. 24 shows FACS dot-plot diagrams showing analysis results of the expression of Venus and Foxp3 of CD4 cells in various tissues of SPF $Il10^{venus}$ mice.

[Fig. 25] Fig. 25 shows FACS dot-plot diagrams showing analysis results of the expression of Foxp3 and Venus in $Il10^{venus}$ mice in which specific commensal bacteria were colonized.

[Fig. 26] Fig. 26 is a graph showing analysis results of the expression of Foxp3 and/or Venus of CD4⁺ cells in the small intestine of $Il10^{venus}$ mice in which specific commensal bacteria were colonized.

[Fig. 27] Fig. 27 is a graph showing analysis results of the expression of Foxp3 and/or Venus of CD4⁺ cells in the colon of $Il10^{venus}$ mice in which specific commensal bacteria were colonized.

[Fig. 28] Fig. 28 is a plot diagram showing analysis results of the ratios of Venus⁺ cells in CD4⁺ cells isolated from various tissues of $Il10^{venus}$ mice treated with antibiotics.

[Fig. 29] Fig. 29 is a graph showing analysis results of immunoregulatory functions of CD4⁺ Venus⁺ cells from the colonic lamina propria of GF $Il10^{venus}$ mice in which the genus Clostridium was colonized, CD4⁺ Venus⁺ cells from the colonic lamina propria of SPF $Il10^{venus}$ mice, and CD4⁺ GFP⁺ cells from the spleen of Foxp3^{eGFP} reporter mice.

[Fig. 30] Fig. 30 is a graph showing the results obtained when SPF B6 mice were treated with polymyxin B or vancomycin for 4 weeks, and then analyzed for the ratio of Foxp3⁺ cells in the CD4⁺ cell group.

[Fig. 31] Fig. 31 is a graph showing the results obtained when SPF mice-derived chloroform-treated feces were orally administered to GF mice, and then the ratio of Foxp3⁺ cells in the CD4⁺ cell group was analyzed.

[Fig. 32] Fig. 32 is a graph showing the general results of flow cytometry analysis on Helios expression in LP lymphocytes in the thymuses or the colons of SPF mice, GF mice, Lactobacillus-colonized mice, or Clostridium-colonized mice.

[Fig. 33] Fig. 33 shows plot diagrams showing representative results of flow cytometry analysis on CD4 expression, Foxp3 expression, and Helios expression in the LP lymphocytes in the thymuses or the colons of the SPF mice, the GF mice, the Lactobacillus-colonized mice, or the Clostridium-colonized mice.

[Fig. 34] Fig. 34 is a graph showing the results obtained when the whole colons derived from GF mice, Lactobacillus-colonized mice, or Clostridium-colonized mice were cultured, and the culture supernatants thereof were analyzed for the TGF- β 1 concentration by ELISA.

[Fig. 35] Fig. 35 is a graph showing the results obtained when intestinal epithelial cells (IECs) derived from GF mice or Clostridium-colonized mice were cultured, and the culture supernatants thereof were analyzed for the TGF- β 1 concentration by ELISA.

[Fig. 36] Fig. 36 is a graph showing the results obtained when splenic CD4⁺ T cells were cultured together with an anti-CD3 antibody and with a culture supernatant of IECs isolated from GF mice or mice colonized with 46 bacterial strains of the genus Clostridium (Clost.) in the presence or absence of an anti-TGF- β antibody, and the T cells were collected on day 5 of the culture and analyzed for Foxp3 expression by real-time RT-PCR.

[Fig. 37] Fig. 37 is a graph showing the results obtained when C57BL/6 GF mice were orally inoculated with 46 bacterial strains of the genus Clostridium (Clost.) or three bacterial strains of the genus Lactobacillus (Lacto.), and IECs were collected three weeks after the inoculation and analyzed for the relative mRNA expression level of the MMP2 gene by real-time RT-PCR.

[Fig. 38] Fig. 38 is a graph showing the results obtained when C57BL/6 GF mice were orally inoculated with 46 bacterial strains of the genus Clostridium (Clost.) or three bacterial strains of the genus Lactobacillus (Lacto.), and IECs were collected three weeks after the inoculation and analyzed for the relative mRNA expression level of the MMP9 gene by real-time RT-PCR.

[Fig. 39] Fig. 39 is a graph showing the results obtained when C57BL/6 GF mice were orally inoculated with 46 bacterial strains of the genus Clostridium (Clost.) or three bacterial strains of the genus Lactobacillus (Lacto.), and IECs were collected three weeks after the inoculation and analyzed for the relative mRNA expression level of the MMP13 gene by real-time RT-PCR.

[Fig. 40] Fig. 40 is a graph showing the results obtained when C57BL/6 GF mice were orally inoculated with 46 bacterial strains of the genus Clostridium (Clost.) or three bacterial strains of the genus Lactobacillus (Lacto.), and IECs were collected three weeks after the inoculation and analyzed for the relative mRNA expression level of the IDO gene by real-time RT-PCR.

[Fig. 41] Fig. 41 is a graph showing the results obtained when control mice (SPF) and Clostridium-administered mice (SPF+Clost.) were treated with 2% DSS, observed and measured for the body weight loss, the hardness of

stool, and bleeding for six days, and then evaluated numerically.

[Fig. 42] Fig. 42 is a photograph showing the state of the colons collected on day 6 after the control mice (SPF) and the Clostridium-administered mice (SPF+Clost.) were treated with 2% DSS.

[Fig. 43] Fig. 43 shows photomicrographs showing the results obtained when the control mice (SPF) and the Clostridium-administered mice (SPF+Clost.) were treated with 2% DSS, and the colons thereof were collected on day 6 and analyzed histologically by HE staining.

[Fig. 44] Fig. 44 is a graph showing the results obtained when control mice (SPF) and Clostridium-administered mice (SPF+Clost.) were sensitized with oxazolone, and subsequently the inside of each rectum was treated with a 1% oxazolone/50% ethanol solution, and the body weight loss was measured.

[Fig. 45] Fig. 45 shows photomicrographs showing the results obtained when the control mice (SPF) and the Clostridium-administered mice (SPF+Clost.) were sensitized with oxazolone, and subsequently the inside of each rectum was treated with a 1% oxazolone/50% ethanol solution, and the colons obtained by the treatment were analyzed histologically by HE staining.

[Fig. 46] Fig. 46 is a graph showing the results obtained when control mice (SPF) and Clostridium-administered mice (SPF+Clost.) were immunized by administering alum-absorbed ovalbumin (OVA) twice at a 2-week interval, and the sera were collected therefrom and analyzed for the concentration of OVA-specific IgE in these sera by ELISA.

[Fig. 47] Fig. 47 is a graph showing the results obtained when the control mice (SPF) and the Clostridium-administered mice (SPF+Clost.) were immunized by administering the alum-absorbed OVA twice at a 2-week interval, and splenic cells were collected and analyzed for IL-4 production of these splenic cells by in-vitro OVA restimulation.

[Fig. 48] Fig. 48 is a graph showing the results obtained when the control mice (SPF) and the Clostridium-administered mice (SPF+Clost.) were immunized by administering the alum-absorbed OVA twice at a 2-week interval, and the splenic cells were collected and analyzed for IL-10 production of these splenic cells by the in-vitro OVA restimulation.

[Fig. 49] Fig. 49 is Phylogenetic tree constructed by the neighbor-joining method with the resulting sequences of the 41 strains of Clostridium and those of known bacteria obtained from Genbank database using Mega software.

[Fig. 50] Fig. 50 is histograms showing Foxp3 expression gated CD4 cells from GF mice (Germ-free mouse #1 and #2) or GF mice colonized with three strains of Clostridium belonging to cluster IV (3 strains of Clost. mouse #1 and #2).

[Fig. 51] Fig. 51 is histograms showing Foxp3 expression by CD4 positive lymphocytes from GF mice (GF) or GF mice gavaged with chloroform-treated human stool (GF+Chloro.).

[Fig. 52] Fig. 52 is a graph showing Foxp3 expression by CD4 positive lymphocytes from GF mice (GF) or GF mice gavaged with chloroform-treated human stool (GF+Chloro.).

[Fig. 53] Fig. 53 is a graph showing amounts of Clostridium and Bacteroides in feces of mice gavaged with chloroform-treated human stool

[Description of Embodiments]

[0018] "Regulatory T cells" mean transcription factor Foxp3-positive CD4-positive T cells.

[0019] The meaning of the "induces proliferation or accumulation of regulatory T cells" in the present invention includes an effect of inducing the differentiation of immature T cells into regulatory T cells, which differentiation leads to the proliferation or the accumulation of regulatory T cells. In addition, the meaning of the "induces proliferation or accumulation of regulatory T cells" in the present invention includes in-vivo effects, in vitro effects, and ex vivo effects. Accordingly, all of the following effects are included: an effect of inducing in vivo proliferation or accumulation of regulatory T cells through administration or ingestion of the bacteria belonging to the genus Clostridium or the physiologically active substance or the like derived from the bacteria; an effect of inducing proliferation or accumulation of cultured regulatory T cells by causing the bacteria belonging to the genus Clostridium or the physiologically active substance or the like derived from the bacteria to act on the cultured regulatory T cells; and an effect of inducing proliferation or accumulation of regulatory T cells which are collected from a living organism and which are intended to be subsequently introduced into a living organism, such as the organism from which they were obtained or another organism, by causing the bacteria belonging to the genus Clostridium or the physiologically active substance or the like derived from the bacteria to act on the regulatory T cells. The effect of inducing proliferation or accumulation of regulatory T cells can be evaluated, for example, as follows. Specifically, the bacteria belonging to the genus Clostridium or the physiologically active substance or the like derived from the bacteria is orally administered to an experimental animal such as a germ-free mouse, then CD4-positive cells in the colon are isolated, and the ratio of regulatory T cells contained in the CD4-positive cells is measured by flow cytometry (refer to Example 7).

[0020] The regulatory T cells of which proliferation or accumulation is induced by the composition of the present invention are transcription factor Foxp3-positive regulatory T cells.

[0021] The "bacteria belonging to the genus Clostridium," which are the active ingredient in the composition of the present invention, are as defined in the claims appended hereto.

[0022] Two or more strains of the bacteria can be used together for the composition of the present invention. The use

of multiple strains of bacteria belonging to the cluster XIVa or the cluster IV in combination can bring about an excellent effect on regulatory T cells. In addition to the bacteria belonging to these clusters, bacteria belonging to other clusters (for example, bacteria belonging to the cluster III) can also be used in combination. If more than one strain of bacteria is used (e.g., one or more strain belonging to cluster XIVa, one or more strain belonging to cluster IV, one or more strain belonging to a cluster other than cluster XIVa or cluster IV, such as one or more strain belonging to cluster III), the type and number of strains used can vary widely. The type and number to be used can be determined based on a variety of factors (e.g., the desired effect, such as induction or inhibition of proliferation or accumulation of regulatory T cells; the disease or condition to be treated, prevented or reduced in severity; the age or gender of the recipient) The strains can be present in a single composition, in which case they will be consumed or ingested together, or can be present in more than one composition (e.g., each can be in a separate composition), in which case they can be consumed individually or the compositions can be combined and the resulting combination (combined compositions) consumed or ingested. Any number or combination of strains that proves effective (e.g., any number from one to 200, such as 1 to 100, 1 to 50, 1 to 40, 1 to 30, 1 to 20, 1 to 10, 1 to 5 and any number therebetween) can be administered. In certain embodiments of the present invention, a combination of some or all of the 46 strains described in Document (Itoh, K., and Mitsuoka, T. Characterization of clostridia isolated from faeces of limited flora mice and their effect on caecal size when associated with germ-free mice. Lab. Animals 19: 111-118 (1985)) is used. For example, at least one, two or more, three, three or more, four, four or more, five, five or more, six, six or more or any other number of the 46 described strains, including 46 strains, can be used. They can be used in combination with one another and in combination with strains not described in the cited reference (e.g., in combination with one or more strains belonging to cluster III).

[0023] Note that, the cluster of "bacteria belonging to the genus Clostridium" can be identified, for example, as follows. Specifically, the bacteria belonging to the genus Clostridium are classified by PCR using a primer set consisting of SEQ ID NOs 64 and 65 (for Clostridium spp. belonging to the cluster XIVa) or a primer set consisting of SEQ ID NOs 66 and 67 (for Clostridium spp. belonging to the cluster IV) (refer to Example 18). In addition, the bacteria belonging to the genus Clostridium are classified by sequencing of 16S rRNA gene amplified using a primer set consisting of SEQ ID NOs 19 and 20 (refer to Example 7).

[0024] Viable cells of the bacteria belonging to the genus Clostridium can be used for the composition of the present invention, and killed cells thereof may also be used for the composition. In addition, from the viewpoint of stability to heat, resistance to antibiotics and the like, and long storage period, the bacteria belonging to the genus Clostridium are preferably in the form of spore.

[0025] The meaning of the "physiologically active substance derived from bacteria belonging to the genus Clostridium" as used herein includes substances contained in the bacteria, secretion products of the bacteria, and metabolites of the bacteria. Such a physiologically active substance can be identified by purifying an active component from the bacteria, a culture supernatant thereof, or intestinal tract contents in the intestinal tract of a mouse in which only bacteria belonging to the genus Clostridium are colonized by an already known purification method.

[0026] The active ingredient "spore-forming fraction of a fecal sample obtained from a mammal" in the composition of the present invention is not particularly limited, as long as the fraction includes spore-forming bacteria present in feces of a mammal, and has the effect of inducing proliferation or accumulation of regulatory T cells.

[0027] The active ingredient "chloroform-treated fraction of a fecal sample obtained from a mammal" in the composition of the present invention is not particularly limited, as long as the fraction is obtained by treating feces of a mammal with chloroform (for example, 3% chloroform), and has the effect of inducing proliferation or accumulation of regulatory T cells.

[0028] Note that the "mammal" in the present invention is not particularly limited, and examples thereof include humans, mice, rats, cattle, horses, pigs, sheep, monkeys, dogs, and cats.

[0029] Meanwhile, when the "spore-forming fraction of a fecal sample obtained from a mammal" or the "chloroform-treated fraction of a fecal sample obtained from a mammal" is cultured in a medium, substances contained in the bacteria, secretion products of the bacteria, metabolites of the bacteria are released from the bacteria and the like contained in the fraction. The meaning of the active ingredient "culture supernatant of the fraction" in the composition described herein includes such substances, secretion products, and metabolites. The culture supernatant is not particularly limited, as long as the culture supernatant has the effect of inducing proliferation or accumulation of regulatory T cells. Examples of the culture supernatant include a protein fraction of the culture supernatant, a polysaccharide fraction of the culture supernatant, a lipid fraction of the culture supernatant, and a low-molecular weight metabolite fraction of the culture supernatant.

[0030] The composition described herein may be in the form of a pharmaceutical composition, a food or beverage (which may also be an animal feed), or a reagent used for an animal model experiment, the pharmaceutical composition, the food or beverage, and the reagent having the effect of inducing proliferation or accumulation of regulatory T cells. An example of the present invention revealed that regulatory T cells (Treg cells) induced by bacteria or the like belonging to the genus Clostridium suppressed the proliferation of effector T-cells. Accordingly, the composition of the present invention can be used suitably as a composition having an immunosuppressive effect. The immunosuppressive effect can be evaluated, for example, as follows. Specifically, regulatory T cells isolated from an experimental animal, such as

a mouse, to which the composition of the present invention is orally administered are caused to act on effector T-cells (CD4⁺ CD25⁻ cells) isolated from the spleen, and then proliferation ability thereof is measured by using the intake amount of [³H]-thymidine as an index (refer to Example 14).

[0031] ~~The composition of the present invention can be used, for example, as a pharmaceutical composition for preventing or treating an autoimmune disease such as chronic inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, or Hashimoto's disease, or an allergic disease such as pollenosis or asthma; a pharmaceutical composition for suppressing rejection in organ transplantation or the like; a food or beverage for improving immune functions; or a reagent for suppressing the proliferation or function of effector T-cells.~~

[0032] More specific examples of target diseases of the composition of the present invention include autoimmune diseases, allergic diseases, and rejection in organ transplantations and the like, such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, sprue, autoimmune arthritis, rheumatoid arthritis, Type I diabetes, multiple sclerosis, graft vs. host disease following bone marrow transplantation, osteoarthritis, juvenile chronic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthritis, systemic lupus erythematosus, insulin dependent diabetes mellitus, thyroiditis, asthma, psoriasis, dermatitis scleroderma, atopic dermatitis, graft versus host disease, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpura, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, polyglandular deficiency type I syndrome and polyglandular deficiency type II syndrome, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia areata, seronegative arthropathy, arthropathy, Reiter's disease, psoriatic arthropathy, chlamydia, yersinia and salmonella associated arthropathy, spondyloarthritis, atheromatous disease/arteriosclerosis, atopic allergy, food allergies, autoimmune bullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome, Acquired Immunodeficiency Related Diseases, Hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, fibrotic lung disease, cryptogenic fibrosing alveolitis, postinflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjogren's disease associated lung disease, ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycemia, type B insulin resistance with acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthritis, primary sclerosing cholangitis, idiopathic leucopenia, autoimmune neutropenia, renal disease NOS, glomerulonephritis, microscopic vasculitis of the kidneys, discoid lupus, erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), insulindependent diabetes mellitus, sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Takayasu's disease/arteritis, autoimmune thrombocytopenia, idiopathic thrombocytopenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis, vitiligo, allergic rhinitis (pollen allergies), anaphylaxis, pet allergies, latex allergies, drug allergies, allergic rhinoconjunctivitis, eosinophilic esophagitis, hypereosinophilic syndrome, eosinophilic gastroenteritis cutaneous lupus erythematosus, eosinophilic esophagitis, hypereosinophilic syndrome, and eosinophilic gastroenteritis.

[0033] ~~The composition of the present invention can also be used as a pharmaceutical composition for preventing or treating infectious diseases in an individual whose resistance to the infectious diseases is impaired because of damage due to excessive inflammation caused by the immunity.~~

[0034] Example of infectious pathogens which impair maintenance or recovery of homeostasis of a host, and which eventually bring about such immunopathological tissue damage include Salmonella, Shigella, Clostridium difficile, Mycobacterium (which cause the disease tuberculosis), protozoa (which cause the disease malaria), filarial nematodes (which cause the disease filariasis), Schistosoma (which cause the disease schistosomiasis), Toxoplasma (which cause the disease toxoplasmosis), Leishmania (which cause the disease leishmaniasis), HCV and HBV (which cause the disease hepatitis C and hepatitis B), and herpes simplex viruses (which cause the disease herpes).

Amended paragraphs [0031] - [0033]
(paragraphs [0030] and [0034],
unamended)
EP 2 575 835 B1

~~a mouse, to which the composition of the present invention is orally administered are caused to act on effector T-cells (CD4⁺ CD25⁻ cells) isolated from the spleen, and then proliferation ability thereof is measured by using the intake amount of [³H]-thymidine as an index (refer to Example 14).~~

[0031] The composition of the present invention can be used, for example, as a pharmaceutical composition for preventing or treating ~~an autoimmune disease such as chronic inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, or Hashimoto's disease, or an allergic disease such as pollenosis or asthma; a pharmaceutical composition for suppressing rejection in organ transplantation or the like; a food or beverage for improving immune functions; or a reagent for suppressing the proliferation or function of effector T-cells.~~

[0032] ~~More specific examples of target diseases of the composition of the present invention include autoimmune diseases, allergic diseases, and rejection in organ transplantations and the like, such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, sprue, autoimmune arthritis, rheumatoid arthritis, Type I diabetes, multiple sclerosis, graft vs. host disease following bone marrow transplantation, osteoarthritis, juvenile chronic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthritis, systemic lupus erythematosus, insulin dependent diabetes mellitus, thyroiditis, asthma, psoriasis, dermatitis scleroderma, atopic dermatitis, graft versus host disease, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpura, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, polyglandular deficiency type I syndrome and polyglandular deficiency type II syndrome, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia areata, seronegative arthropathy, arthropathy, Reiter's disease, psoriatic arthropathy, chlamydia, yersinia and salmonella associated arthropathy, spondyloarthritis, atheromatous disease/arteriosclerosis, atopic allergy, food allergies, autoimmune bullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome, Acquired Immunodeficiency Related Diseases, Hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, fibrotic lung disease, cryptogenic fibrosing alveolitis, postinflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjogren's disease associated lung disease, ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycemia, type B Insulin resistance with acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthritis, primary sclerosing cholangitis, idiopathic leucopenia, autoimmune neutropenia, renal disease NOS, glomerulonephritis, microscopic vasculitis of the kidneys, discoid lupus, erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), insulindependent diabetes mellitus, sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Takayasu's disease/arteritis, autoimmune thrombocytopenia, idiopathic thrombocytopenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis, vitiligo, allergic rhinitis (pollen allergies), anaphylaxis, pet allergies, latex allergies, drug allergies, allergic rhinoconjunctivitis, eosinophilic esophagitis, hypereosinophilic syndrome, eosinophilic gastroenteritis cutaneous lupus erythematosus, eosinophilic esophagitis, hypereosinophilic syndrome, and eosinophilic gastroenteritis.~~ *include*

[0033] The composition of the present invention can also be used ~~as a pharmaceutical composition for preventing or treating infectious diseases in an individual whose resistance to the infectious diseases is impaired because of damage due to excessive inflammation caused by the immunity.~~ *according to the claim*

~~[0034] Example of infectious pathogens which impair maintenance or recovery of homeostasis of a host, and which eventually bring about such immunopathological tissue damage include Salmonella, Shigella, Clostridium difficile, Mycobacterium (which cause the disease tuberculosis), protozoa (which cause the disease malaria), filarial nematodes (which cause the disease filariasis), Schistosoma (which cause the disease schistosomiasis), Toxoplasma (which cause the disease toxoplasmosis), Leishmania (which cause the disease leishmaniasis), HCV and HBV (which cause the disease hepatitis C and hepatitis B), and herpes simplex viruses (which cause the disease herpes).~~

20.2.2019

D. C. OGLE, JAMES

[0035] Pharmaceutical preparations can be formulated from the composition of the present invention by already known drug formulation methods. For example, the composition of the present invention can be used orally or parenterally in the forms of capsules, tablets, pills, liquids, powders, granules, fine granules, film-coated preparations, pellets, troches, sublingual preparations, chewables, buccal preparations, pastes, syrups, suspensions, elixirs, emulsions, liniments, ointments, plasters, cataplasms, transdermal absorption systems, lotions, inhalations, aerosols, injections, suppositories, and the like.

[0036] For formulating these preparations, the composition of the present invention can be used in appropriate combination with carriers acceptable pharmacologically or acceptable for a food or beverage, specifically, with sterile water, physiological saline, vegetable oil, solvent, a base material, an emulsifier, a suspending agent, a surfactant, a stabilizer, a flavoring agent, an aromatic, an excipient, a vehicle, a preservative, a binder, a diluent, a tonicity adjusting agent, a soothing agent, a bulking agent, a disintegrating agent, a buffer agent, a coating agent, a lubricant, a colorant, a sweetener, a thickening agent, a flavor corrigent, a solubilizer, other additives, or the like.

[0037] Meanwhile, for formulating a pharmaceutical preparation thereof, and particularly for formulating a pharmaceutical preparation for oral administration, it is preferable to use in combination a composition which enables an efficient delivery of the composition of the present invention to the colon, from the viewpoint of more efficiently inducing the proliferation or accumulation of regulatory T cells in the colon.

[0038] Such a composition or method which enables the delivery to the colon is not particularly limited, and known compositions or methods can be employed as appropriate. Examples thereof include pH sensitive compositions, more specifically, enteric polymers which release their contents when the pH becomes alkaline after the enteric polymers pass through the stomach. When a pH sensitive composition is used for formulating the pharmaceutical preparation, the pH sensitive composition is preferably a polymer whose pH threshold of the decomposition of the composition is 6.8 to 7.5. Such a numeric value range is a range where the pH shifts toward the alkaline side at a distal portion of the stomach, and hence is a suitable range for use in the delivery to the colon.

[0039] Moreover, another example of the composition enabling the delivery to the colon is a composition which ensures the delivery to the colon by delaying the release of the contents by approximately 3 to 5 hours, which corresponds to the small intestinal transit time. In an example of formulating a pharmaceutical preparation using the composition for delaying the release, a hydrogel is used as a shell. The hydrogel is hydrated and swells upon contact with gastrointestinal fluid, so that the contents are effectively released. Furthermore the delayed release dosage units include drug-containing compositions having a material which coats or selectively coats a drug. Examples of such a selective coating material include in vivo degradable polymers, gradually hydrolyzable polymers, gradually water-soluble polymers, and/or enzyme degradable polymers. A preferred coating material for efficiently delaying the release is not particularly limited, and examples thereof include cellulose-based polymers such as hydroxypropyl cellulose, acrylic acid polymers and copolymers such as methacrylic acid polymers and copolymers, and vinyl polymers and copolymers such as polyvinylpyrrolidone.

[0040] Examples of the composition enabling the delivery to the colon further include bioadhesive compositions which specifically adhere to the colonic mucosal membrane (for example, a polymer described in the specification of US Patent No. 6,368,586), and compositions into which a protease inhibitor is incorporated for protecting particularly a biopharmaceutical preparation in the gastrointestinal tracts from decomposition due to an activity of a protease.

[0041] An example of a system enabling the delivery to the colon is a system of delivering a composition to the colon by pressure change in such a way that the contents are released by utilizing pressure change caused by generation of gas in bacterial fermentation at a distal portion of the stomach. Such a system is not particularly limited, and a more specific example thereof is a capsule which has contents dispersed in a suppository base and which is coated with a hydrophobic polymer (for example, ethyl cellulose).

[0042] Another example of the system enabling the delivery to the colon is a system of delivering a composition to the colon, the system being specifically decomposed by an enzyme (for example, a carbohydrate hydrolase or a carbohydrate reductase) present in the colon. Such a system is not particularly limited, and more specific examples thereof include systems which use food components such as non-starch polysaccharides, amylose, xanthan gum, and azopolymers.

[0043] When used as a pharmaceutical composition, the composition of the present invention may be used in combination with an already known pharmaceutical composition for use in immunosuppression. Such a known pharmaceutical composition is not particularly limited, and may be at least one therapeutic composition selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-IgE antibodies, vaccines (preferably vaccines used for vaccination where the amount of an allergen is gradually increased), and combinations thereof. It is preferable to use these therapeutic compositions in combination with the composition described herein.

[0044] When the composition described herein is used as a food or beverage, the food or beverage can be, for example, a health food, a functional food, a food for specified health use, a dietary supplement, a food for patients, or an animal

feed. The food or beverage described herein can be ingested in the forms of the compositions as described above, and also can be ingested in the forms of various foods and beverages. Specific examples of the foods and beverages include various beverages such as juices, refreshing beverages, tea beverages, drink preparations, jelly beverages, and functional beverages; alcoholic beverages such as beers; carbohydrate-containing foods such as rice food products, noodles, breads, and pastas; paste products such as fish hams, sausages, paste products of seafood; retort pouch products such as curries, food dressed with a thick starchy sauces, and Chinese soups; soups; dairy products such as milk, dairy beverages, ice creams, cheeses, and yogurts; fermented products such as fermented soybean pastes, yogurts, fermented beverages, and pickles; bean products; various confectionery products such as Western confectionery products including biscuits, cookies, and the like, Japanese confectionery products including steamed bean-jam buns, soft adzuki-bean jellies, and the like, candies, chewing gums, gummies, cold desserts including jellies, crème caramels, and frozen desserts; instant foods such as instant soups and instant soy-bean soups; microwavable foods; and the like. Further, the examples also include health foods and beverages prepared in the forms of powders, granules, tablets, capsules, liquids, pastes, and jellies. The composition described herein can be used for animals including humans. The animals, other than humans, are not particularly limited, and the composition can be used for various livestock, poultry, pets, experimental animals, and the like. Specific examples of the animals include pigs, cattle, horses, sheep, goats, chickens, wild ducks, ostriches, domestic ducks, dogs, cats, rabbits, hamsters, mice, rats, monkeys, and the like, but the animals are not limited thereto.

[0045] Without wishing to be bound by theory, individuals in which the relative abundance of bacteria belonging to the group Firmicutes (the group to which the Clostridium clusters IV and XIVa belong) is large gain more body weight than individuals in which the relative abundance of bacteria belonging to the group Bacteroidetes is large. Accordingly, the composition described herein is capable of conditioning absorption of nutrients and improving feed efficiency. From such a viewpoint, the composition described herein can be used for promoting body weight gain, or for an animal feed good in feed efficiency.

[0046] Moreover, the addition of the composition described herein to an antibiotic-free animal feed makes it possible to increase the body weight of a subject that ingests the animal feed to a level equal to or higher than those achieved by antibiotic-containing animal feeds, and also makes it possible to reduce pathogenic bacteria in the stomach to a level equal to those achieved by typical antibiotic-containing animal feeds. Accordingly, the composition described herein can be used for an animal feed which does not need the addition of antibiotics.

[0047] In addition, unlike conventional bacteria (Lactobacillus and Bifidobacteria) in commercial use which are not easy to incorporate into the livestock production, the composition of the present invention in the spore form can be pelletized, sprayed, or easily mixed with an animal feed, and also can be added to drinking water.

[0048] The feeding of such an animal feed using the composition described herein is not particularly limited, and the animal feed may be fed to a subject at regular intervals in a selective manner, or may be fed for a certain period (for example, at its birth, during weaning, or when the subject to be fed is relocated or shipped).

[0049] Moreover, from the above-described viewpoint, the composition described herein can be used for malnourished humans. In other words, also when the subject who ingests the composition is a human, the composition described herein can be used for promoting the body weight gain, and enhancing the energy absorption from foods.

[0050] Food or beverage can be manufactured by a manufacturing technique which is well known in the technical field. To the food or beverage, one or more components (for example, a nutrient) which are effective for the improvement of an immune function by the immunosuppressive effect may be added. In addition, the food or beverage may be combined with another component or another functional food exhibiting a function other than the function of the improvement of an immune function to thereby serve as a multi-functional food or beverage.

[0051] Moreover, the composition described herein can be incorporated into foods requiring a processing step which may destroy ordinary probiotic strains. Specifically, most commercially usable probiotic strains cannot be incorporated into foods which need to be processed by any one of a heat treatment, long term storage, a freezing treatment, a mechanical stress treatment, and a high-pressure treatment (for example, extrusion forming or roll forming). On the other hand, because of an advantageous nature of forming spores, the composition of the present invention can be easily incorporated into such processed foods.

[0052] For example, compositions in the form of spore can survive even in a dried food, and can remain living even after being ingested. Likewise, the composition described herein can withstand low-temperature sterilization processes, typically processes at a temperature in a range from 70°C to the boiling point, both inclusive. Thus, the composition described herein can be incorporated into all kinds of dairy products. Furthermore, the composition described herein can withstand long-term storage of many years; high-temperature processing such as baking and boiling; low-temperature processing such as freezing and cold storage; and high-pressure treatments such as extrusion forming and roll forming.

[0053] The foods which need to be processed under such harsh conditions are not particularly limited, and examples thereof include foods which need to be processed in a microwave oven to be edible (for example, oatmeal), foods which need to be baked to be edible (for example, muffin), foods which need to be subjected to a sterilization high-temperature treatment for a short period of time to be edible (for example, milk), and foods which need to be heated to be drinkable

(for example, hot tea).

[0054] When the composition is administered or ingested, the amount thereof for the administration or ingestion is selected as appropriate depending on the age, body weight, symptoms, health conditions, of a subject, the kind of the composition (a pharmaceutical product, a food or beverage, or the like), and the like. For example, the amount per administration or ingestion is generally 0.01 mg/kg body weight to 100 mg/kg body weight, and preferably 1 mg/kg body weight to 10 mg/kg body weight.

[0055] Also described herein is a product of the composition (a pharmaceutical product, a food or beverage, or a reagent) or a manual thereof which may be provided with a note stating that the product can be used to suppress the immunity (including a note stating that the product has an immunosuppressive effect, and a note stating that the product has an effect of suppressing the proliferation or function of effector T-cells). Here, the "provision to the product or the manual thereof with the note" means that the note is provided to a main body, a container, a package, or the like of the product, or the note is provided to a manual, a package insert, a leaflet, or other printed matters, which disclose information on the product.

<Method for Inducing Proliferation or Accumulation of Regulatory T Cells>

[0056] As described above, and as will be shown in Examples, the administration of the composition described herein to an individual makes it possible to induce proliferation or accumulation of regulatory T cells in the individual.

[0057] Note that, the term "individual" as used herein is not particularly limited, and examples thereof include humans, various kinds of livestock, poultry, pets, experimental animals, and the like. The "individual" may be in a healthy state or a diseased state.

[0058] Moreover, as will be shown in Example 5 to be described later, Gram-positive commensal bacteria play principal roles in the proliferation or accumulation of regulatory T cells.

[0059] As used herein, the term "antibiotic against Gram-negative bacteria" is not particularly limited, and examples thereof include aminoglycoside antibiotics (amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, and paromomycin), cephalosporin antibiotics (cefactor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, and cefoxotin), sulfonamides, ampicillin, and streptomycin. Without wishing to be bound by theory, the "antibiotic against Gram-negative bacteria" according to the present invention is preferably one which reduces Gram-negative bacteria, and contributes to the colonization of Gram-positive bacteria.

[0060] Moreover, a prebiotic composition such as almond skin, inulin, oligofructose, raffinose, lactulose, pectin, hemicellulose (such as xyloglucan and alpha-glucans), amylopectin, and resistant starch which are not decomposed in the upper gastrointestinal tract and promote the growth of intestinal microbes in the intestinal tract, as well as growth factors such as acetyl-Co A, biotin, beet molasses, and yeast extracts, contribute to the proliferation of bacteria belonging to the genus Clostridium.

[0061] The above-described "antibiotic against Gram-negative bacteria," and the above-described "prebiotic composition or growth factor" may be used in combination. Such combined use is not particularly limited, and examples of the combined use are as follows: the "antibiotic against Gram-negative bacteria" is administered to an individual in advance, and then the composition of the present invention is administered; the "antibiotic against Gram-negative bacteria" and the composition of the present invention are simultaneously administered to an individual; the "prebiotic composition or growth factor" is administered to an individual in advance, and then the composition of the present invention is administered; the "prebiotic composition or growth factor" and the composition of the present invention are simultaneously administered to an individual; the composition of the present invention, the "antibiotic against Gram-negative bacteria," and the "prebiotic composition or growth factor" are administered to an individual simultaneously or individually at any appropriate time.

[0062] Moreover, a therapeutic composition may be administered to an individual together with at least one substance selected from the group consisting of the composition of the present invention, the "antibiotic against Gram-negative bacteria," and the "prebiotic composition or growth factor."

[0063] Such a therapeutic composition is not particularly limited, and may be at least one therapeutic composition selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-IgE antibodies, vaccines (preferably, vaccines used for vaccination where the amount of an allergen is gradually increased), and combinations thereof. It is preferable to use these therapeutic compositions in combination with the above-described substance.

[0064] Moreover, there is no particular limitation imposed on the combined use of the therapeutic composition with at least one substance selected from the group consisting of the composition described herein, the "antibiotic against Gram-negative bacteria," and the "prebiotic composition or growth factor". For example, the "one substance" and the

therapeutic composition are administered orally or parenterally to an individual simultaneously or individually at any appropriate time.

[0065] Moreover, in the above-described "method for inducing proliferation or accumulation of regulatory T cells," whether or not the administration of the composition described herein or the like actually induces the proliferation or accumulation of regulatory T cells can be determined by using, as an index, increase or reinforcement of at least one selected from the group consisting of the number of regulatory T cells, the ratio of regulatory T cells in the T cell group of the colon, a function of regulatory T cells, and expression of a marker of regulatory T cells. It is preferable to use one measurement selected from the group consisting of promotion of IL-10 expression, promotion of CTLA4 expression, promotion of IDO expression, and suppression of IL-4 expression, as the index of the induction of proliferation or accumulation of regulatory T cells.

[0066] Note that examples of a method for detecting such expression include the northern blotting, the RT-PCR, and the dot blotting for detection of gene expression at the transcription level; and the ELISA, the radioimmunoassay, the immunoblotting, the immunoprecipitation, and the flow cytometry for detection of gene expression at the translation level.

[0067] Meanwhile, a sample used for measuring such an index is not particularly limited, and examples thereof include blood sampled from an individual and tissue pieces obtained in a biopsy.

<Method for Predicting Response of Individual to Composition of Present Invention and/or Prognosis of Individual>

[0068] Described herein is a method in which the absolute amount or the ratio of bacteria belonging to the genus *Clostridium* in a microbiota of an individual is determined, and, when the ratio or the absolute value of the bacteria belonging to the genus *Clostridium* is reduced in comparison with a base line value obtained by performing a similar determination on an individual in a typical health state, it is determined that the individual is possibly responsive to the composition described herein.

[0069] Contemplated herein is a method to predict a subject's response to a substance and/or the subject's prognosis is provided. The method comprises measuring the percentage or absolute amounts of *Clostridium* clusters IV and XIV in the microbiota of the subject and comparing them to a baseline value of the same measurements in a prototypical healthy subject, wherein a decreased absolute amount or percentage level of *Clostridium* clusters IV and/or XIV indicates that the subject may respond favorably to the compositions described herein.

[0070] The method may further comprise measuring the composition of the microbiota of the subject after administration of the substance, wherein an increase in the percentage or absolute number of *Clostridium* spp. belonging to clusters IV, XIV after administration of the compositions of the present invention relative to prior to the administering is a positive indicator of enhanced immunosuppression (or immunoregulation). The measurement of the composition of the subject's microbiota can be made with techniques known in the art, such as 16srRNA sequencing.

[0071] Note that, in these methods, the substance is at least one substance selected from the group consisting of the following (a) to (e) :

- (a) bacteria belonging to the genus *Clostridium* or a physiologically active substance derived from the bacteria;
- (b) a spore-forming fraction of a fecal sample obtained from a mammal or a culture supernatant of the fraction;
- (c) a chloroform-treated fraction of a fecal sample obtained from a mammal or a culture supernatant of the fraction;
- (d) an antibiotic against Gram-negative bacteria; and
- (e) at least one substance selected from the group consisting of almond skin, inulin, oligofructose, raffinose, lactulose, pectin, hemicellulose (such as xyloglucan and alpha-glucans), amylopectin, acetyl-Co A, biotin, beet molasses, yeast extracts, and resistant starch.

<Method for Inhibiting Proliferation or Accumulation of Regulatory T Cells>

[0072] As will be shown in Example 5 to be described later, Gram-positive commensal bacteria have principal roles in the proliferation or accumulation of regulatory T cells. Accordingly, described herein is a method for inhibiting proliferation or accumulation of regulatory T cells in an individual, the method comprising a step of administering an antibiotic against Gram-positive bacteria to the individual.

[0073] As used herein, the term "antibiotic against Gram-positive bacteria" is not particularly limited, and examples thereof include cephalosporin antibiotics (cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, ceftiofur, cefprozil, and ceftibiprole); fluoroquinolone antibiotics (cipro, Levaquin, floxin, tequin, avelox, and norflox); tetracycline antibiotics (tetracycline, minocycline, oxytetracycline, and doxycycline); penicillin antibiotics (amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin, and methicillin); and carbapenem antibiotics (ertapenem, doripenem, imipenem/cilastatin, and meropenem).

[0074] As described above, the term "individual" as used herein is not particularly limited, and examples thereof include humans, various kinds of livestock, poultry, pets, experimental animals, and the like. The "individual" may be in a healthy

state or a diseased state. Such a diseased state is not particularly limited, and examples thereof include states of being subjected to cancer immunotherapy and of suffering from an infectious disease.

[0075] Moreover, as another mode of the "method for inhibiting proliferation or accumulation of regulatory T cells," described herein is a method for inhibiting proliferation or accumulation of regulatory T cells in an individual, the method comprising a step of administering, to the individual, any one of an antibody, an antibody fragment, and a peptide, which are against an antigen that is at least one substance selected from the group consisting of the following (a) to (c):

- (a) bacteria belonging to the genus *Clostridium* or a physiologically active substance derived from the bacteria;
- (b) a spore-forming fraction of a fecal sample obtained from a mammal or a culture supernatant of the fraction; and
- (c) a chloroform-treated fraction of a fecal sample obtained from a mammal or a culture supernatant of the fraction.

<Vaccine Composition and Method for Treating or Preventing Infectious Disease or Autoimmune Disease by Using the Vaccine Composition>

[0076] As described above, and as will be shown in Example 15 to be described later, the induction of Treg cells in the colon by the *Clostridium* has an important role in local and systemic immune responses. Accordingly, also described herein is a "vaccine composition comprising at least one substance selected from the group consisting of the following (a) to (c): (a) bacteria belonging to the genus *Clostridium*; (b) a spore of bacteria in a spore-forming fraction of a fecal sample obtained from a mammal; and (c) bacteria in a chloroform-treated fraction of a fecal sample obtained from a mammal" and a "method for treating, aiding in treating, reducing the severity of, or preventing at least one disease selected from infectious diseases and autoimmune diseases in an individual, the method comprising administering the vaccine composition to the individual."

[0077] Note that such "autoimmune diseases" are not particularly limited, and examples thereof include those described as the "specific examples of target diseases" in <Composition Having Effect of Inducing Proliferation or Accumulation of Regulatory T cells>. The "infectious diseases" are also not particularly limited, and examples thereof include infectious diseases associated with "infectious pathogens" described as the "example of infectious pathogens" in <Composition Having Effect of Inducing Proliferation or Accumulation of Regulatory T cells>.

<Method for Screening for Compound Having Activity to Promote Proliferation or Accumulation of Regulatory T Cells>

[0078] Also described herein is a method for screening for a compound having an activity to promote proliferation or accumulation of regulatory T cells, the method comprising:

- (1) preparing a test substance from at least one substance selected from the group consisting of the following (a) to (c):

- (a) bacteria belonging to the genus *Clostridium* or a physiologically active substance derived from the bacteria;
- (b) a spore-forming fraction of a fecal sample obtained from a mammal or a culture supernatant of the fraction; and
- (c) a chloroform-treated fraction of a fecal sample obtained from a mammal or a culture supernatant of the fraction.

- (2) preparing non-human mammals in which a reporter gene is to be expressed under control of IL-10 gene expression;

- (3) bringing the test substance into contact with the non-human mammal;

- (4) after the contact with the test substance, detecting cells expressing the reporter gene in a CD4⁺ Foxp3⁺ cell group of the non-human mammal, and determining the number of cells in the CD4⁺ Foxp3⁺ cell group expressing the reporter gene or a ratio of cells in the CD4⁺ Foxp3⁺ cell group expressing the reporter gene to cells in the CD4⁺ Foxp3⁺ cell group not expressing the reporter gene;

- (5) detecting cells expressing the reporter gene in a CD4⁺ Foxp3⁺ cell group of the non-human mammal which has not been in contact with the test substance, and determining the number of cells in the CD4⁺ Foxp3⁺ cell group expressing the reporter gene or a ratio of cells in the CD4⁺ Foxp3⁺ cell group expressing the reporter gene to cells in the CD4⁺ Foxp3⁺ cell group not expressing the reporter gene; and

- (6) comparing the absolute numbers or the ratios determined in steps (4) with the number or the ratio determined in (5), and determining, when the number or the ratio determined in (4) is greater than that determined in (5), that the test substance is a compound that promotes proliferation or accumulation of Treg cells.

[0079] The term "test substance" as used herein is not particularly limited, as long as the test substance is a substance prepared from at least one substance selected from the group consisting of the substances (a) to (c). Examples of the test substance include proteins, polysaccharides, lipids, and nucleic acids which are derived from at least one substance selected from the group consisting of the above described substances (a) to (c).

[0080] The term "non-human mammal in which a reporter gene is to be expressed under control of IL-10 gene expression" as used herein is not particularly limited, as long as the non-human mammal is a non-human mammal having a reporter gene whose expression is controlled by an IL-10 gene expression control region (for example, a promoter, or an enhancer). Examples of such a reporter gene include genes encoding fluorescent proteins (for example, GFP), and genes encoding luciferase. As the "non-human mammal in which a reporter gene is to be expressed under control of IL-10 gene expression" according to the present invention, an IL10^{venus} mouse to be shown later in Examples can be preferably used.

[0081] The term "contact" as used herein is not particularly limited, and examples thereof include administration of the test substance to the non-human mammal orally or parenterally (for example, intraperitoneal injection, or intravenous injection).

[0082] Also described herein is a non-human mammal which is used for the method, and in which the reporter gene is to be expressed under the control of the IL-10 gene expression.

[0083] Furthermore, also described herein is a method for isolating, from a sample of bacteria belonging to the genus *Clostridium*, a compound having an activity to promote proliferation or accumulation of regulatory T cells, the method comprising the following steps (1) to (3):

- (1) preparing a genomic DNA from the sample of bacteria belonging to the genus *Clostridium*;
- (2) inserting the genomic DNA into a cloning system, and preparing a gene library derived from the sample of bacteria belonging to the genus *Clostridium*; and
- (3) isolating a compound having an activity to promote proliferation or accumulation of regulatory T cells, by use of the gene library obtained in step (2).

[0084] In such steps, methods for the preparation and the isolation are not particularly limited, and known techniques for an in-vitro or in-vivo system can be used as appropriate. Moreover, the compound isolated by this method is not particularly limited, and examples thereof include nucleic acids (for example, a DNA, a mRNA, and a rRNA) derived from bacteria belonging to the genus *Clostridium*, as well as polypeptides and proteins derived from the bacteria belonging to the genus *Clostridium*.

[0085] Also described herein is a method for determining the composition of a microbiota in an individual, wherein the increase in the ratio or the absolute number of bacteria belonging to the genus *Clostridium* after the administration of the composition as described herein to the individual with respect to the ratio or the absolute number before the administration is used as an index of increased immunosuppression. In such a method, the method for determining the composition of the microbiota is not particularly limited, and known techniques (for example, 16S rRNA sequencing) can be used as appropriate.

[0086] Also described herein is a method for measuring differentiation of Treg cells, wherein the increase in differentiation of Treg cells in an individual after administration of the composition described herein to the individual with respect to that before the administration is used as an index of increased immunosuppression (or immunoregulation).

[0087] Moreover, the composition described herein can also be administered to an individual under an antibiotic treatment. The timing of the administration is not particularly limited, and the composition can be administered before or simultaneously with the antibiotic treatment, for example. Meanwhile, the composition is preferably administered in the spore form from the viewpoint of resistance to antibiotics.

[0088] Moreover, in a preferred mode of such administration, the composition described herein is administered after or simultaneously with administration of an antibiotic against Gram-positive bacteria, for example. Note that such an "antibiotic against Gram-positive bacteria" is not particularly limited, and examples thereof include cephalosporin antibiotics (cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, and ceftibiprole); fluoroquinolone antibiotics (cipro, Levaquin, floxin, tequin, avelox, and norflox); tetracycline antibiotics (tetracycline, minocycline, oxytetracycline, and doxycycline); penicillin antibiotics (amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin, and methicillin); and carbapenem antibiotics (ertapenem, doripenem, imipenem/cilastatin, and meropenem).

[0089] Meanwhile, in another preferred mode of such administration, the composition described herein is administered after (or simultaneously with) a treatment using vancomycin, metronidazole, linezolid, ramoplanin, or fidaxomicin, for example.

[Examples]

[0090] Hereinafter, the present invention is described more specifically on the basis of Examples. However, the present invention is not limited to Examples below.

[0091] Note that mice used in Examples were prepared or produced as follows. In the following description, mice may be referred to with "SPF" or "GF" attached in front thereof. These "SPF" and "GF" indicate that the mice were maintained

in the absence of specific pathogenic bacteria (specific pathogen-free, SPF), and that the mice were maintained under Germ-Free (GF) conditions, respectively.

<Mice>

[0092] C57BL/6, Balb/c, and IqI mice maintained under SPF or GF conditions were purchased from Sankyo Labo Service Corporation, Inc. (Japan), JAPAN SLC, INC. (Japan), CLEA Japan, Inc. (Japan), or The Jackson Laboratory (USA). GF mice and gnotobiotic mice were bred and maintained within the gnotobiotic facility of The University of Tokyo, Yakult Central Institute for Microbiological Research, or Sankyo Labo Service Corporation, Inc. *Myd88*^{-/-}, *Rip2*^{-/-}, and *Card9*^{-/-} mice were produced as described in Non-Patent Documents 1 to 3, and backcrossed for 8 generations or more, so that a C57BL/6 genetic background was achieved. *Foxp3*^{eGFP} mice were purchased from the Jackson Laboratory.

<*Il10*^{venus} mice>

[0093] To form a bicistronic locus encoding both *Il10* and Venus under control of an *Il10* promoter, a targeting construct was first created. Specifically, a cassette (IRES-Venus-SV40 polyA signal cassette, refer to Non-Patent Document 4) which was made of an internal ribosome entry site (IRES), a yellow fluorescent protein (Venus), and a SV40 polyA signal (SV40 polyA) and which was arranged next to a neomycin-resistant gene (neo), was inserted between a stop codon and a polyA signal (Exon 5) of a *Il10* gene. Next, the obtained targeting construct was used to cause homologous recombination with the *Il10* gene region in the genome of mice. Thus, *Il10*^{venus} mice having an *Il10*^{venus} alleles were produced (refer to Fig. 1). Note that in Fig. 1 "tk" represents a gene coding thymidine kinase, "neo" represents the neomycin-resistant gene, and "BamH1" represents a cleavage site by the restriction enzyme BamH1.

[0094] Genomic DNAs were extracted from the *Il10*^{venus} mice, treated with BamH1, and Southern blotted by use of a probe shown in Fig. 1. Fig. 2 shows the obtained results. Wild-type and *Il10*^{venus} alleles were detected as bands having sizes of 19 kb and 5.5 kb, respectively. Hence, as is apparent from the results shown in Fig. 2, it was found that the homologous recombination shown in Fig. 1 occurred in the genome of the *Il10*^{venus} mice.

[0095] Further, CD4⁺ Venus⁻ cells or CD4⁺ Venus⁺ cells in the colonic lamina propria of the *Il10*^{venus} mice were sorted by use of a FACSaria. Then, real-time RT-PCR was carried out on an ABI 7300 system by a method to be described later, to determine the amount of IL-10 mRNA expressed. Figs. 3 and 4 show the obtained results. As is apparent from the results shown in Figs. 3 and 4, it was found that, since the development of the IL-10 mRNA was detected only in the CD4⁺ Venus⁺ cells, the expression of IL-10 mRNA in the *Il10*^{venus} mice was correctly reflected in the expression of Venus. Note that the germ-free states of such *Il10*^{venus} mice were established in Central Institute for Experimental Animals (Kawasaki, Japan). The *Il10*^{venus} mice in the germ-free states were maintained in vinyl isolators in Sankyo Labo Service Corporation, Inc. (Tokyo, Japan), and used in the following Examples.

[0096] Meanwhile, experiments and analyses in Examples were carried out as follows.

<Method for Colonization of Mice with Bacteria and Analysis Thereof>

[0097] According to the description in Non-Patent Documents 5 and 6, mice in which SFB or Clostridium were colonized were produced. Cecal contents or feces of the obtained gnotobiotic mice were dissolved in sterile water or an anaerobic dilution solution. The dissolved cecal contents or feces as they were or after a chloroform treatment were orally administered to GF mice. Three strains of the Lactobacillus and 16 strains of the Bacteroides were cultured separately from each other in a BL or EG agar medium in an anaerobic manner. The cultured bacteria were harvested, suspended in an anaerobic TS broth, and orally administrated forcibly to GF mice. The state of the colonization of the bacteria in the mice was assessed by microscopic observation conducted on a smear preparation of fecal pellets.

<Cell Separation and Flow Cytometry>

[0098] In order to isolate lymphocytes from the colonic lamina propria and the small intestinal lamina propria, the small intestine and the colon were collected, and cut open longitudinally. Then, fecal content and the like therein were washed to remove. Subsequently, the small intestine and the colon were shaken in HBSS containing 5 mM of EDTA at 37°C for 20 minutes. After removal of epithelium and fat tissue, the intestinal tissues were cut into small pieces. To the small pieces, RPMI 1640 (4% fetal bovine serum (FBS), 1 mg/ml of collagenase D, 0.5 mg/ml of dispase, and 40 µg/ml of DNaseI (all of which were manufactured by Roche Diagnostics K.K.)) were added, and the mixture was shaken in a water bath kept at 37°C for 1 hour. The digested tissues were washed with HBSS containing 5 mM of EDTA, and resuspended in 5 ml of 40% percoll (GE Healthcare). The suspension was overlaid on 2.5 ml of 80% percoll in a 15-ml Falcon tube. Then, centrifugation was carried out at room temperature and at 2000 rpm for 20 minutes to conduct

cell separation by percoll density gradient centrifugation. Cells at the interface were collected, and used as lamina propria lymphocytes. The collected cells were suspended in a staining buffer (PBS, 2% FBS, 2 mM EDTA, and 0.09% NaN₃), and stained by use of an anti-CD4 antibody (RM4-5, BD Biosciences) labeled with PE or PE-Cy7. After the staining of CD4, Foxp3 in the cells were stained by use of Cytofix/Cytoperm Kit Plus with GolgiStop (BD Biosciences) or Foxp3 Staining Buffer Set (eBioscience), as well as an anti-Foxp3 antibody (FJK-16s, eBioscience) labeled with Alexa647. Flow cytometry was performed by use of a FACScant II, and the data were analyzed by FlowJo software (TreeStar Inc.). The sorting of the cells were performed by use of a FACSaria.

<Real-Time RT-PCR>

[0099] From an RNA prepared by using RNeasy Mini Kit (Qiagen), a cDNA was synthesized by use of a MMV reverse transcriptase (Promega KK). The obtained cDNA was analyzed by real-time RT-PCR using Power SYBR Green PCR Master Mix (Applied Biosystems) and ABI 7300 real time PCR system (Applied Biosystems), or real-time RT-PCR using SYBR Premix Ex Taq (TAKARA) and Light Cycler 480. For each sample, a value obtained was normalized for the amount of GAPDH. A primer set was designed by using Primer Express Version 3.0 (Applied Biosystems), and those exhibiting a 90% or higher sequence identity at an initial evaluation were selected. The primer set used was as follows:

Foxp3 5'-GGCAATAGTTCCTTCCCAGAGTT-3' (SEQ ID NO: 1) 5'-GGGTCGCATATTGTGGTACTTG-3' (SEQ ID NO: 2)
 CTLA4 5'-CCTTTTGTAGCCCTGCTCACTCT-3' (SEQ ID NO: 3) 5'-GGGTACCTGTATGGCTTCAG-3' (SEQ ID NO: 4)
 GTR 5'-TCAGTGCAAGATCTGCAAGCA-3' (SEQ ID NO: 5) 5'-ACACCGGAAGCCAAACACA-3' (SEQ ID NO: 6)
 IL-10 5'-GATTTTAATAAGCTCCAAGACCAAGGT-3' (SEQ ID NO: 7) 5'-CTTCTATGCAGTTGATGAAGATGTCAA-3' (SEQ ID NO: 8)
 GAPDH 5'-CCTCGTCCCGTAGACAAAATG-3' (SEQ ID NO: 9) 5'-TCTCCACTTTGCCACTGCAA-3' (SEQ ID NO: 10)
 Mmp2 5'-GGACATTGTCTTTGATGGCA-3' (SEQ ID NO: 11) 5'-CTTGTCACGTGGTGTCACTG-3' (SEQ ID NO: 12)
 Mmp9 5'-TCTCTGGACGTCAAATGTGG-3' (SEQ ID NO: 13) 5'-GCTGAACAGCAGAGCCTTC-3' (SEQ ID NO: 14)
 Mmp13 5'-AGGTCTGGATCACTCCAAGG-3' (SEQ ID NO: 15) 5'-TCGCCTGGACCATAAAGAA-3' (SEQ ID NO: 16)
 Ido1 5'-AGAGGATGCGTGACTTTGTG-3' (SEQ ID NO: 17) 5'-ATACAGCAGACCTTCTGGCA-3' (SEQ ID NO: 18).

<Preparation and Culturing of Large Intestinal Epithelial Cells (IECs)>

[0100] First, the colon was collected, cut open longitudinally, and rinsed with PBS. Subsequently, the colon was treated with 1mM dithiothreitol (DTT) at 37°C for 30 minutes on a shaker, and then vortexed for one minute to disrupt the epithelial integrity. The released IECs were collected, and suspended in 5 ml of 20% percoll. The suspension was overlaid on 2.5 ml of 80% percoll in a 15-ml Falcon tube. Then, the tube was centrifuged at 25°C and 780 g for 20 minutes to conduct cell separation by percoll density gradient centrifugation. Cells at the interface were collected, and used as colonic IECs (purity: 90% or higher, viability: 95%). The obtained IECs thus collected were suspended in RPMI containing 10% FBS, and 1×10⁵ cells of the IECs were cultured in a 24-well plate for 24 hours. Thereafter, the culture supernatant was collected, and measured for active TGF-β1 level by ELISA (Promega).

[0101] Meanwhile, for culturing T cells in vitro, 1.5×10⁵ MACS-purified splenic CD4⁺ T cells were cultured in each well of a round-bottomed 96-well plate, together with a 50% conditioned medium in which IECs isolated from GF mice or Clostridium-colonized mice were cultured, and with 25 ng/ml of hIL-2 (Peprotech), in the presence or absence of 25 μg/ml of an anti-TGF-β antibody (R&D). Note that 10 μg/ml of an anti-CD3 antibody and an anti-CD28 antibody (BD Bioscience) were bound to the round-bottomed plate. After a 5-day culture, the CD4⁺ T cells were collected, and subjected to a real-time PCR.

<Colitis Experimental Model>

[0102] A fecal suspension of Clostridium-colonized mice was orally administered to C57BL/6 mice (2-week old), and grown in a conventional environment for six weeks.

[0103] For preparing a DSS-induced colitis model, 2% (wt/vol) DSS (reagent grade, DSS salt, molecular weight = 36 to 50 kD, manufactured by MP Biomedicals), together with drinking water, was given to the mice for six days.

[0104] Meanwhile, for preparing an oxazolone-induced colitis model, the mice were presensitized by transdermally applying, onto the mice, 150 μl of a 3% oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, Sigma-Aldrich)/100% ethanol solution. Five days after that, 150 μl of a 1% oxazolone/50% ethanol solution was intrarectally administered again to the presensitized mice under a light anesthesia. Note that the intrarectal administration was conducted by using

a 3.5F catheter.

[0105] Each mouse was analyzed daily for body weight, occult blood, bleeding visible with the naked eyes (gross blood), and the hardness of stool. Moreover, the body weight loss percentage, intestinal bleeding (no bleeding, occult blood (hemocult+), or bleeding visible with the naked eyes), and the hardness of stool (normal stool, loose stool, or diarrhea) were evaluated numerically, and the disease activity index (DAI) was calculated in accordance with the description in "S. Wirtz, C. Neufert, B. Weigmann, M. F. Neurath, Nat Protoc 2, 541 (2007)."

<OVA Specific IgE Reaction>

[0106] BALB/c SPF mice were inoculated with a fecal suspension of Clostridium-colonized mice (2-week old), and grown in a conventional environment. Then, 1 µg of OVA (grade V, Sigma) and 2 mg of alum (Thermo Scientific), 0.2 ml in total, were intraperitoneally injected to the mice (at their ages of 4 weeks and 6 weeks). Sera were collected every week from the mice at the root of their tail, and OVA-specific IgE was measured by ELISA (Chondrex). Then, at their ages of 8 weeks, splenic cells were collected, inoculated in a 96-well plate at 1×10^6 cells per well, and stimulated with OVA (100 µg/ml) for three days. Thereafter, the culture supernatant was collected, and measured for IL-4 and IL-10 levels by ELISA (R&D).

<Statistical Analysis>

[0107] The difference between control and experimental groups was evaluated by the Student's t-test.

(Example 1)

[0108] First, it was investigated whether or not accumulation of regulatory T cells (Treg cells) in the colonic lamina propria was dependent on commensal bacteria. Specifically, lymphocytes were isolated from peripheral lymph nodes (pLN) of Balb/c mice bred in the absence of specific pathogenic bacteria (SPF) or from lamina propria of the colon or the small intestine (SI) of the mice. The CD4 and Foxp3 were stained by antibodies. Then, the ratio of Foxp3⁺ cells in CD4⁺ lymphocytes was analyzed by flow cytometry. Fig. 5 shows the obtained results. As is apparent from the results shown in Fig. 5, it was found that Foxp3⁺ Treg cells were present at a high frequency in the lamina propria of the gastrointestinal tracts, especially in the colonic lamina propria, of the mice kept under the environment free from specific pathogenic microorganisms (SPF). In addition, it was also found that the number of the Foxp3⁺ Treg cells in the colonic lamina propria gradually increased up to three months after their birth, whereas the number of the Foxp3⁺ Treg cells in the peripheral lymph nodes was basically constant from the time of two weeks after their birth.

(Example 2)

[0109] Next, it was investigated whether or not the temporal accumulation of the Treg cells in the colon as found in Example 1 had a relationship with the colonization of intestinal commensal microbiota. Specifically, the expression of CD4 and the expression of Foxp3 in lymphocytes isolated from the small intestine, the colon, and the peripheral lymph nodes of mice bred under a germ-free (GF) or SPF environment (8 weeks old: Balb/c mice, IqI mice, and C57BL/6 mice) were analyzed. Similar results were obtained in three or more independent experiments. Figs. 6 and 7 show the obtained results. Note that, in Fig. 7, each white circle represents the absolute number of CD4⁺ Foxp3⁺ cells in an individual mouse, and the error bars represent standard deviations (SDs).

[0110] In addition, lamina propria lymphocytes were collected from SPF mice and GF mice (Balb/c mice or C57BL/6 mice). CD4 and Foxp3 were stained with antibodies. Then, the lamina propria lymphocytes were analyzed by FACS. Fig. 8 shows the obtained results. Note that in Fig. 8 each white circle represents the absolute number of CD4⁺ Foxp3⁺ cells in an individual mouse, ** indicates that "P < 0.001", and * indicates that "P < 0.01."

[0111] Further, lymphocytes were isolated from the lamina propria of the colon, the lamina propria of the small intestine (SI), Peyer's patches (PPs), and mesenteric lymph nodes (MLNs) of mice (SPF C57BL/6 mice) to which antibiotics were orally administered with water for eight weeks. CD4 and Foxp3 were stained with antibodies. Then, the lymphocytes were analyzed by FACS. Similar results were obtained in two or more independent experiments. Fig. 9 shows the obtained results (the ratio of the Foxp3⁺ cells in the CD4⁺ cells of an individual mouse). Note that the following antibiotics were used in combination in accordance with the description in the following document:

ampicillin (A; 500 mg/L, Sigma)
vancomycin (V; 500 mg/L, NACALAI TESQUE, INC.)
metronidazole (M; 1g/L, NACALAI TESQUE, INC.)
neomycin (N; 1g/L, NACALAI TESQUE, INC.)

[0112] Rakoff-Nahoum, J. Paglino, F. Eslami-Varzaneh, S. Edberg, R. Medzhitov, Cell 118, 229 (Jul 23, 2004)

[0113] Fagarasan et al., Science 298, 1424 (Nov 15, 2002)

[0114] In Fig. 9, each white circle represents the absolute number of the CD4⁺ Foxp3⁺ cells in an individual mouse, each horizontal bar represents the average value of the absolute numbers, * indicates that "P < 0.01," and "AVMN" represents the kinds of the administered antibiotics by using the first letters of the antibiotics.

[0115] As is apparent from the results shown in Figs. 6 to 9, the frequencies and the absolute numbers of Foxp3⁺ CD4⁺ cells in the small intestine and the peripheral lymph nodes of the GF mice were equal to or greater than those of the SPF mice (refer to Figs. 6 to 8). In addition, the numbers of the Treg cells in the small intestinal lamina propria, Peyer's patches, and mesenteric lymph nodes of the SPF mice to which the antibiotics were orally administered for eight weeks were equal to or greater than those of the SPF mice (refer to Fig. 9). Meanwhile, the number of the Foxp3⁺ CD4⁺ cells in the colonic lamina propria of the GF mice was decreased significantly in comparison with that of the SPF mice (refer to Figs. 6 and 7). This decrease was commonly observed among mice of different genetic backgrounds (Balb/c, IqI, and C57BL/6), as well as among mice bred in different animal facilities (refer to Fig. 7 for the data regarding the different genetic backgrounds, the data regarding the mice bred in the different animal facilities are not shown in the drawings). In addition, it was also shown that the number of Treg cells in the colonic lamina propria of the SPF C57BL/6 mice to which the antibiotics were administered was decreased significantly (refer to Fig. 9).

(Example 3)

[0116] Next, it was directly checked whether or not the decrease in the number of the Treg cells in the colonic lamina propria of the GF mice shown in Example 2 was attributed to the absence of microbiota. Specifically, a fecal suspension of B6 SPF mice purchased from The Jackson Laboratory was orally administered to GF-IqI mice (conventionalization). Three weeks after the administration, lymphocytes were isolated from the colonic lamina propria, and the expression of Foxp3 in CD4⁺ lymphocytes was analyzed. Figs. 10 and 11 show the obtained results. Note that each white circle in Fig. 11 represents the absolute number of CD4⁺ Foxp3⁺ cells in an individual mouse, the error bars represent standard deviations (SD), * indicates that "P < 0.01" in Student's t-test, and ** indicates that "P < 0.001." As is apparent from the results shown in Figs. 10 and 11, the number of Treg cells in the small intestinal lamina propria did not change. However, the number of the Treg cells in the colonic lamina propria increased significantly. Hence, it was shown that host-microbial interaction played an important role in the accumulation of Foxp3⁺ Treg cells in the colonic lamina propria, while the accumulation of the Treg cells in the small intestinal lamina propria had a different mechanism.

(Example 4)

[0117] Next, the relationship between the gut-associated lymphoid tissues of mice and the number of Foxp3⁺ cells in the colonic lamina propria of the mice was investigated in accordance with the method described in M. N. Kweon et al., J Immunol 174, 4365 (Apr 1, 2005). Specifically, 100 µg of an extracellular domain recombinant protein (a fusion protein (LTβR-Ig) between a lymphotoxin β receptor (LTβR) and a Fc region of human IgG1, refer to Honda et al., J Exp Med 193, 621 (Mar 5, 2001)) was injected intraperitoneally into pregnant C57BL/6 mice 14 days after conception. The LTβR-Ig was again injected intraperitoneally into fetuses obtained from such mice, so that mice from which isolated lymphoid follicles (ILFs), Peyer's patches (PPs), and colonic-patches (CPs) were completely removed were produced. Then, the ratios of Foxp3⁺ cells in CD4⁺ cells in the colonic lamina propria of the mice treated with the LTβR-Ig, and mice treated with rat IgG (control) were analyzed by FACS. Fig. 12 shows the obtained results. Note that in Fig. 12 each white circle represents the ratio of Foxp3⁺ cells in an individual mouse, and the error bars represent standard deviations. As is apparent from the results shown in Fig. 12, it was found that the ratio of the Foxp3⁺ cells in the colonic lamina propria of the mice deficient in isolated lymphoid follicles, Peyer's patches, and the colonic-patches (the mice treated with the LTβR-Ig) rather increased. Accordingly, it was suggested that the decrease in the number of the Treg cells in the colonic lamina propria of the GF mice and the mice treated with the antibiotics was caused because the transmission of specific signals which promotes the accumulation of Treg cells in the colonic lamina propria and which is caused by the intestinal microbes did not occur, rather than simply because of a secondary effect of disorganized gut-associated lymphoid tissues.

(Example 5)

[0118] To investigate whether or not a specific intestinal flora induced the accumulation of colonic Treg cells, vancomycin as an antibiotic against Gram-positive bacteria or polymyxin B as an antibiotic against Gram-negative bacteria was administered to SPF mice (from 4 weeks of age) for four weeks, and analyzed for the ratio of Foxp3⁺ cells in the CD4⁺ cell group ([%] Foxp3⁺ in CD4). Fig. 30 shows the obtained results. Note that, in Fig. 30, "SPF" indicates the result of SPF mice (control), "poly B" indicates the result of the SPF mice to which polymyxin B was administered, and "Vanco" indicates the result of the SPF mice to which vancomycin was administered. Meanwhile, * indicates that "P < 0.01."

[0119] As is apparent from the results shown in Fig. 30, the number of Treg cells in the colon of the mice to which vancomycin was administered was markedly decreased in comparison with that of the control. In contrast, no influence was observed on the number of Treg cells of the mice to which polymyxin B was administered. Those facts suggested that Gram-positive commensal bacteria played a major role in accumulation of Treg cells.

(Example 6)

[0120] A recent report has suggested that spore-forming bacteria play an important role in intestinal T cells response (see V. Gaboriau-Routhiau et al., *Immunity* 31, 677 (Oct 16, 2009)). In this respect, fecal microorganisms (spore-forming fraction) resistant to 3% chloroform were orally administered to GF mice, which were then analyzed for the ratio of Foxp3⁺ cells in the CD4⁺ cell group ([%] Foxp3⁺ in CD4). Fig. 31 shows the obtained results. Note that, in Fig. 31, "GF" indicates the result of GF mice, and "+chloro" indicates the result of the GF mice to which the chloroform-treated feces were administered. Meanwhile, ** indicates that "P < 0.001."

[0121] As is apparent from the results shown in Fig. 31, three weeks after the administration of the chloroform-treated feces, the number of Treg cells in the administered mice was markedly increased to the same level as those of the SPF mice and the GF mice to which the untreated feces was forcibly administered (see Figs. 7 and 11).

[0122] Accordingly, considering the results shown in Example 5 in combination, it was revealed that the specific components of the indigenous microbiota were highly likely to belong to the Gram-positive group, and that the spore-forming fraction played an important role in the induction of Treg cells.

(Example 7)

[0123] Next, the species of the intestinal microbiota which induced the accumulation of Treg cells in the colon as suggested in Examples 4 to 6 were identified. Specifically, segmented filamentous bacteria (SFB), 16 strains of the *Bacteroides* spp. (Bactero. (6 strains of *B. vulgatus*, 7 of the *B. acidifaciens* group 1, and 3 of the *B. acidifaciens* group 2)), 3 strains of the *Lactobacillus* (Lacto. (*L. acidophilus*, *L. fermentum*, and *L. murinum*)), and 46 strains of *Clostridium* spp. (Clost., refer to "Itoh, K., and Mitsuoka, T. Characterization of clostridia isolated from faeces of limited flora mice and their effect on caecal size when associated with germ-free mice. *Lab. Animals* 19: 111-118 (1985)"), or microbiota collected from mice (SPF) bred under a conventional environment was orally administered to GF-Balb/c mice or GF-IQI mice. The mice were maintained in vinyl isolators for three weeks. Then, CD4⁺ cells were isolated from the colon and the small intestine of these mice. The numbers of Treg cells in the colon and the small intestine were analyzed by flow cytometry.

[0124] Fig. 13 shows FACS dot-plots obtained when a gate was set on CD4⁺ cells of the Balb/c mice. Fig. 14 shows the ratio of Foxp3⁺ cells in CD4⁺ cells of each mouse.

[0125] Note that, the bacteria belonging to the genus *Clostridium* are classified by sequencing of 16S rRNA gene, as follows. Specifically, the 16S rRNA genes of the bacteria were amplified by PCR using 16S rRNA gene-specific primer pairs: 5'-AGAGTTTGATCMTGGCTCAG-3' (SEQ ID NO: 19) and 5'-ATTACCGCGGCKGCTG-3' (SEQ ID NO: 20) (see T. Aebischer et al., *Vaccination prevents Helicobacter pylori-induced alterations of the gastric flora in mice. FEMS Immunol. Med. Microbiol.* 46,221-229(2006)). The 1.5-kb PCR product was then introduced into pCR-Blunt Vector. The inserts were sequenced and aligned using the ClustalW software program. The resulting sequences of 16S rRNA genes derived from strain 1-41 of 46 strains of *Clostridium* spp. were shown in SEQ ID NO: 21-61. Phylogenetic tree which was constructed by the neighbor-joining method with the resulting sequences of the 41 strains of *Clostridium* and those of known bacteria obtained from Genbank database using Mega software was shown in Fig.49.

[0126] As is apparent from the results shown in Figs. 13 and 14, no effect on the number of the Treg cells in the colon was observed in the GF mice in which the segmented filamentous bacteria (SFB) were colonized (refer to Fig. 14). Moreover, mice in which the cocktail of three strains of *Lactobacillus* was colonized gave similar results (refer to Fig. 14). On the other hand, it was shown that the accumulation of Foxp3⁺ cells in the colonic lamina propria was strongly induced in the mice in which 46 strains of *Clostridium* spp. were colonized. Importantly, such accumulation was promoted irrespective of the genetic backgrounds of the mice, and led to the increase in number similar to that in the SPF mice although intestinal microbiota of only a single genus were colonized. It was also shown that the colonization of the *Clostridium* did not change the number of Treg cells in the small intestinal lamina propria (refer to Fig. 14). Note that, when the 16 strains of *Bacteroides* spp. were colonized, the number of Treg cells in the colon was increased significantly. However, the extent of the increase varied depending on the genetic background of the mice in which the bacteria were colonized (refer to Figs. 13 and 14).

(Example 8)

[0127] Next, CD4 expression, Foxp3 expression, and Helios expression in LP lymphocytes of the thymuses and the

colons of SPF mice, GF mice, Lactobacillus-colonized mice, and Clostridium-colonized mice were analyzed by flow cytometry.

Figs. 32 and 33 show the obtained results. Note that, in Figs. 32 and 33, "GF" or "Germ Free" indicates the results of the GF mice, "SPF" indicates the results of the SPF mice, "Lacto." indicates the results of the Lactobacillus-colonized mice, and "Clost." indicates the results of the Clostridium-colonized mice. In Fig. 32, the vertical axis represents the ratio of Helios⁺ cells in the Foxp3⁺ cell group ([%] Helios⁺ in Foxp3⁺), and ** indicates that "P < 0.001."

[0128] As is apparent from the results shown in Figs 32 and 33, most Foxp3⁺ cells found in the SPF mice or the Clostridium-colonized mice did not express Helios. Note that Helios is a transcription factor known to be expressed in thymic-derived natural Treg cells (see A. M. Thornton et al., J Immunol 184, 3433 (Apr 1, 2010)). Accordingly, it was suggested that most of the Treg cells in the SPF mice and the Clostridium-colonized mice were Treg cells induced in peripheral portions, i.e., so-called iTreg cells.

(Example 9)

[0129] Next, it was investigated whether or not the colonization of the Clostridium or the like had an influence on other T cells. Specifically, SFB, 16 strains of Bacteroides spp. (Bactero.), 46 strains of Clostridium spp. (Clost.), or microbiota collected from mice bred under a conventional environment (SPF) was colonized in GF ICI mice. Three weeks later, lymphocytes in the colonic lamina propria were isolated from these mice, and stimulated with PMA (50 ng/ml) and ionomycin (1 µg/ml) for four hours in the presence of Golgistop (BD Bioscience). After the stimulation was given, intracellular cytokines were stained by using an anti-IL-17 PE antibody (TC11-18H10) and an anti-IFN-γ FITC antibody (BD Bioscience) in accordance with the manual of a cytofix/cytoperm kit (BD Bioscience). Then, the ratio of IFN-γ⁺ cells or IL-17⁺ cells in CD4⁺ leucocytes was analyzed by flow cytometry. Figs. 15 and 16 show the obtained results. Note that, in Figs. 15 and 16, each white circle represents the absolute number of CD4⁺ IFN-γ⁺ cells or the absolute number of CD4⁺ IL-17⁺ cells in each individual mouse, and the error bars represent standard deviations (SD). As is apparent from the results shown in Figs. 15 and 16, the colonization of the Clostridium did not have any influence on Th1 cells (CD4⁺ IFN-γ⁺ cells) in the colon, and caused only a slight increase of Th17 cells (CD4⁺ IL-17⁺ cells). Accordingly, it was suggested that the genus Clostridium was a genus of bacteria which specifically induced Treg cells.

(Example 10)

[0130] It has been reported that 46 strains of Clostridium spp. exert an influence on the accumulation of CD8⁺ intestinal tract intraepithelial lymphocytes (IELs) in the colon. Accordingly, it is conceivable that Clostridium regulates the immune system in various aspects, and that Clostridium exhibits a marked ability to induce and maintain Treg cells especially in the colon, as described above. In addition, a kind of cytokines, transforming growth factor-β (TGF-β), is known to play an important role in regulation of Treg cell generation.

[0131] In this respect, it was examined whether or not the colonization of Clostridium provided a colonic environment rich in TGF-β. Specifically, first, the whole colons of GF mice, Clostridium-colonized mice, and Lactobacillus-colonized mice were cultured for 24 hours, and the culture supernatants thereof were measured for the concentration of active TGF-β (TGF-β1) by ELISA (the number of mice analyzed was four per group). Fig. 34 shows the obtained results. Note that, in Fig. 34, "GF" indicates the result of the GF mice, "Clost." indicates the result of the Clostridium-colonized mice, and "Lacto." indicates the result of Lactobacillus-colonized mice. Meanwhile, * indicates that "P < 0.02," and ** indicates that "P < 0.001."

[0132] As is apparent from the results shown in Fig. 34, the amount of TGF-β produced in the colons of the Clostridium-colonized mice was significantly larger than those of the GF mice and the Lactobacillus-colonized mice.

[0133] Next, intestinal epithelial cells (IECs) of GF mice and Clostridium-colonized mice were cultured for 24 hours, and the culture supernatants thereof were measured for the concentration of active TGF-β (TGF-β1) by ELISA (the number of mice analyzed was four per group). Fig. 35 shows the obtained results. Note that, in Fig. 35, "GF" indicates the result of the GF mice, and "Clost." indicates the result of the Clostridium-colonized mice. Meanwhile, ** indicates that "P < 0.001."

[0134] As is apparent from the results shown in Fig. 35, TGF-β was detected in the culture supernatant of the IECs isolated from the Clostridium-colonized mice, whereas no TGF-β was detected in the culture supernatant of the IECs isolated from the GF mice.

[0135] Next, as described above, splenic CD4⁺ T cells were cultured for five days together with a 50% conditioned medium in which IECs isolated from the GF mice or the Clostridium-colonized mice were cultured, and with the anti-CD3 antibody, in the presence or absence of an anti-TGF-β antibody. Then, the T cells were collected, and analyzed for expression of Foxp3 by real-time RT-PCR. Fig. 36 shows the obtained results. Note that, in Fig. 36, "Medium" indicates the result of a medium in which no cells were cultured, "GF" indicates the result of the conditioned medium in which the IECs of the GF mice were cultured, "Clost." indicates the result of the conditioned medium in which the IECs of the

Clostridium-colonized mice were cultured, and "Clost. + α TGF β " indicates the result of the conditioned medium to which the anti-TGF- β antibody was added and in which the IECs of the Clostridium-colonized mice were cultured. Meanwhile, ** indicates that "P < 0.001."

[0136] As is apparent from the results shown in Fig. 36, when the culture supernatant of the IECs derived from the Clostridium-colonized mice was added to the splenic CD4⁺ T cells, the differentiation into Foxp3-expressing cells was accelerated. Meanwhile, the differentiation into the Treg cells was inhibited by the anti-TGF- β antibody.

[0137] Moreover, the expression of MMP2, MMP9, and MMP13, which are thought to contribute to the activation of latent TGF- β was investigated. The expression of indoleamine 2,3-dioxygenase (IDO), which is thought to be involved in the induction of Treg cells, was also investigated. Specifically, 46 bacterial strains of the genus Clostridium (Clost.), or three bacterial strains of the genus Lactobacillus (Lacto.) were orally administered to C57BL/6 germ-free mice. Three weeks after the administration, IECs were collected, and analyzed for relative mRNA expression levels of MMP2, MMP9, MMP13, and IDO genes by real-time RT-PCR (the number of mice analyzed was three per group). Figs. 37 to 40 show the obtained results. Note that, in Figs. 37 to 40, "GF#1 to 3" indicate the results of GF mice, "Clost.#1 to 3" indicate the results of the Clostridium-colonized mice, and "Lacto.#1 to 3" indicate the results of the Lactobacillus-colonized mice.

[0138] For the relationship between the activation of latent TGF- β and the above-describe MMP, see D'Angelo et al., J. Biol. Chem. 276, 11347-11353, 2001; Heidinger et al., Biol. Chem. 387, 69-78, 2006; Yu et al., Genes Dev. 14, 163-176, 2000. For the relationship between IDO and the induction of Treg cells, see G. Matteoli et al., Gut 59, 595 (May, 2010).

[0139] As is apparent from the results shown in Figs 37 to 39, in agreement with the production of TGF- β described above, transcription products of the genes encoding MMP2, MMP9, and MMP13 were expressed at higher levels in the IECs derived from the Clostridium-colonized mice than those in the GF mice and in the Lactobacillus-colonized mice.

[0140] Moreover, as is apparent from the results shown in Fig. 40, IDO was expressed only in the Clostridium-colonized mice.

[0141] Accordingly, it was revealed that the Clostridium activated the IECs, and led to the production of TGF- β and other Treg cell-inducing molecules in the colon.

(Example 11)

[0142] Next, it was investigated whether or not the Treg cell accumulation induced by the colonization of the Clostridium was dependant on signal transmission by pathogen-associated molecular pattern recognition receptors. Specifically, the numbers of Treg cells in the colonic lamina propria of each of SPF mice of *Myd88*^{-/-} (deficient in Myd88 (signaling adaptor for Toll-like receptor)), *Rip2*^{-/-} (deficient in Rip2 (NOD receptor adaptor)), and *Card9*^{-/-} (deficient in Card9 (essential signal transmission factor for Dectin-1 signal transmission)) were examined. In addition, Clostridium spp. were caused to be colonized in the *Myd88*^{-/-} GF mice, and the change in the number of Treg cells was investigated. Figs. 17 and 18 show the obtained results. As is apparent from the results shown in Figs. 17 and 18, the number of Treg cells of each kind of the SPF mice deficient in the associated factors of the pathogen-associated molecular pattern recognition receptors did not change relative to that of wild-type mice of the same litter, which served as a control. In addition, it was found that also when Clostridium spp. were colonized in GF mice deficient in Myd88, the accumulation of Treg cells in the colonic lamina propria was induced. Accordingly, it has been suggested that the mechanism of inducing the accumulation of Treg cells in the colonic lamina propria relies not on activation of recognition pathway for major pathogen-associated molecular patterns as is caused by most of bacterium, but on specific commensal bacterial species.

(Example 12)

[0143] Intestinal tract Foxp3⁺ Treg cells are known to exert some immunosuppressive functions through IL-10 production (refer to Non-Patent Document 9). Meanwhile, animals having CD4⁺ Foxp3⁺ cells from which IL-10 is specifically removed are known to develop inflammatory bowel disease (refer to Non-Patent Document 18). In this respect, first, the expression of IL-10 in lymphocytes of various tissues was examined. Specifically, lymphocytes were isolated from various tissues of SPF *Il10*^{venus} mice, and the expression of CD4 and the expression of Venus were analyzed by flow cytometry. Fig. 19 shows the obtained results. Note that each numeric value in Fig. 19 represents the ratio of cells within the corresponding one of regions divided into four.

[0144] Moreover, lymphocytes in the colonic lamina propria were isolated from *Il10*^{venus} mice, and the expression of T cell receptor β chain (TCR β) on the surfaces of the cells was detected by FACS. Fig. 20 shows the obtained results (FACS dot-plots obtained when a gate was set on CD4⁺ cells). Note that each numeric value in Fig. 20 represents the ratio of cells within the corresponding one of regions divided into four.

[0145] Furthermore, lymphocytes in the colonic lamina propria were isolated from *Il10*^{venus} mice. The lymphocytes were stimulated with PMA (50 ng/ml) and ionomycin (1 μ g/ml) for four hours in the presence of Golgistop (BD Bioscience). Then, after the stimulation was given, intracellular cytokines were stained by using an anti-IL-17 PE antibody, an anti-IL-4 APC antibody (11B11), and an anti-IFN- γ FITC antibody (BD Bioscience) in accordance with the manual of a

cytofix/cytoperm kit (BD Bioscience). Fig. 21 shows the obtained results (FACS dot-plots obtained when a gate was set on CD4⁺ cells).

Note that each numeric value in Fig. 21 represents the ratio of cells within the corresponding one of regions divided into four.

[0146] In addition, Foxp3⁺ CD4⁺ cells and Foxp3⁻ CD4⁺ cells were isolated from the spleen (Spl) of Foxp3^{eGFP} reporter mice, and Venus⁺ cells were isolated from the colonic lamina propria and the small intestine (SI) lamina propria of Il10^{venus} mice. Then, the obtained cells were analyzed in terms of the expression of predetermined genes. The gene expression was analyzed by real-time RT-PCR using a Power SYBR Green PCR Master Mix (Applied Biosystems) and an ABI 7300 real time PCR system (Applied Biosystems). Here, the value for each cell was normalized for the amount of GAPDH. Fig. 22 shows the obtained results. Note that in Fig. 22 the error bars represent standard deviations.

[0147] As is apparent from the results shown in Figs. 19 to 22, almost no Venus⁺ cells (IL-10-producing cells) were detected in the cervical lymph nodes (peripheral lymph nodes), thymus, peripheral blood, lung, and liver of mice kept under the SPF conditions. Meanwhile, in the spleen, Peyer's patches, and mesenteric lymph nodes thereof, Venus⁺ cells were slightly detected (refer to Fig. 19). On the other hand, many Venus⁺ cells were found in the lymphocytes in the small intestine lamina propria and colonic lamina propria. In addition, most of the Venus⁺ cells in the intestines were positive for CD4, and also positive for T cell receptor β chain (TCR β) (refer to Figs. 19 and 20). Moreover, it was found that the Venus⁺ CD4⁺ T cells expressed Foxp3 and other Treg cell-associated factors such as a cytotoxic T-Lymphocyte antigen (CTLA-4) and a glucocorticoid-induced TNFR-associated protein (GITR) although the Venus⁺ CD4⁺ T cells showed none of the phenotypes of Th2 (IL-4-producing) and Th17 (IL-17-producing) (refer to Figs. 21 and 22). In addition, it was shown that the expression level of CTLA-4 in the intestinal Venus⁺ cells was higher than that in the splenic GFP⁺ Treg cells isolated from the Foxp3^{eGFP} reporter mice (refer to Fig. 22).

(Example 13)

[0148] Venus⁺ cells can be classified into at least two subsets, namely, Venus⁺ Foxp3⁺ double positive (DP) Treg cells and Venus⁺ Foxp3⁻ Treg cells on the basis of intracellular Foxp3 expression. Cells of the latter subset correspond to type 1 regulatory T cells (Tr1) (refer to Non-Patent Documents 8 and 9). In this respect, the Venus⁺ cells (IL-10-producing cells) observed in Example 8 were investigated in terms of the expression of Foxp3. Specifically, the expression of CD4, Foxp3, and Venus in the lamina propria of the colon and the lamina propria of the small intestine of Il10^{venus} mice kept under GF or SPF conditions was analyzed by FACS, and the numbers of Venus⁺ cells in the intestinal tract lamina propria were compared between SPF and GF Il10^{venus} mice. Fig. 23 shows the obtained results (dot-plots obtained when a gate was set on CD4⁺ cells).

[0149] In addition, the intracellular expression of Venus and Foxp3 in CD4 cells in various tissues of SPF Il10^{venus} mice was analyzed by flow cytometry. Fig. 24 shows the obtained results (dot-plots obtained when a gate was set on CD4⁺ cells). Note that each numeric value in Fig. 24 represents the ratio of cells within the corresponding one of regions divided into four.

[0150] Moreover, in order to investigate whether or not the presence of commensal bacteria had any influence on the expression of IL-10 in regulatory cells in the gastrointestinal tracts, germ-free (GF) Il10^{venus} mice were prepared. Then, predetermined species of bacteria were caused to be colonized in the obtained GF Il10^{venus} mice. Three weeks after the species of bacteria were colonized, a CD4⁺ cell group (V⁺F⁻, Venus⁺ Foxp3⁻ cells; V⁺F⁺, Venus⁺ Foxp3⁺ cells; and V⁻F⁺, Venus⁻ Foxp3⁺ cells) in which Foxp3 and/or Venus were expressed in the colon and the small intestine was analyzed by flow cytometry. Fig. 25 shows dot-plots obtained when a gate was set on colonic CD4⁺ cells, and Figs. 26 and 27 show the ratios in the CD4⁺ cell group of each mouse. Note that each numeric value in Fig. 25 represents the ratio of cells within the corresponding one of regions divided into four. Meanwhile, the error bars in Figs. 26 and 27 represent standard deviations, * indicates that "P < 0.02," and ** indicates that "P < 0.001."

[0151] Moreover, in order to check whether or not the presence of commensal bacteria had any influence on the expression of IL-10 in regulatory cells in the gastrointestinal tracts, antibiotics were orally given with water to five or six Il10^{venus} mice per group for 10 weeks. The following antibiotics were used in combination.

ampicillin (A; 500 mg/L Sigma)
vancomycin (V; 500 mg/L NACALAI TESQUE, INC.)
metronidazole (M; 1 g/L NACALAI TESQUE, INC.)
neomycin (N; 1 g/L NACALAI TESQUE, INC.)

[0152] Then, CD4 and Foxp3 of lymphocytes in the lamina propria of the colon, the lamina propria of the small intestine (SI), mesenteric lymph nodes (MLN), and Peyer's patches (PPs) were stained with antibodies, and analyzed by FACS. The results were obtained from two or more independent experiments which gave similar results. Fig. 28 shows the obtained results (the ratio of Venus⁺ cells in CD4⁺ cells in each sample). Note that each white circle in Fig. 28 represents

an individual sample, each horizontal bar represents an average value, * indicates that "P < 0.02," and "AVMN" represents the kinds of the administered antibiotics by using the first letters of the antibiotics.

[0153] As is apparent from the results shown in Figs. 23 and 24, it was shown that the small intestinal lamina propria was rich in Venus⁺ Foxp3⁻ cells, namely, Tr1-like cells, and that the Venus⁺ Foxp3⁺ DP Treg cells were present at a high frequency in the colon of the SPF mice (refer to Figs. 23 and 24). In contrast, although sufficient numbers of Foxp3⁺ cells were observed also in other tissues, the expression of Venus was not observed in almost all of the cells (refer to Fig. 24).

[0154] In addition, as is apparent from the results shown in Figs. 23 and 25 to 28, it was shown that all regulatory T cell fractions of Venus⁺ Foxp3⁻, Venus⁺ Foxp3⁺, and Venus⁻ Foxp3⁺ in the colon significantly decreased under the GF conditions (Figs. 23 and 26 to 27). Moreover, similar decrease in Venus⁺ cells was observed also in the SPF IL10^{Venus} mice treated with the antibiotics (refer to Fig. 28).

[0155] Moreover, as is apparent from the results shown in Figs. 25 to 27, the colonization of Clostridium spp. strongly induced all regulatory T cell fractions of Venus⁺ Foxp3⁻, Venus⁺ Foxp3⁺, and Venus⁻ Foxp3⁺ in the colon, and the degrees of the induction thereof were equal to those in the SPF mice (refer to Figs. 25 and 27). In addition, it was found that the colonization of the three strains of Lactobacillus or the colonization of SFB had an extremely small influence on the number of Venus⁺ and/or Foxp3⁺ cells in the colon (refer to Figs. 25 and 27). Moreover, the colonization of 16 strains of Bacteroides spp. also induced Venus⁺ cells, but the influence of the colonization was specific to Venus⁺ Foxp3⁻ Tr1-like cells (refer to Figs. 25 and 27). On the other hand, it was found that none of the bacterial species tested exerted any significant influence on the number of IL-10-producing cells in the small intestinal lamina propria (refer to Fig. 26).

[0156] Hence, it was shown that the genus Clostridium colonized in the colon or a physiologically active substance derived from the bacteria provided a signal for inducing the accumulation of IL-10⁺ regulatory T cells in the colonic lamina propria or the expression of IL-10 in T cells. Meanwhile, it was shown that the number of Venus⁺ cells in the small intestine was not significantly influenced by the situation where no commensal bacteria were present or commensal bacteria were decreased (refer to Figs. 23 and 26 to 28), and that IL-10⁺ regulatory cells (Tr1-like cells) accumulated in the small intestinal lamina propria independently of commensal bacteria.

(Example 14)

[0157] It was investigated whether or not Venus⁺ cells induced by the genus Clostridium had an immunosuppressive function similar to that of Venus⁺ cells in the colon of SPF mice. Specifically, CD4⁺ CD25⁻ cells (effector T cells, T_{eff} cells) isolated from the spleen were seeded in a flat-bottomed 96-well plate at 2×10^4 /well, and cultured for three days together with 2×10^4 splenic CD11c⁺ cells (antigen-presenting cells) subjected to 30 Gy radiation irradiation treatment, 0.5 µg/ml of an anti-CD3 antibody, and a lot of Treg cells. In addition, for the last six hours, the CD4⁺ CD25⁻ cells were cultured, with [³H]-thymidine (1 µCi/well) was added thereto. Note that, Treg cells used in Example 14 were CD4⁺ GFP⁺ T cells isolated from the spleen of Foxp3^{eGFP} reporter mice, or CD4⁺ Venus⁺ T cells in the colonic lamina propria of GF IL10^{Venus} mice in which Clostridium spp. were colonized or SPF IL10^{Venus} mice. Then, proliferation of the cells was determined based on the uptake amount of [³H]-thymidine, and represented by a count per minute (cpm) value.

[0158] As is apparent from the results shown in Fig. 29, Venus⁺ CD4⁺ cells of the mice in which the genus Clostridium was colonized suppressed in vitro proliferation of CD25⁻CD4⁺ activated T cells. The suppression activity was slightly inferior to that of GFP⁺ cells isolated from the Foxp3^{eGFP} reporter mice, but equal to that of Venus⁺ cells isolated from the SPF IL10^{Venus} mice. Accordingly, it has been shown that the genus Clostridium induces IL-10-expressing T cells having sufficient immunosuppressive activities, and thereby plays a critical role in maintaining immune homeostasis in the colon.

(Example 15)

[0159] Next, the influence, on the local immune response, of the colonization of a large number of Clostridium and the resultant proliferation of Treg cells was investigated.

<Dextran Sulfate Sodium (DSS)-Induced Colitis Model>

[0160] First, the DSS-induced colitis model was prepared as described above, and the influence, on the model mice, of the inoculation of the Clostridium and the proliferation of Treg cells was investigated. Specifically, control mice and Clostridium-inoculated mice were treated with 2% DSS, then observed and measured for six days for the body weight loss, the hardness of stool, and bleeding, and then were evaluated numerically. In addition, on day 6, the colons were collected, dissected, and analyzed histologically by HE staining. Figs. 41 to 43 show the obtained results. Note that, in Figs. 41 to 43, "SPF+Clost." or "SPF+Clost.#1 to 3" indicate the results of C57BL/6 mice inoculated with a fecal suspension of Clostridium-colonized mice, and grown in a conventional environment for six weeks, and "SPF" or "SPF#1 to 3"

indicate the results of C57BL/6 mice (control mice) grown in a conventional environment for six weeks without being inoculated with the fecal suspension. In addition, in Fig. 41, the vertical axis "Disease score" represents the disease activity index (DAI) described above, and the horizontal axis "post 2% DSS (d)" represents the days elapsed after the initial administration of 2% DSS to the mice. Moreover, in Fig. 41, * indicates that "P < 0.02," and ** indicates that "P < 0.001." Meanwhile, Treg cells induced by regulatory dendritic cells are known to play a preventive role in a DSS-induced colitis model (see S. Manicassamy et al., Science 329, 849 (Aug 13, 2010)).

[0161] As is apparent from the results shown in Figs. 41 to 43, the symptoms of the colitis such as body weight loss and rectal bleeding were significantly suppressed in the mice having a large number of Clostridium (hereinafter also referred to as "Clostridium-abundant mice") in comparison with the control mice (see Fig. 41). All the features typical for colonic inflammation, such as shortening of the colon, edema, and hemorrhage, were observed markedly in the control mice in comparison with the Clostridium-abundant mice (see Fig. 42). Moreover, histological features such as mucosal erosion, edema, cellular infiltration, and crypt loss were less severe in the DSS-treated Clostridium-abundant mice than in the control mice (see Fig. 43).

<Oxazolone-Induced Colitis Model>

[0162] Next, the oxazolone-induced colitis model was prepared as described above, and the influence, on the model mice, of the inoculation of Clostridium and the proliferation of Treg cells was investigated. Specifically, control mice and Clostridium-inoculated mice were sensitized with oxazolone, and subsequently the inside of the rectums thereof were treated with a 1% oxazolone/50% ethanol solution. Then, the body weight loss was observed and measured. In addition, the colons were dissected, and analyzed histologically by HE staining. Figs. 44 and 45 show the obtained results. Note that, in Figs. 44 and 45, "SPF+Clost." indicates the results of C57BL/6 mice (Clostridium-abundant mice) inoculated with a fecal suspension of Clostridium-colonized mice, and grown in a conventional environment for six weeks, and "SPF" indicates the results of C57BL/6 mice (control mice) grown in a conventional environment for six weeks without being inoculated with the fecal suspension. In addition, in Fig. 44, the vertical axis "Weight (% of initial)" represents the body weight after the administration of 1% oxazolone where the body weight before the administration was taken as 100%, and the horizontal axis "post 1% oxazolone (d)" represents the days elapsed after the administration of 1% oxazolone to the mice. Meanwhile, it is known that Th2-type T cells are involved in colitis induced by oxazolone. (see M. Boirivant, I. J. Fuss, A. Chu, W. Strober, J Exp Med 188, 1929 (Nov 16, 1998)).

[0163] As is apparent from the results shown in Figs. 44 and 45, the colitis proceeded along with persistent body weight loss in the control mice. Meanwhile, the body weight loss of the Clostridium-abundant mice was reduced (see Fig. 44). In addition, it was also revealed that portions having histological diseases such as mucosal erosion, edema, cellular infiltration, and hemorrhage were reduced in the colon of the Clostridium-abundant mice (see Fig. 45).

(Example 16)

[0164] Next, the influence, on the systemic immune response (systemic IgE production), of the colonization of a large number of Clostridium and the resultant proliferation of Treg cells was investigated. Specifically, as described above, control mice and Clostridium-inoculated mice were immunized by administering alum-absorbed ovalbumin (OVA) twice at a 2-week interval. Then, sera were collected from these mice, and the OVA-specific IgE level thereof was investigated by ELISA. In addition, splenic cells were collected from the mice in each group, and IL-4 and IL-10 production by in-vitro OVA restimulation was investigated. Figs. 46 to 48 show the obtained results. Note that, in Figs. 46 to 48, "SPF+Clost." indicates the results of BALB/c SPF mice (Clostridium-abundant mice) inoculated with a fecal suspension of Clostridium-colonized mice, and grown in a conventional environment, "SPF" indicates the results of BALB/c SPF mice (control mice) grown in a conventional environment without being inoculated with the fecal suspension, and ** indicates that "P < 0.001." Meanwhile, in Fig. 46, the vertical axis "OVA-specific IgE (ng/ml)" represents the concentration of OVA-specific IgE in the sera. Moreover, in Fig. 46, the horizontal axis represents the days elapsed after the initial administration of the alum-absorbed ovalbumin to the Clostridium-abundant mice or the control mice (4-week old), and "OVA+Alum" indicates the timing of the administration of the alum-absorbed ovalbumin. In addition, in Figs. 47 and 48, "OVA" on the horizontal axis indicates the results in the case where the in-vitro OVA restimulation was performed, and "-" indicates the results in the case where no in-vitro OVA restimulation was performed. Moreover, in Figs. 47 and 48, the vertical axes "IL-4 (pg/ml)" and "IL-10 (pg/ml)" show the IL-4 concentration and the IL-10 concentration in culture supernatants of splenic cells, respectively.

[0165] As is apparent from the results shown in Figs. 46 to 48, the IgE level was significantly lower in the Clostridium-abundant mice than in the control mice (see Fig. 46). Moreover, the IL-4 production by the OVA restimulation was reduced (see Fig. 47) and the IL-10 production thereby was increased (see Fig. 48) in the splenic cells of the Clostridium-abundant mice sensitized with OVA and alum, in comparison with those of the control mice.

[0166] Accordingly, in consideration of the results shown in Example 15 in combination, it has been revealed that the

induction of Treg cells by Clostridium in the colon plays an important role in local and systemic immune responses.

(Example 17)

[0167] Next, GF Balb/c were colonized with three strains of Clostridium belonging to cluster IV (strains 22, 23 and 32 listed in Fig.49). Three weeks later, colonic Foxp3⁺ Treg cells were analyzed by FACS. Fig.50 shows the obtained results. As is apparent from the results shown in Fig. 50, gnotobiotic mice colonized with three strains of Clostridium showed an intermediate pattern of Treg induction between GF mice and mice inoculated with all 46 strains.

(Example 18)

[0168] Next, it was investigated whether or not a spore-forming (for example, a chloroform resistant) fraction of a fecal sample obtained from humans had the effect of inducing proliferation or accumulation of regulatory T cells similar to the spore-forming fraction of the fecal sample obtained from mice.

[0169] Specifically, human stool from a healthy volunteer (Japanese, male, 29 years old) was suspended with phosphate-buffered saline (PBS), mixed with chloroform (final concentration 3%), and then incubated in a shaking water bath for 60 min. After evaporation of chloroform by bubbling with N₂ gas, the aliquots containing chloroform-resistant (for example, spore-forming) fraction of human intestinal bacteria were orally inoculated into germ-free (GF) mice (IQ1, 8 weeks old). The treated mice were kept in a vinyl isolator for 3 weeks. The colon was collected and opened longitudinally, washed to remove fecal content, and shaken in Hanks' balanced salt solution (HBSS) containing 5 mM EDTA for 20 min at 37°C. After removing epithelial cells and fat tissue, the colon was cut into small pieces and incubated with RPMI1640 containing 4% fetal bovine serum, 1 mg/ml collagenase D, 0.5 mg/ml dispase and 40 µg/ml DNase I (all manufactured by Roche Diagnostics) for 1 hour at 37 °C in a shaking water bath. The digested tissue was washed with HBSS containing 5 mM EDTA, resuspended in 5 ml of 40% Percoll (manufactured by GE Healthcare) and overlaid on 2.5 ml of 80% Percoll in a 15-ml Falcon tube. Percoll gradient separation was performed by centrifugation at 780 g for 20 min at 25 °C. The interface cells were collected and suspended in staining buffer containing PBS, 2% FBS, 2 mM EDTA and 0.09% NaN₃ and stained for surface CD4 with Phycoerythrin-labeled anti-CD4 Ab (RM4-5, manufactured by BD Biosciences). Intracellular staining of Foxp3 was performed using the Alexa647-labeled anti-Foxp3 Ab (FJK-16s, manufactured by eBioscience) and Foxp3 Staining Buffer Set (manufactured by eBioscience). The percentage of Foxp3 positive cells within the CD4 positive lymphocyte population was analyzed by flow cytometry. Figs. 51 and 52 show the obtained results.

[0170] In figures, representative histograms (Fig. 51) and combined data (Fig. 52) for Foxp3 expression by CD4 positive lymphocytes from GF mice (GF) or GF mice gavaged with chloroform-treated human stool (GF+Chloro.) are shown. In addition, numbers in Fig. 51 indicate the percentages of cells in the gate. Each circle in Fig. 52 represents a separate animal, error bars indicate the SD, and ** indicates that "P < 0.001."

[0171] As is apparent from the results shown in Figs. 51 and 52, it was found that also when the spore-forming (for example, the chloroform resistant) fraction of human intestinal bacteria was colonized in GF mice, the accumulation of Foxp3⁺ regulatory (Treg) cells in the colonic lamina propria of the mice was induced.

[0172] Next, it was investigated what species of bacteria grew by gavaging with chloroform-treated human stool.

[0173] Specifically, using a QIAamp DNA Stool mini kit (manufactured by QIAGEN), bacterial genomic DNA was isolated from the human stool from a healthy volunteer as described above (human stool) or fecal pellets from GF mice gavaged with chloroform-treated human stool (GF+Chloro.). Quantitative PCR analysis was carried out using a Light-Cycler 480 (manufactured by Roche). Relative quantity was calculated by the ΔCt method and normalized to the amount of total bacteria, dilution, and weight of the sample. The following primer sets were used:

5'-GGTGAATACGTTCCCGG-3' (SEQ ID NO: 62) and
5'-TACGGCTACCTTGTTACGACTT-3' (SEQ ID NO: 63)

Clostridium cluster XIVa (Clostridium coccoides subgroup)

[0174]

5'-AAATGACGGTACCTGACTAA-3' (SEQ ID NO: 64) and 5'-CTTTGAGTTTCATTCTTGCGAA-3' (SEQ ID NO: 65)

[0175] Clostridium cluster IV (Clostridium leptum)

5'-GCACAAGCAGTGGAGT-3' (SEQ ID NO: 66) and

5'-CTTCCTCCGTTTTGTCAA-3' (SEQ ID NO: 24)

Bacteroides

5'-GAGAGGAAGGTCCCCCAC-3' (SEQ ID NO: 67) and

5'-CGCTACTTGGCTGGTTCAG-3' (SEQ ID NO: 68).

[0176] Fig. 53 shows the obtained results.

[0177] As is apparent from the results shown in Fig. 53, mice gavaged with chloroform-treated human stool exhibited high amounts of spore-forming bacteria, such as Clostridium clusters XIVa and IV, and a severe decrease of non-spore-forming bacteria, such as Bacteroides, compared with the human stool before chloroform treatment.

[Industrial Applicability]

[0178] As has been described above, the present invention makes it possible to provide an excellent composition for inducing proliferation or accumulation of regulatory T cells (Treg cells) by utilizing bacteria belonging to the genus Clostridium or a physiologically active substance or the like derived from the bacteria. Since the composition of the present invention has immunosuppressive effects, the composition can be used, for example, to prevent or treat autoimmune diseases or allergic diseases, as well as to suppress immunological rejection in organ transplantation or the like. In addition, healthy individuals can easily and routinely ingest the composition as a food or beverage, such as a health food, to improve their immune functions.

[Sequence Listing]

[0179]

SEQ ID NO:1 to 20, 62 to 69

<223> Artificially synthesized primer sequence

[0180] SEQ ID NO:21 to 61

<223> 16S rRNA coding gene sequence of each Clostridium strain

SEQUENCE LISTING

[0181]

<110> The University of Tokyo

<120> Composition for inducing proliferation or accumulation of regulatory T cells

<130> 11B1040011

<150> JP2010/129134

<151> 2010-06-04

<150> PCT/JP2010/071746

<151> 2010-12-03

<160> 69

<170> PatentIn version 3.1

<210> 1

<211> 23

<212> DNA

<213> Artificial

<220>

<223> Artificially synthesized primer sequence

<400> 1

ggcaatagtt ccttcccaga gtt 23

<210> 2

<211> 22

<212> DNA

<213> Artificial

Amended paragraph [0178]
(paragraphs [0175] to [0177] and [0179] to [0181] unamended)
EP 2 575 835 B1

5'-CTTCCTCCGTTTGTCAA-3' (SEQ ID NO: 24)

Bacteroides

5'-GAGAGGAAGGTCCCCCAG-3' (SEQ ID NO: 67) and

5'-CGCTACTTGGCTGGTTCAG-3' (SEQ ID NO: 68).

[0176] Fig. 53 shows the obtained results.

[0177] As is apparent from the results shown in Fig. 53, mice gavaged with chloroform-treated human stool exhibited high amounts of spore-forming bacteria, such as Clostridium clusters XIVa and IV, and a severe decrease of non-spore-forming bacteria, such as Bacteroides, compared with the human stool before chloroform treatment.

[Industrial Applicability]

[0178] As has been described above, the present invention makes it possible to provide an excellent composition for inducing proliferation or accumulation of regulatory T cells (Treg cells) by utilizing bacteria belonging to the genus Clostridium or a physiologically active substance or the like derived from the bacteria. Since the composition of the present invention has immunosuppressive effects, the composition can be used, for example, to prevent or treat autoimmune diseases or allergic diseases, as well as to suppress immunological rejection in organ transplantation or the like. In addition, healthy individuals can easily and routinely ingest the composition as a food or beverage, such as a health food, to improve their immune functions.

[Sequence Listing]

[0179]

SEQ ID NO:1 to 20, 62 to 69

<223> Artificially synthesized primer sequence

[0180] SEQ ID NO:21 to 61

<223> 16S rRNA coding gene sequence of each Clostridium strain

SEQUENCE LISTING

[0181]

<110> The University of Tokyo

<120> Composition for inducing proliferation or accumulation of regulatory T cells

<130> 11B1040011

<150> JP2010/129134

<151> 2010-06-04

<150> PCT/JP2010/071746

<151> 2010-12-03

<160> 69

<170> PatentIn version 3.1

<210> 1

<211> 23

<212> DNA

<213> Artificial

<220>

<223> Artificially synthesized primer sequence

<400> 1

ggcaagagtt cctccaga gtt 23

<210> 2

<211> 22

<212> DNA

<213> Artificial

20.2.2019

J. GLE

OGLE, JAMES

EP 2 575 835 B1

<220>
 <223> Artificially synthesized primer sequence
 <400> 2
 gggtcgcata ttgtgtact tg 22
 5 <210> 3
 <211> 23
 <212> DNA
 <213> Artificial
 <220>
 10 <223> Artificially synthesized primer sequence
 <400> 3
 cctttgtag ccctgtcac tct 23
 <210> 4
 <211> 21
 15 <212> DNA
 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 <400> 4
 20 gggtcacctg tatggcttca g 21
 <210> 5
 <211> 21
 <212> DNA
 <213> Artificial
 25 <220>
 <223> Artificially synthesized primer sequence
 <400> 5
 tcagtgaag atctgaagc a 21
 <210> 6
 30 <211> 19
 <212> DNA
 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 35 <400> 6
 acaccggaag ccaaacaca 19
 <210> 7
 <211> 27
 <212> DNA
 40 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 <400> 7
 gattttaata agctccaaga ccaaggt 27
 45 <210> 8
 <211> 27
 <212> DNA
 <213> Artificial
 <220>
 50 <223> Artificially synthesized primer sequence
 <400> 8
 cttctatgca gttgatgaag atgtcaa 27
 <210> 9
 <211> 21
 55 <212> DNA
 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence

EP 2 575 835 B1

<400> 9
 cctcgtcccg tagacaaaat g 21
 <210> 10
 <211> 20
 5 <212> DNA
 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 <400> 10
 10 tctccacttt gccactgcaa 20
 <210> 11
 <211> 20
 <212> DNA
 <213> Artificial
 15 <220>
 <223> Artificially synthesized primer sequence
 <400> 11
 ggacattgtc ttgatggca 20
 <210> 12
 20 <211> 20
 <212> DNA
 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 25 <400> 12
 cltgtcacgt ggtgcactg 20
 <210> 13
 <211> 20
 <212> DNA
 30 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 <400> 13
 tctctggacg tcaaattgtg 20
 35 <210> 14
 <211> 19
 <212> DNA
 <213> Artificial
 <220>
 40 <223> Artificially synthesized primer sequence
 <400> 14
 gctgaacagc agagccttc 19
 <210> 15
 <211> 20
 45 <212> DNA
 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 <400> 15
 50 aggtctggat cactccaagg 20
 <210> 16
 <211> 19
 <212> DNA
 <213> Artificial
 55 <220>
 <223> Artificially synthesized primer sequence
 <400> 16
 tcgcctggac cataaagaa 19

<210> 17
 <211> 20
 <212> DNA
 <213> Artificial
 5 <220>
 <223> Artificially synthesized primer sequence
 <400> 17
 agaggatgcg tgactttgtg 20
 <210> 18
 10 <211> 20
 <212> DNA
 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 15 <400> 18
 atacagcaga cctctggca 20
 <210> 19
 <211> 20
 <212> DNA
 20 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 <400> 19
 agagtttgat cmtggctcag 20
 25 <210> 20
 <211> 16
 <212> DNA
 <213> Artificial
 <220>
 30 <223> Artificially synthesized primer sequence
 <400> 20
 attaccgagg ckgctg 16
 <210> 21
 <211> 1460
 35 <212> DNA
 <213> Clostridium leptum
 <220>
 <221> rRNA
 <222> (1)..(1460)
 40 <223> 16S rRNA coding gene sequence of Clostridium strain 1
 <400> 21
 45
 50
 55

EP 2 575 835 B1

	agagtttgat cctggctcag gatgaacgct ggcggcgtgc ttaacacatg caagtogaac	60
	gagaaccatt ggatcgagga ttcgtccaag tgaaggtggg gaaagtggcg gacgggtgag	120
5	taacgcgtga gcaatctgcc ttggagtggg gaataacggc tggaaacagc cgctaatacc	180
	gcatgataca gctgggaggc atctccctgg ctgtcaaaga tttatcgctc tgagatgagc	240
	tcgcgtctga ttagctagtt ggcggggtaa cgccccacca aggcgacgat cagtagccgg	300
10	actgagaggt tggccggcca cattgggact gagacacggc ccagactcct acgggaggca	360
	gcagtgggga atattgggca atgggcgcaa gcctgaccca gcaacgccgc gtgaaggaag	420
	aaggctttcg ggttgtaaac ttcttttgtc agggacgaag caagtgacgg tacctgacac	480
15	ggctactacg gtcagcagcg cgtatacgta ggtgccagcg tatccggaat tacctgggtt	540
	aaggcgtggt agccggactg cagtcagatg tgaatcacgg gctcaacttg tgetgcattg	600
20	gaactgtagt tctgagtact gagagcagac ggaattctag gtagcgggtga atgcgtagat	660
	ataggaggac acagtgcgag gcgtctgctg acagcaactg acgctgaggc gggaagcgtg	720
	ggggagccaa caggattaga tacctggtag ttcacgcctg gtaaaacgat ggatactagg	780
25	tgtgggggga ctgacccctt cgtggccgcc agttaacacc aataaagtat cccacctggg	840
	agtacgatcg caaggttgaa actcaaagga attgacgggg cccgcacaag cgggtggagta	900
	tgtggtttaa ttcgaagcaa cgcaagaac cttaccaggg cttgacatcc cgaggaccgg	960
30	actagagata gtcttttctc ttcggagacc tcggtgacag gtggtgcatg gttgtcgtca	1020
	gctcgtgtcg taagatggtg ggttaagtcc cgcaacgagc gcaaccctta ttgttagttg	1080
	ctacgcaaga gcaactctagc gagactgccg ttgacaaaac ggaggaaggt ggggacgacg	1140
35	tcaaatcatc atgcccctta tgtcctgggc cacacacgta ctacaatggt ggtcaacaga	1200
	gggaagcaat accgcgaggt ggagcaaadc cctaaaagcc atcccagttc ggatcgagc	1260
40	ctgcaaccgg cctgcgtgaa gttggaatcg ctagtaatcg cggatcagca tgccgcggtg	1320
	aatacgttcc cgggccttgt acacaccgcc cgtcacacca tgagagtcgg gaacaccgca	1380
	agtcgtagc ctaaccgcaa gggggggcgc ggccgaaggt gggttcgata attggggtga	1440
45	agtcgtaaca aggtagccgt	1460

<210> 22

<211> 1485

<212> DNA

50 <213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1485)

<223> 16S rRNA coding gene sequence of Clostridium strain 2

55 <400> 22

EP 2 575 835 B1

agagtttgat cctggctcag gatgaacgct ggcggtgctg ttaacacatg caagtcgaac 60
 ggagcaccac tgaaggagtt ttcggacaac ggaagggact gcttagtggt ggacgggtga 120
 5 gtaacgcgtg aggaacctgc cttggagtgg ggaataacag ctggaaacag ctgctaatac 180
 cgcataatat atctgggccc catggctctg gatatcaaag atttatcgct ctgagatgga 240
 ctgcgctctg attagctagt tggcggggta acggcccacc aaggcgacga tcagtagccg 300
 10 gactgagagg ttggccggcc acattgggac tgagacacgg cccagactcc tacgggagggc 360
 agcagtgggg aatattgggc aatgggcgca agcctgacct agcaacgccg cgtgaaggaa 420
 gaaggctttc ggggtgtaaa cttcttttgt cagggacgaa gcaagtgcgc gtacctgacg 480
 15 aataagccac ggctaactac gtgccagcag ccgcggtaat acgtagggtg caagcgttat 540
 ccggatttac tgggtgtaaa gggcggtgtag gcgggactgc aagtcagatg tgaaaaccac 600
 20 gggctcaacc tgtgggcctg cttttgaaac tgtagttctt gactactgga gaggcagacg 660
 gaattctagt tgtagcgtga aatgcgtaga tatagaagaa cacagttgcg gagccggtct 720
 gcaactgacg ctgagcgcga aagcgtgggg agcaaacagg attagatacc ctggtagtcc 780
 25 acgctgtaaa cgatggatta ctagggtgtg ggggactgac cccctccgtg ccgcagttaa 840
 cacaataagt atcccacctg gggagtacga tcgcaagggt gaaactcaaa aggaattgac 900
 gggggccccc acaagcgggt gagtatgtgg tttaaattcg aagcaacgcg aagaacctta 960
 30 ccagggtctg acatcccggg gaccgtccta gagataggat ttcccttcg gggacactgg 1020
 agacaggtgg tgcattggtg tcgtcagctc gtgtcgtgag atgttgggtt aagtcgccga 1080
 acgagcgcaa cccttattgt tagttgctac gcaagagcac tctagcgaga ctgccgttga 1140
 35 caaaacggag gaagggtggg acgacgtcaa atcatcatgc cccttatgtc ctgggccaca 1200
 cacgtactac aatggtgggt aacagaggga agcaaagccg cgagggtggag caaatcccta 1260
 aaagccatcc cagttcggat cgcaggctgc aaccgcctg cgtgaagttg gaatcgctag 1320
 40 taatcgcgga tcagaatgcc gcggtgaata cgttcccggg ccttgtagac accgcccgtc 1380
 acaccatgag agtcgggaac acccgaagtc cgtagcctaa ccgcaagggg ggcgcggccg 1440
 45 aagggtgggt cgataattgg ggtgaagtcg taacaaggta gccgt 1485

<210> 23

<211> 1491

<212> DNA

50 <213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1491)

<223> 16S rRNA coding gene sequence of Clostridium strain 3

55 <400> 23

EP 2 575 835 B1

agagtttgat cctggctcag gacgaacgct ggcggtgtgc ttaacacatg caagtcgaac 60
 ggagcacctt cgaaagagac ttcgggtcaat ggaaaagaat gcttagtggtc ggacgggtga 120
 5 gtaacgcgtg aggaacctgc ctttcagtgg gggacaacag ttggaaacga ctgctaatac 180
 cgcataacgt acgggtatcg catgggtatct gtaccaaaga tttatcgctg agagatggcc 240
 tcgctgtcga ttagctagtt ggtagggtta cggcctacca aggcgacgat cagtagccgg 300
 10 actgagaggt tggccggcca cattgggact gagatacggc ccagactcct acgggaggca 360
 gcagtgggga atattgggca atgggagaaa gcctgaccca gcaacgccgc gtgaaggaag 420
 aaggctttcg ggttgtaaac ttcttttgac ggggaagagc agaagacggt acctgtcgaa 480
 15 taagccacgg ctaactacgt gccagcagcc gcggttaatac gtaggtggca agcgttgtcc 540
 ggatttactg ggtgtaaagg gcgtgtagcc gggctgacaa gtcagatgtg aaatccgggg 600
 gctcaacccc cgaactgcat ttgaaactgt tggctctgag tatcgagagc gcaggcggaa 660
 20 ttcctagtgt agcgggtgaaa tgcgtagata ttagggggaa caccagtggc gaagcggcct 720
 gctggacgac aactgacggt gaggcgcgaa agcgtgggga gcaaacagga ttagataccc 780
 tggtagtcca cgctgtaaac gatggatact aggtgtgcgg ggactgacct ctgcgtgccg 840
 25 cagctaacgc aataagtatc ccacctgggg agtacgatcg caagggtgaa actcaaagga 900
 attgacgggg gcccgcacaa gcggtggatt atgtggttta attcgatgca acgcgaagaa 960
 30 ccttaccagg gcttgacatc ctactaacga agtagagata cattaggtac ccttcggggg 1020
 aagtagagac aggtggtgca tgggtgtcgt cagctcgtgt cgtgagatgt tgggttaagt 1080
 cccgcaacga gcgcaacct tattgttagt tgctacgcaa gagcactcta gcgagactgc 1140
 35 cgttgacaaa acggaggaag gtggggacga cgtcaaatca tcatgcccct tatgtcctgg 1200
 gctacacacg taatacaatg gcggtcaaca gagggatgca aaaccgcgag gtggagcgaa 1260
 cccctaaaag ccgtcccagt tcagatcgca gtctgcaacc cgactgcgtg aagtcggaat 1320
 40 cgctagtaat cgcggatcag catgccgcgg tgaatacgtt cccgggcctt gtacacaccg 1380
 cccgtcacac catgagagtc gggaacaccc gaagtcgta gcctaaccgc aaggagggcg 1440
 45 cggccgaagg tgggttcgat aattgggggtg aagtcgtaac aaggtagccg t 1491

<210> 24

<211> 1491

<212> DNA

50 <213> Clostridium coccoides

<220>

<221> rRNA

<222> (1)..(1491)

<223> 16S rRNA coding gene sequence of Clostridium strain 4

55 <400> 24

EP 2 575 835 B1

agagtttgat cctggctcag gatgaacgct ggcggcgtgc ctaacacatg caagtcgaac 60
gggtgtacgg ggaggaaggc ttcggccgga aaacctgtgc atgagtggcg gacgggtgag 120

5

taacgcgtgg gcaacctggc ctgtacaggg ggataacact tagaaatagg tgctaatacc 180
gcataacggg ggaagccgca tggcttttcc ctgaaaactc cggtggtaca ggatgggccc 240
10 gcgtctgatt agccagttgg cagggtaacg gcctaccaa gcgacgatca gtagccggcc 300
tgagagggcg gacggccaca ctgggactga gacacggccc agactcctac gggaggcagc 360
agtgggggat attgcacaat ggggggaaac cctgatgcag cgacgccgcg tgagtgaaga 420
15 agtatttcgg tatgtaaagc tctatcagca gggaagaaaa tgacggtacc tgactaagaa 480
gccccggcta actacgtgcc agcagccgcg gtaatacgta gggggcaagc gttatccgga 540
20 ttactgggt gtaaaggag cgtagacggc agcgcaagtc tgagtgaat cccatggctt 600
aaccatggaa ctgctttgga aactgtgcag ctggagtga ggagagtaag cggaattcct 660
agtgtagcgt gaaatgcgta gattatagga ggaacaccag tggcgaaggc ggctaactga 720
25 actgtaactg acgttgaggc tcgaaagcgt ggggagcaaa caggattaga taccctggta 780
gtccacgccg taaacgatga ttactaggtg ttgggggacc aaggtcttcg gtgccggcgc 840
aaacgcatta agtaatccac ctggggagta cgttcgcaag aatgaaactc aaaggaattg 900
30 acggggaccc gcacaagcgg tggagcatgt ggtttaattc gaagcaacgc gaagaacctt 960
acctggtctt gacatcccga tgacgagtga gcaaagtcac tttcccttcg gggcattgga 1020
gacaggtggt gcatggttgt cgtcagctcg tgcgtgaga tgttgggtta agtcccgcaa 1080
35 cgagcgcaac ccctatttcc agtagccagc aggtagagct gggcactctg gagagactgc 1140
ccgggataac cgggaggaag gcggggatga cgtcaaatca tcatgcccct tatgatcagg 1200
gctacacacg tgctacaatg gcgtaaaaa agggaagcga gacggtgacg ttgagcaaat 1260
40 cccaaaaata acgtcccagt tcggattgta gtctgcaact cgactacatg aagctggaat 1320
cgctagtaat cgcgaatcag aatgtcgcgg tgaatacggt cccgggtctt gtacacaccg 1380
45 cccgtcacac catgggagtc ggaaatgccc gaagtcagtg acctaaccga aaggaaggag 1440
ctgccgaagg tggagccggt aactggggtg aagtcgtaac aaggtagccg t 1491

50

<210> 25
<211> 1467
<212> DNA
<213> Clostridium leptum
<220>
<221> rRNA
55 <222> (1)..(1467)
<223> 16S rRNA coding gene sequence of Clostridium strain 5
<400> 25

EP 2 575 835 B1

agagtttgat cctggctcag gacgaacgct ggcggcacgc ctaacacatg caagtcgaac 60
 ggagtgaaga tgctcgcatac tgaacttagt ggcggacggg tgagtaacac gtgagcaacc 120
 5 tgcctttcag agggggatta cgtttggaaa cgaacgctaa taccgcataa aatatacgag 180
 tcgcatggca ctgatatcaa aggagcaatc cgctgaaaga tgggctcgcg tccgattagg 240
 cagttggcgg ggtatcggcc caccaaaccg acaatcggtg gccggactga gaggttgaac 300
 10
 ggccacattg ggactgagac gcggcccaga ctctacggg aggcagcagt gggggatatt 360
 gcacaatggg ggaaaccctg atgcagcgat gccgcgtgaa tgaagacggc cttcgggttg 420
 15 taaagttctg tcgcagggga cgaaaatgac ggtaccctgc aagaaagctc cggctaacta 480
 cgtgccagca gccgcggtaa tacgtaggga gcaagcgttg tccggaatta ctgggtgtaa 540
 agggagcgta ggcgggagga taagttgaat gtgaaatcta tgggctcaac ccatagctgc 600
 20 gttcaaactg ttcttcttga gtgaagtaga ggcaggcgga attcctagt tagcggtgaa 660
 atgcgtagat attaggagga caccagtggc gaaggcgggc tgctgggctt tactgacgct 720
 25 gaggctcgaa agcgtgggta gcaaacagga ttagataccc tggtagtcca cgcggtaaac 780
 gatgattact aggtgtgggt ggactgacc catccgtgcc ggagttaaca caataagtaa 840
 tccacctggg gagtacggcc gcaaggttga aactcaaagg aattgacggg ggcccgcaca 900
 30 agcagtggag tatgtggttt aattcgacgc aacgcgaaga accttaccag gtcttgacat 960
 cgagtgcagg acatagagat atgtctttcc ttcgggacac gaagacaggt ggtgcatggt 1020
 tgtcgtcagc tcgtgtcgtg agatggtggg ttaagtcccg caacgagcgc aacccttacc 1080
 35 attagttgct acgcaagagc actctaattg gactgccgtt gacaaaacgg aggaagggtg 1140
 ggatgacgtc aaatcatcat gcccttatg acctgggcga cacacgtact acaatggcgg 1200
 tcaacagagg gaggcaaagc cgcgaggcag agcaaaccac taaaagccgt ctgagttcgg 1260
 40 attgcaggct gcaactcgcc tgcataaggt cggaattgct agtaatcgcg gatcagcatg 1320
 ccgcggtgaa tacgttcccc ggccctgtac acaccgcccg tcacaccatg agagccggta 1380
 45 acaccggaag tcaatagtct aaccgcaagg aggacattgc cgaagggtgg attggttaatt 1440
 ggggtgaagt cgtaacaagg tagccgt 1467

50 <210> 26
 <211> 1474
 <212> DNA
 <213> Clostridium coccooides
 <220>
 <221> rRNA
 55 <222> (1)..(1474)
 <223> 16S rRNA coding gene sequence of Clostridium strain 6
 <400> 26

EP 2 575 835 B1

	agagtttgat catggctcag gatgaacgct ggcggcgtgc ctaacacatg caagtcgaac	60
	gggtgtacgg gaaggaaggc ttcggccgga aaacctgtgc atgagtggcg gacgggtgag	120
5	taacgcgtgg gcaacctggc ctgtacaggg ggataacact tagaaatagg tgctaatacc	180
	gcataacggg ggaagccgca tggcttttcc ctgaaaactc cggtggtaca ggatgggccc	240
	gcgtctgatt agccagttgg cagggtaacg gcctaccaa gcgacgatca gtagccggcc	300
10	tgagagggcg gacggccaca ctgggactga gacacggccc agactcctac gggaggcagc	360
	agtgggggat attgcacaat ggggggaacc ctgatgcagc gacgccgcgt gggtgaagaa	420
15		
	gcgcctcggc gcgtaaagcc ctgtcagcag ggaagaaaat gacgggtacct gaagaagaag	480
	ccccggctaa ctacgtgcc aacagccgcg taatacgtag gggggcaagc gttatccgga	540
20	tttactgggt gtaaaggggg cgcagacggc gatgcaagcc aggagtgaag gcccggggccc	600
	caacccccgg actgctcttg ggaactgcgt ggctggagtg cagagggcag cggaattcct	660
	gggtgaatgc gtagatatca gaagacacgg tgcgagggcg cctgctgact gcactgacgt	720
25	tgagccgaag cgtgggggagc aaacaggatt agataccgtg gtagtcacgc cgtaaaccat	780
	gattactagg tgtcggggag cagagactgc ccggtgccgc agccaacgca ttaagtaatc	840
	cacctgggga gtacgttcgc aagaatgaaa ctcaaaggaa ttgacgggga cccgcacaag	900
30	cggtggagca tgtggtttaa ttcgaagcaa cgcgaagaac cttacctggt cttgacatcc	960
	cgatgacgag tgagcaaagt cactttccct tcggggcatt ggagacaggt ggtgcatggt	1020
35	tgtcgtcagc tcgtgtcgtg agatgttggg ttaagtcccg caacgagcgc aaccctatt	1080
	tccagtagcc agcaggtaga gctgggcact ctggagagac tgcccgggat aaccgggagg	1140
	aaggcgggga tgacgtcaaa tcatcatgcc cttatgatc agggctacac acgtgctaca	1200
40	atggcgtaaa caaagggaag cgagacggtg acgttaagca aatccccaaa ataacgtccc	1260
	agttcggatt gtagtctgca actcgactac atgaagctgg aatcgctagt aatcgcgat	1320
	cagaatgtcg cgggtgaatac gttccccggg cttgtacaca ccgcccgtca caccatggga	1380
45	gtcggaaatg cccgaagtca gtgacctaac cgaaagggaag gagctgccga aggtggagcc	1440
	ggtaactggg gtgaagtcgt aacaaggtag ccgt	1474
50	<210> 27 <211> 1484 <212> DNA <213> Clostridium leptum <220>	
55	<221> rRNA <222> (1)..(1484) <223> 16S rRNA coding gene sequence of Clostridium strain 7 <400> 27	

EP 2 575 835 B1

	agagtttgat cctggctcag gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac	60
	gagaatccag tgaaggagtt ttcggacaac ggatctggag gaaagtggcg gacgggtgag	120
5	taacgcgtga gcaatctgcc ttggagtggg gaataacggt tggaaacagc cgctaatacc	180
	gcatgatgcg tctgggaggc atctctctgg acgccaaga tttatcgctc tgagatgagc	240
	tcgcgtctga ttagcttggt ggcggggtaa aggccacca aggcgacgat cagtagccgg	300
10	actgagaggt tggccggcca cattgggact gagacacggc ccagactcct acgggaggca	360
	gcagtgggga atattgggca atgggcgcaa gcctgacca gcaacgccgc gtgaaggaag	420
	aaggctttcg ggttgtaaac ttcttttctg agggacgaag aaagtgacgg tacctcagga	480
15	ataagccacg gctaactacg tgccagcagc cgcggtaata cgtaggtggc aagcgttata	540
	cggatttatt ggggtgtaaag ggcgtgtagg cgggaaagca agtcagatgt gaaaactcag	600
20	ggctcaaccc tgagcctgca tttgaaactg ttttcttga gtgctggaga ggcaatcgga	660
	attccgtgtg tagcggtgaa atgcgtagat atacggagga caccagtggc gagcggattg	720
	ctggacagta ctgacgtga agcgcgaaag cgtgggagca aacagataga tacctggtag	780
25	tcacgcgtaa acgatggata ctaggtgtgg ggggactgac cccctccgtg ccgcagctaa	840
	cgcaataagt atcccacctg gggagtagca tcgcaagggt gaaactcaaa ggaattgacg	900
30	ggggcccgc caagcggtag agtatgtggt ttaattcgaa gcaacgcgaa gaaccttacc	960
	agggttgac atcctgctaa cgaaccagag atggattagg tgcccttcgg ggaaagcaga	1020
	gacaggtggt gcatgggtgt cgtcagctcg tgtcgtgaga tgttgggtta agtcccga	1080
35	cgagcgcaac ccttattggt agttgctacg caagagcact ctagcgagac tgccgttgac	1140
	aaaacggagg aagggtggga cgacgtcaaa tcatcatgcc ccttacgtcc tgggccacac	1200
	acgtactaca atggcggcca acaaagagag gcaagaccgc gaggtggagc aaatctcaaa	1260
40	aagccgtccc agttcggatc gcaggctgca accgcctgc gtgaagttgg aatcgctagt	1320
	aatcgcggat cagcatgccg cgggtgaatac gttcccgggc cttgtacaca ccgccgtca	1380
	caccatgaga gtcgggaaca ccgaagtcc gtagcctaac cgcaaggggg gcgcggccga	1440
45	aggtgggttc gataattggg gtgaagtcgt aacaaggtag ccgt	1484

<210> 28

<211> 1483

50 <212> DNA

<213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1483)

55 <223> 16S rRNA coding gene sequence of Clostridium strain 8

<400> 28

EP 2 575 835 B1

agagtttgat cctggctcag gacgaacgct ggcggcgtgc ttaacacatg caagtcgaac 60
 ggagcacccc tgaaggagtt ttcggacaac ggatgggaat gcttagtggc ggactggtga 120
 5 gtaacgcgtg aggaacctgc cttccagagg gggacaacag ttggaaacga ctgctaatac 180
 cgcgatgatgc gttggagccg catgactccg acgtcaaaga tttatcgctg gaagatggcc 240
 tcgcgtctga ttagctagtt ggtgaggtaa cggcccacca aggcgacgat cagtagccgg 300
 10 actgagaggt tggccggcca cattgggact gagatacggc ccagactcct acgggaggca 360
 gcagtgggga atattgggca atggacgcaa gtctgacca gcaacgccgc gtgaagggaag 420
 aaggctttcg ggttgtaaac ttcttttaag ggggaagagc agaagacggt accccttgaa 480
 15 taagccacgg ctaactacgt gccagcagcc gcggtaatag gtaggtggca agcgttgtcc 540
 ggatttactg ggtgtaaagg gcgtgcagcc ggagagacaa gtcagatgtg aaatccacgg 600
 20 gctcaacccg tgaactgcat ttgaaactgt ttctttgag tgcggagag gtaatcggga 660
 ttccttgtgt agcggtgaat gcgtagatat agagaccaca gtgccgacgc cgaatactga 720

 25 cgatactgac ggtgagcgcg aaagcgtggg gagcaaacag gattagatac cctggtagtc 780
 cacgctgtaa acgatcgata ctaggtgtgc ggggactgac ccctgcgtgc cggagttaac 840
 30 acaataagta tcgcacctgg ggagtacgat cgcaagggtg aaactcaaag gaattgacgg 900
 gggcccgcac aagcggtgga ttatgtggtt taattcgaag caacgcgaag aaccttacca 960
 gggcttgaca tcctgctaac gaagtagaga tacattaggt gcccttcggg gaaagcagag 1020
 35 acagggtggtg catggttgtc gtcagctcgt gtcgtgagat gttgggttaa gtcccgaac 1080
 gagcgcaacc cctattgtta gttgctacgc aagagcactc tagcgagact gccgttgaca 1140
 aaacggagga agggggggac gacgtcaaat catcatgccc cttatgtcct gggctacaca 1200
 40 cgtaatacaa tggcgggtta caaagggatg caaagccgcg aggcagagcg aaccccaaaa 1260
 agccgtccca gttcggatcg caggctgcaa cccgcctgcg tgaagtcgga atcgctagta 1320
 atcgcggtac agcatgccgc ggtgaatacg ttcccgggcc ttgtacacac cgcccgtcac 1380
 45 accatgagag tcgggaacac ccgaagtccg tagcctaacc gcaaggaggg cgcgccgaa 1440
 ggtgggttcg ataattgggg tgaagtcgta acaaggtagc cgt 1483

 50 <210> 29
 <211> 1480
 <212> DNA
 <213> Clostridium coccooides
 <220>
 55 <221> rRNA
 <222> (1)..(1480)
 <223> 16S rRNA coding gene sequence of Clostridium strain 9
 <400> 29

EP 2 575 835 B1

	ggagtttgat cctggctcag gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac	60
	gggctcatat tgaacacctag tgatgtatga gttagtggcg gacgggtgag taacgcgtgg	120
5	agaacctgcc gtatactggg ggataacact tagaaatagg tgctaatacc gcataagcgc	180
	acagcttcgc atgaagcagt gtgaaaaact ccggtggtat acgatggatc cgcgtctgat	240
	tagctggttg gcggggtaac agcccaccaa ggcgacgatc agtagccggc ctgagagggt	300
10	gaacggccac attgggactg agacacggcc caaactccta cgggaggcag cagtggggaa	360
	tattgcacaa tgggggaaac cctgatgcag cgacgccgcg tgagtgaaga agtatttcgg	420
	tatgtaaagc tctatcagca ggggaagaaat actgacctta cggtcagcag acggtacctg	480
15	actaagaagc cccgggctaa ctacgtgcc a gcagccgcg taatacgtag gggcaagcgt	540
	tatccggatt tactgggtgt aaagggggcg cagacggcga tgcaagccag gagtgaagc	600
20	cggggcccaa ccccgggact gctcttgac tgctggctg gagtgcagag ggcagcgaat	660
	tcctgtgtag cgtgaatgcg tagattcaga ggacacgtgc gagcgctgc tgactgcact	720
	gacgtgagcc cgaagcgtgg ggagcaaaca ggattagata cctggtagtc cacgccgtaa	780
25	acgatgatta ctaggtgtcg gggagcagag actgcccggg gccgcagcca acgcattaag	840
	taatccacct ggggagtagc ttcgcaagaa tgaaactcaa aggaattgac ggggacccgc	900
30	acaagcgggtg gagcatgtgg tttaattcga agcaacgcga agaaccttac caggccttga	960
	catccccctg gatggcccgt aacgggggtca gcctttcggg gcaggggaga cagggtgtgc	1020
	atggttgtcg tcagctcgtg tcgtgagatg ttgggttaag tcccgcacg agcgcaaccc	1080
35	ctgcccgcag tagccagcat tttagatggg gactctgcgg ggactgccgg ggacaacccg	1140
	gaggaaggcg gggatgacgt caaatcatca tgcccccttat ggctgggct acacacgtgc	1200
40	tacaatggcg ccgacagagg gaggcgaagc ggcgacgcgg agcgaacccc aaaaacggcg	1260
	tcccagttcg gattgtagtc tgcaaccgca ctacatgaag ccggaatcgc tagtaatcgc	1320
	ggatcagaat gccgcggtga atacgttccc ggggtcttgta cacaccgcc gtcacaccat	1380
45	gggagccggg aatgcccga gtcgtgacc gaaccgtaa ggggaggggc agccgaaggc	1440
	aggcccgggtg actgggggtga agtcgtaaca aggtagccgt	1480
50	<210> 30 <211> 1489 <212> DNA <213> Clostridium leptum <220> <221> rRNA	
55	<222> (1)..(1489) <223> 16S rRNA coding gene sequence of Clostridium strain 10 <400> 30	

EP 2 575 835 B1

agagtttgat cctggctcag gatgaacgct ggcggcgtgc ttaacacatg caagtcgagc 60
gaagcacttt tttagaactc ttcggaggga agagaggggtg acttagcggc ggacgggtga 120
5 gtaacgcgtg ggcaacctgc cttacacagg gggataacaa ttagaaatga ttgctaatac 180
cgcataagac cacggtactg catggtacag tggtaaaaaac tgaggtggtg taagatgggc 240
ccgcgtctga ttaggtagtt ggtggggtag aagcctacca agccgacgat cagtagccga 300
10 cctgagaggg cgaccggcca cattgggact gagacacggc caaaactcct acgggaggca 360
gcagtgggga atattgcaca atgggggaaa ccctgatgca gcgacgccgc gtgagtgagg 420
aagtatttcg gtatgtaaag ctctatcagc agggaagaaa atgacggtac ctgactaaga 480
15 agccccggc taactacgtg ccagcagccg cggtaatacg tagggggcaa gcgttatccg 540
gatttactgg gtgtaaaggg agcgtagacg gacttgcaag tctgatgtga aaatccgggg 600
cccaaccgg gactgcattg aaactgtatt ttttgagggg gtccgaggag gcaagtggaa 660
20 tcctgggtag cggtgaaatg gcgtagaatt caggaggaa caccagtggc ggaaggcgaa 720
ttactggacg ataactgacg gtgaggcgcg aagcgtggga gcaaacaaga attagatacc 780
ctggtagtca cgctgtaacg atcgatacta ggtgtgcggg gactgacccc tgcgtgccgg 840
25 agttaacaca ataagtatcg cactggggag tacgatcgca aggttgaaac tcaaaggaat 900
tgacgggggc ccgcacaagc ggtggattat gtggtttaat tcgaagcaac gcgaagaacc 960
30 ttaccagggc ttgacatcct gctaacgaag tagagataca ttaggtgcc ttcggggaaa 1020

gcagagacag gtggtgcatg gttgtcgtca gctcgtgtcg tgagatgttg ggtaagtcc 1080
35 cgcaacgagc gcaacccta ttgttagttg ctacgcaaga gcaacttagc gagactgccg 1140
ttgacaaaac ggaggaaggc ggggacgacg tcaaatcadc atgccccta tgctctgggc 1200
tacacacgta atacaatggc ggtaacaaa gggatgcaaa gccgcgaggc agagcgaacc 1260
40 ccaaaaagcc gtcccagttc ggatcgcagg ctgcaaccg cctgcgtgaa gtcggaatcg 1320
ctagtaatcg cggatcagca tgccgcgggtg aatacgttcc cgggccttgt acacaccgcc 1380
45 cgtcacacca tgagagtcgg gaacaccga agtccgtagc ctaaccgcaa ggagggcgcg 1440
gccgaaggtg ggttcgataa ttggggtgaa gtcgtaacaa ggtagccgt 1489

<210> 31

<211> 1490

<212> DNA

<213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1490)

<223> 16S rRNA coding gene sequence of Clostridium strain 11

<400> 31

EP 2 575 835 B1

	agagtttggat cctgggtcag gatgaacgct ggcggtcgtgc ttaacacatg caagtcgaac	60
	gagaatccag tgaaggagtt ttcggacaac ggatctggag gaaagtggcg gacgggtgag	120
5	taacgcgtga gcaatctgcc ttggagtggg gaataacggt tggaaacagc cgctaatacc	180
	gcatgatgcg tctgggaggc atctctcttg acgcccaga tttatcgctc tgagatgagc	240
	tcgcgtctga ttagcttggt ggcggggtta agggccacca aggcgacgat cagtagccgg	300
10	actgagaggt tggccggcca cattgggact gagacacggc ccagactcct acgggaggca	360
	gcagtgggga atattgggca atgggacgaa gcctgaccca gcaacgccgc gtgaagggaag	420
	aaggctttcg ggttgtaaac ttcttttctg agggacgaag aaagtgacgg tacctcagga	480
15	ataagccacg gctaactacg tgccagcagc cgcggtaata cgtaggtggc aagcggtatc	540
	cggatttatt ggggtgtaaag ggcgtgtagg cgggaaagca agtcagatgt gaaaactcag	600
	ggctcaaccc tgagcctgca tttgaaactg tttttcttga gtgctggaga ggcaatcgga	660
20	attccgtggt gttagcgtga aatgcgtaga ttataccgga ggaaccacca gtggcggaag	720
	gcggtattgt ggaacagtaa ctgacgctga ggcgccgaaa gcgtggggag caaacaggat	780
	agataccctg gtagtcacag ccgtaaacga tggatactaa gtgtggggga ctgacccctt	840
25	cgtgccacg taagcaataa gtttccacc tggggagtac gatcgaggt gaaactcaaa	900
	ggaattgacg ggggcccgc caagcgggtg gagtaggggt taattggagc aacgggaaga	960
30	accttaccag ggcttgacat cctgtaacga accagaagag ggattaggtg ccttcgggga	1020
	aagcagagac aggtggtgca tgggtgtcgt cagctcgtgt cgtgagatgt gggtaaagtc	1080
	ccgcaacgag cgcaaccctt attgttagtt gctacgcaag agcactctag cgagactgcc	1140
35	gttgacaaaa cggaggaagg tggggacgac gtcaaatcat catgcccctt acgtcctggg	1200
	ccacacacgt actacaatgg cggccaacaa agagaggcaa gaccgcgagg tggagaaaat	1260
40	ctcaaaaagc cgtcccagtt cggatcgag gctgcaaccc gcctgcgtga agttggaatc	1320
	gctagtaatc gcggtacgac atgcccggt gaatacgttc ccgggccttg tacacaccgc	1380
	ccgtcacacc atgagagtcg ggaacacccg aagtcgtag cctaaccgca aggggggcgc	1440
45	ggccgaaggt gggttcgata attgggggtga agtcgtaaca aggtagccgt	1490

50	<210> 32
	<211> 1489
	<212> DNA
	<213> Clostridium coccoïdes
	<220>
	<221> rRNA
55	<222> (1)..(1489)
	<223> 16S rRNA coding gene sequence of Clostridium strain 12
	<400> 32

EP 2 575 835 B1

agagtttgat catggctcag gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac 60
 gggctcatat tgaaacctag tgatgtatga gttagtggcg gacgggtgag taacgcgtgg 120
 5 agaacctgcc gtatactggg ggataaacact tagaaatagg tgctaatacc gcataagcgc 180
 acagcttcgc atgaagcagt gtgaaaaact ccggtggtat acgatggatc cgcgtctgat 240
 tagctggttg gcggggtaac agcccaccaa ggcgacgatc agtagccggc ctgagaggggt 300
 10 gaacggccac attgggactg agacacggcc caaactccta cgggaggcag cagtggggaa 360
 tattgcacaa tgggggaaac cctgatgcag cgacgccgcg tgagtgaaga agtatttcgg 420
 tatgtaaagc tctatcagca ggaagaaat actgacctta cggtcagcag acggtacctg 480
 15 actaagaagc cccggctaac tacgtgccag cagccgcggt aatacgtagg gggcaagcgt 540
 tatccggatt tactgggtgt aaaggagcg tagacggcag cgcaagtctg aagtgaatc 600
 ccatggctta accatggaac tgctttggaa actgtgcagc tggagtgcag gagaggtaag 660
 20 cggaattcct agtgtagcgg tgaatgcgta gatattagag gacaccagtg gcgatgcggc 720
 ttactggact gtactgacgt tgagctcgaa agcgtgggga gcaccagaat tagaatactg 780
 tagtcacgcc gtaaccgatg atactaggtg tgggggacca aggtctcgtg ccggcggcaa 840
 25 acgcattaag taatccacct ggggagtacg ttcgcaagaa tgaaactcaa aggaattgac 900
 ggggacccgc acaagcgggtg gagcatgtgg ttaattcga agcaacgcga agaaccttac 960
 30 ctggtcttga catcccgatg acgagtgagc aaagtcactt tcccttcggg gcattggaga 1020
 caggtggtgc atggttgcg tcagctcgtg tcgtgagatg ttgggttaag tcccgcacg 1080
 agcgcaaccc ctatttccag tagccagcag gtagagctgg gcactctgga gagactgcc 1140
 35 gggataaccg ggaggaaggc ggggatgacg tcaaatcatc atgcccccta tgatcagggc 1200
 tacacacgtg ctacaatggc gtaaacaaag ggaagcgaga cggtgacgtt aagcaaattc 1260
 caaaaataac gtcccagttc ggattgtagt ctgcaactcg actacatgaa gctggaatcg 1320
 40 ctagtaatcg cgaatcagaa tgtcgcgggtg aatacgttcc cgggtcttgt acacaccgcc 1380
 cgtcacacca tgggagtcgg aaatgcccgga agtcagtgc ctaaccgaaa ggaaggagct 1440
 45 gccgaaggtg gagccggtaa ctggggtgaa gtcgtaacaa ggtagccgt 1489

<210> 33

<211> 1456

50 <212> DNA

<213> Clostridium coccoides

<220>

<221> rRNA

<222> (1)..(1456)

55 <223> 16S rRNA coding gene sequence of Clostridium strain 13

<400> 33

EP 2 575 835 B1

	agagtttgat catggctcag gatgaacgct ggcggtgtgc ttaacacatg caagtcgaac	60
	gaagcacttg agaacgattc ttcggatgag gactttttgtg actgagtggc ggacgggtga	120
5	gtaacgcgtg ggtaacctgc cctatacagg gggataacag ttagaaatga ctgctaatac	180
	cgcataagcg cactaaaacc gcatgggttcg gtgtgaaaaa ctgaggtggt ataggatgga	240
	cccgcgtctg attagcttgt tgggtgggta acggctcacc aaggcgacga tcagtagccg	300
10	gcctgagagg gcgaccggcc acattgggac tgagacacgg cccaaactcc tacgggaggc	360
	agcagtgggg gatattgcac aatgggggga accctgatgc agcgacgccg cgtgggtgaa	420
	gaagcgccctc ggcgcgtaaa gccctgtcag cagggaaaga aatgacggta cctgaagaag	480
15	aagccccggc taactacgtg ccagcagccg cggtaatagc taggggcaag cgttattccg	540
	ggatttactg ggtgtaaagg gggcgcgagc ggcgatgcaa gccaggagtg aagccccggg	600
20	cccacccggg actgctcttg gactgcgtgc tggagtgcag aaggggcagc gatcctgtgt	660
	accgtgaatt gcgtagatat cagagacacg ttgcgagcgc tgctgactgc actgacgtga	720
	gcgaagctgg agcacagata gatactgtag tcagcgtaac gatgatacta gtgtcgggag	780
25	cagagactgc ccgttgccggc agcccaacgc attagtattc cacttgggga gtacgtttcg	840
	cagaatgaac ttcaaggaaa tgacggggac ccgcacaagg cggtaggagca tgtggtttaa	900
	ttcgaagcaa cgcgaagaac cttaccaggc cttgacatcc cccctggatg gcccgtaacg	960
30	gggtcagcct ttcggggcag gggagacagg tgggtgcatg ttgtcgtcag ctcgtgtcgt	1020
	gagatgttgg gttaagtccc gcaacgagcg caaccctgc ccgcagtagc cagcatttta	1080
	gatggggact ctgcggggac tgccggggac aaccggagg aaggcgggga tgacgtcaaa	1140
35	tcatcatgcc ccttatggcc tgggctacac acgtgctaca atggcgccga cagagggagg	1200
	cgaagcggcg acgcggagcg aacccccaaa acggcgtccc agttcggatt gtagtctgca	1260
	accgactac atgaagccgg aatcgctagt aatcgcgat cagaatgccg cggatgaatac	1320
40	gttccccggg cttgtacaca ccgcccgtca caccatggga gccgggaatg cccgaagtct	1380
	gtgaccgaac ccgtaagggg aggggcagcc gaaggcaggc tcggtgactg gggatgaagtc	1440
45	gtaacaaggt agccgt	1456

<210> 34

<211> 1475

<212> DNA

50 <213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1475)

<223> 16S rRNA coding gene sequence of Clostridium strain 14

55 <400> 34

EP 2 575 835 B1

	agagtttgat cctggctcag gacgaacgct ggcggcgtgc ttaacacatg caagtcgaac	60
	ggagcacccc tgaaggagtt ttcggacaac ggatgggaat gcttagtggc ggactggtga	120
5	gtaacgcgtg aggaacctgc cttccagagg gggacaacag ttggaaacga ctgctaatac	180
	cgcgatgatgc gttggagccg catgactccg acgtcaaaga tttatcgctg gaagatggcc	240
	tcgcgtctga ttagctagtt ggtgaggtaa cggcccacca aggcgacgat cagtagccgg	300
10	actgagaggt tggccggcca cattgggact gagatacggc ccagactcct acgggaggca	360
	gcagtgggga atattgggca atggacgcaa gtctgacca gcaacgccgc gtgaagggaag	420
	aaggctttcg gggtgtaaac ttcttttaag ggggaagagc agaagacggt accccttgaa	480
15	taagccacgg ctaactacgt gccagcagcc gcggtaatag gtaggtggca agcgttgtcc	540
	ggatttactg ggtgtaaagg gcgtgcagcc ggagagacaa gtcagatgtg aaatccacgg	600
20	gctcaacccg tgaactgcat ttgaaactgt ttcccttgag tgtcggagag gtaatcggaa	660
	tttccttgat tagcgtgaa tgcgtagata taaggaagga cacagtggcg agcggattac	720
	tggacgatac tgacgtgagc gcgaaagcgt gggggagcaa cagaaattag atactgtagt	780
25	gcagctgtaa cgatcgatac tagttgcggg actgaccctc tgctgctgag ttacacaata	840
	agtatcgcac ctgggagtac gatcgcaagg ttggaactca aaggaattga cggggcccg	900
	acaagcgttg gattatgtgg ttttaattcga agcaacgcga agaaccctac cagggcctga	960
30	catcctgcta acgaagtaga gatacattag gtgcccttcg gggaaagtag agacaggtgg	1020
	tgcattggtg tcgtcagctc gtgtcgtgag atgttggtt aagtcgccga acgagcgcaa	1080
	cccctattgt tagttgctac gcaagagcac tctagcgaga ctgccgttga caaacggag	1140
35	gaaggcgggg acgacgtcaa atcatcatgc cccttatgtc ctgggctaca cacgtaatac	1200
	aatggcggtt aacaaaggga tgcaaagccg cgaggcagag cgaaccccaa aaagccgtcc	1260
	cagttcggat cgcaggctgc aaccgcctg cgtgaagtcg gaatcgctag taatcgcgga	1320
40	tcagcatgcc gcggtgaata cgttcccggg ccttgtagac accgcccgtc acaccatgag	1380
	agtcgggaac acccgaagtc cgtagcctaa ccgcaaggag ggcgcggccg aaggtgggtt	1440
45	cgataattgg ggtgaagtcg taacaaggta gccgt	1475

<210> 35

<211> 1480

<212> DNA

50 <213> Clostridium coccooides

<220>

<221> rRNA

<222> (1)..(1480)

<223> 16S rRNA coding gene sequence of Clostridium strain 15

55 <400> 35

EP 2 575 835 B1

agagtttgat cctggctcag gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac 60
 gggctcatat tgaaacctag tgatgtatga gttagtggcg gacgggtgag taacgcgtgg 120
 5 agaacctgcc gtatactggg ggataacact tagaaatagg tgctaatacc gcataagcgc 180
 acagcttcgc atgaagcagt gtgaaaaact ccggtggtat acgatggatc cgcgtctgat 240
 tagctggttg gcggggtaac agcccaccaa ggcgacgatc agtagccggc ctgagagggt 300
 10 gaacggccac attgggactg agacacggcc caaactccta cgggaggcag cagtggggaa 360
 tattgcacaa tgggggaaac cctgatgcag cgacgccgcg tgagtgaaga agtatttcgg 420
 tatgtaaaagc tctatcagca ggggaagaaat actgacctta cggtcagcag acggtacctg 480
 15 actaagaagc cccggctaac tacgtgccag cagccgcggt aatacgtagg ggcaagcgtt 540
 atccggattht actgggtgta aaggggagcgt agacggcagc gcaagtctga agtgaaatcc 600
 catggcttaa cccatggaac tgctttggaa actgtgcagc tggagtgcag gagaggtaag 660
 cggaattcct agtgtagcgt gaaatgcgta gattattagg aggacaacag tgcgagcgct 720
 actgacgtga ggctcgaagc gtgggagcaa acaggattag atacctggta gtcacgcgta 780
 25 aacgatgatt actagggtgt tgggggacca aggtcttcgg tgccggcgca aacgcattaa 840
 gtaatccacc tggggagtac gttcgcaaga atgaaactca aaggaattga cggggacccg 900
 cacaagcggg ggagcatgtg gtttaattcg aagcaacgcg aagaacctta cctgggtcttg 960
 30 acatcccgat gacgagttag caaagtcact ttcccttcgg ggcattggag acagggtggtg 1020
 catggttgtc gtcagctcgt gtcgtgagat gttgggttaa gtcccgaac gagcgcaacc 1080
 cctatttcca gtagccagca ggtagagctg ggcactctgg agagactgcc cgggataacc 1140
 35 gggaggaagg cggggatgac gtcaaatcat catgcccctt atgatcaggg ctacacacgt 1200
 gctacaatgg cgtaaacaaa ggggaagcgag acggtgacgt taagcaaata ccaaaaaataa 1260
 cgccccagtt cggattgtag tctgcaactc gactacatga agctggaatc gctagtaatc 1320
 40 gcgaatcaga atgtcgcggg gaatacgttc ccgggtcttg tacacaccgc ccgtcacacc 1380
 atgggagtcg gaaatgcccg aagtcagtga cctaaccgaa aggaaggagc tgccgaagggt 1440
 45 ggagccggta actgggggtga agtcgtaaca aggtagccgt 1480

<210> 36

<211> 1486

<212> DNA

<213> Clostridium papyrosolvens

<220>

<221> rRNA

<222> (1)..(1486)

<223> 16S rRNA coding gene sequence of Clostridium strain 16

<400> 36

EP 2 575 835 B1

agagtttgat cctggctcag gataaacgct ggcgggcgac ataagacatg caagtcgaac 60
 ggacttaact cattctttta gattgagagc ggtagtggtg ggactggtga gtaacacgta 120
 5 agcaacctgc ctatcagagg ggaataacag tgagaaatca ttgctaatac cgcataatgct 180
 cacagtatca catgatacag tgaggaaagg agcaatccgc tgatagatgg gcttgcgctt 240
 gattagttag ttggtggggg aacggcctac caagacgacg atcagtagcc ggactgagag 300
 10 gttgaacggc cacattggga ctgagatacg gccagactc ctacgggagg cagcagtcgg 360
 gaatattgcg caatggagga aactctgacg cagtgcgccc gcgtatagga agaaggtttt 420
 cggattgtaa actattgtcg ttagggaaga taaaagactg tacctaagga ggaagccccg 480
 15 gctaactatg tgccagcagc cgcggttaata catagggggc aagcgttatc cggaattatt 540
 ggggtgtaaag ggtgcgtaga cggaagaaca agttggttgt gaaatccctc ggctcaactg 600
 20 aggaactgca accaaaacta ttctccttga gtgtcggaga ggaaagtgga attcctagtg 660
 tagcggtgaa atgcgtagat attaggagga acaccagtgg cgaaggcgac tttctggacg 720
 ataactgacg ttgaggcacg aaagtgtggg gagcaaacag gattagatac cctggtagtc 780
 25 cacactgtaa acgatggata ctaggtgtag ggtgtattaa gcactctgtg ccgccgctaa 840
 cgcatlaagt atcccacctg gggagtagca ccgcaagggt gaaactcaaa ggaattgacg 900
 gggggcccgc caagcagtgg agtatgtggt ttaattcgaa gcaacgcgaa gaaccttacc 960
 30 agggcttgac atataccgga atataactaga gatagtatag tccttcggga ctggtataca 1020
 ggtggtgcat ggttgtcgtc agctcgtgtc gtgagatgtt gggttaagtc ccgcaacgag 1080
 cgcaaccctc atcggttagtt gctagcaggt aatgctgaga actctagcga gactgccggt 1140
 35 gataaatcgg aggaagggtg ggatgacgtc aaatcatcat gccctttatg tcctgggcta 1200
 cacacgtact acaatggccg taacagaggg aagcaatata gtgatatgga gcaaaaccct 1260
 aaaagcggtc tcagttcgga ttgaaggctg aaattcgctt tcatgaagcc ggaattgcta 1320
 40 gtaatggcag gtcagcatac tgccgtgaat acgttcccg gcttggtaca caccgccgtt 1380
 cacaccatga gagttggaaa taccgaagc ctgtgagcta actgtaaaga ggcagcagtc 1440
 45 gaaggtagag ccaatgattg ggggtgaagtc gtaacaaggt agccgt 1486

<210> 37

<211> 1493

<212> DNA

50 <213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1493)

<223> 16S rRNA coding gene sequence of Clostridium strain 17

55 <400> 37

EP 2 575 835 B1

	agagtttgat catggctcag gatgaacgct ggcggcgtgc ttaacacatg caagtccaac	60
	gagaaccaac ggattgagga ttcgtccaaa tgaagtggg gaaagtggcg gacgggtgag	120
5	taacgcgtga gcaatctgcc ttggagtggg gaataacggt tggaaacagc cgctaatacc	180
	gcatgatgcg tctgggaggc atctctctgg acgccaaaga tttatcgctc tgagatgagc	240
10	tcgcgtctga ttagctagtt ggcggggcaa cggcccacca aggcgacgat cagtagccgg	300
	actgagaggt tggccggcca cattgggact gagacacggc ccagactcct acgggaggga	360
	gcagtgggga atattgggca atgggcgcaa gcctgaccca gcaacgccgc gtgaaggaag	420
15	aaggctttcg ggttgtaaac ttcttttaag ggggacgaac aaatgacggt accccttgaa	480
	taagccacgg ctaactacgt gccagcagcc gcggaatac gtaggtggca agcgttatcc	540
	ggatttattg ggtgtaaagg gcgtgtaggc gggaatgcaa gtcagatgtg aaaactatgg	600
20	gctcaacca tagcctgcat ttgaaactgt atttcttgag tgctggagag gcaatcggaa	660
	ttccgtgtgt agcggtgaaa tgcgtagata tacggaggaa caccagtggc gaagcggatt	720
	gctggacagt aactgacgct gaggcgcgaa agcgtgggga gcaaacaggg attagatacc	780
25	ctggtagtca cgccgtaaac gatggatact aggtgtgggg ggactgacct cctccgtgcc	840
	gcagctaacg caataagtat cccacctggg gagtacgac gcaaggggtg aaactcaaag	900
30	gaattgacgg gggcccgcac aagcggtgga gtatgtggtt taattcgaag caacgcgaag	960
	aaccttacca gggcttgaca tcctgctaac gaaccagaga tggatcaggt gcccttcggg	1020
	gaaagcagag acaggtggtg catggttgtc gtcagctcgt gtcgtgagat gttgggttaa	1080
35	gtcccgcac gagcgcaacc cctattgtta gttgctacgc aagagcactc tagcgagact	1140
	gccgttgaca aaacggagga aggtggggac gacgtcaaat catcatgccc cttacgtcct	1200
	gggccacaca cgtactacaa tggcggccaa caaagagagg caagaccgcg aggtggagca	1260
40	aatctcaaaa agccgtccca gttcggatcg caggctgcaa cccgcctgcg tgaagttgga	1320
	atcgctagta atcgcggatc agcatgccgc ggtgaatacg ttcccgggcc ttgtacacac	1380
45	cgcccgctac accatgagag tcgggaacac ccgaagtccg tagcctgacc gcaagggggg	1440
	cgcggccgaa ggtgggttcg ataattgggg tgaagtagta acaaggtagc cgt	1493
50	<210> 38 <211> 1493 <212> DNA <213> Clostridium leptum <220> <221> rRNA	
55	<222> (1)..(1493) <223> 16S rRNA coding gene sequence of Clostridium strain 18 <400> 38	

EP 2 575 835 B1

agagtttgat cctggctcag gacgaacgct ggcgggcgcg ctaacacatg caagtogaac 60
 ggagcttata tttcagaagt tttcggatgg acgagagata agcttagtg cggacgggtg 120
 5 agtaacacgt gagcaacctg cctttcagag ggggataaca gttggaaacg actgctaata 180
 ccgcataacg ctgcgatggg gcatcccgat gcagccaaag gagcaatccg ctgaaagatg 240
 ggctcgcggc cgattagcta gttgggtggg caacggccca ccaaggcgac gatcggtagc 300
 10
 cggaactgaga ggttgatcgg ccacattggg actgagacac ggcccagact cctacgggag 360
 15 gcagcagtg gggatattgc acaatggagg aaactctgat gcagcgacgc cgcgtgaggg 420
 aagacggtct tcggattgta aacctctgtc tttggggaag aaaatgacgg tacccaaaga 480
 ggaagctccg gctaactacg tgccagcagc cgcggtaata cgtacggagc gagcgttgtc 540
 20 cggaattact ggggtgtaaag ggagcgtacg cgggcgagaa agttgaatgt taaatctacc 600
 ggcttaactg gtagctgcgt tcaaaacttc ttgtcttgag tgaagtagag gcaggcggaa 660
 25 ttcttagtgt agcggtgaaa tgcgtagata taggaggaca ccagtgggag aagccgctg 720
 ctgggcttta actgacgctg aggctcgaaa gcgtggggag caaaccagga ttagataccc 780
 tggtagtcaa cgctgtaaac gatgattact aggtgtgggg gggactgacc cctccgtgc 840
 30 cgcagttaac acaataagta tccacctggg gactacggcc gcaaagttg aaaactcaaa 900
 aggaatgacg ggggcccgc caaagcagtg gactatgttg ttaatttcg aagcaacgcg 960
 aagaacctta ccaggtcttg acatcgtgcg catagcctag agataggtga agcccttcg 1020
 35 ggcgcacaga caggtggtgc atggttgctg tcagctcgtg tcgtgagatg ttgggttaag 1080
 tcccgcacag agcgcacccc ttattattag ttgctacgca agagcactct aatgagactg 1140
 ccgttgacaa aacggaggaa ggtggggatg acgtcaaata atcatgcccc ttatgacctg 1200
 40 ggctacacac gtactacaat ggcactgaaa cagaggggag cgacatcgcg aggtgaagcg 1260
 aatccccaaa aagtgtccca gttcggattg caggctgcaa ctgcctgca tgaagtcgga 1320
 attgctagta atcgcgatc agcatgccgc ggtgaatacg tccccgggcc ttgtacacac 1380
 45 cgcccgctac accatgggag tcggtaacac ccgaagccag tagcctaacc gcaaggaggg 1440
 cgctgtcgaa ggtgggattg atgactgggg tgaagtcgta acaaggtagc cgt 1493
 50 <210> 39
 <211> 1483
 <212> DNA
 <213> Clostridium leptum
 <220>
 55 <221> misc_feature
 <222> (1)..(1483)
 <223> 16S rRNA coding gene sequence of Clostridium strain 19
 <400> 39

EP 2 575 835 B1

agagttttgat cctggctcag gacgaacgct ggcggcacgc ctaacacatg caagtcgaac 60
 ggagtgaaga tgcttgcatc tgaacttagt ggcggaacgg tgagtaacac gtgagcaacc 120
 5 tgcctttcag agggggataa cgtttgga aa cgaacgctaa taccgcataa aatatcggag 180
 tcgcatggca ctgatatcaa aggagcaatc cgctgaaaga tgggctcgcg tccgattagg 240
 cagttggcgg ggtaacggcc caccaaaccg acaatcggta gccggactga gaggttgaac 300
 10 ggccacattg ggactgagac acggcccaga ctccctacggg aggcagcagt gggggatatt 360
 gcacaatggg ggaaaccctg atgcagcgat gccgcgtgaa tgaagacggc cttcggggtg 420
 15 taaagttctg tcgcagggga cgaaaatgac ggtaccctgc aagaaagctc cggctaacta 480
 cgtgccagca gccgcggtaa tacgtaggga gcaagcggtt tccggaatta ctgggtgtaa 540
 agggagcgta ggcgggagga taaagttgaa tgtgaaatct atgggctcaa cccatagctg 600
 20 cgttcaaaac tgttcttctt gagtgaagta gaggcaggcg gaattcctag tgtagcggtg 660
 aaatgcgtag atattaggag gaacaccagt ggcgaaagcg gcctgctggg cttttactga 720
 cgctgagggt cgaaagcggt ggtagcaaac agaattagat taccctgtta ttcacggcgg 780
 25 taaacgatga ttactagggt tgggttgacc tgacccccat tcgtgccgga agtaacacca 840
 taaagtaatc cacctggggg agtacggccg ccagggtgaa acttcaaaag gaattgacgg 900
 30 gggcccgcac aagcagtgga ggtatgtggt ttaatttcga cgcaaacgcg aagaacctta 960
 ccagggtctt gacatcgagt gacggacata gagatatgtc tttcctttcg ggacacgaag 1020
 acagggtggt catggttgtc gtcagctcgt gtcgtgagat gttgggttaa gtcccgcaac 1080
 35 gagcgcaacc cttaccatta gttgctacgc aagagcactc tgatgggact gccgttgaca 1140
 aaacggagga aggtggggat gacgtcaaat catcatgccc cttatgacct gggcgacaca 1200
 cgtactacaa tggcgggtcaa cagagggagg caaagccgcg aggcagagca aaccctaaa 1260
 40 agccgtctca gttcggattg caggctgcaa ctgcctgca tgaagtcgga attgctagta 1320
 atcgcggtac agcatgccgc ggtgaatacg ttcccgggcc ttgtacacac cggccgtcac 1380
 accatgagag ccggtaacac ccgaagtcaa tagtctaacc gcaaggagga cattgccgaa 1440
 45 ggtgggattg gtaattgggg tgaagtcgta acaaggtagc cgt 1483

<210> 40

<211> 1511

<212> DNA

<213> Clostridium coccoides

<220>

<221> rRNA

<222> (1)..(1511)

<223> 16S rRNA coding gene sequence of Clostridium strain 20

<400> 40

EP 2 575 835 B1

	agagtttgat cctggctcag gatgaacgct ggcggcggtgc ttaacacatg caagtcgaac	60
	gggctcatat tgaaacctag tgatgtatga gttagtggcg gacgggtgag taacgcgtgg	120
5	agaacctgcc gtatactggg ggataacact tagaaatagg tgctaatacc gcataagcgc	180
	acagcttcgc atgaaacagt gtgaaaaact ccggtgggtat acgatggatc cgcgtctgat	240
	tagctgggtg gcggggtaac agcccaccaa ggcgacgatc agtagccggc ctgagaggggt	300
10	gaacggccac attgggactg agacacggcc caaactccta cgggaggcag cagtggggaa	360
	tattgcacaa tgggggaaac cctgatgcag cgacgccgcg tgagtgaaga agtatttcgg	420
	tatgtaaagc tctatcagca gggaagaaat actgacctta cggtcagcag acggtacctg	480
15	actaagaagc cccggctaac tacgtgccag cagccgcggt aatacgtagg ggcaagcggt	540
	atccggattt actgggtgta aaggggagcgt agacggcagc gcaagtctga gtgaaatccc	600
20		
	atggcttaac catggaactg ctttggaaac tgtgcagctg gagtgcagga gaggtaaagc	660
25	ggaattccta gtgtagcggg tgaaatgcgt agatatagga ggaacaacag tggcggaagg	720
	cggctactgg gactgtaact gacgttgagg ctcgaaagcg tggggagcaa acaggattag	780
	ataccctggt agtcacgccg taaacgatga ttactaggtg ttgggggacc ataggtcttc	840
30	ggtgccggcg caaacgcaat taagtaatcc acctggggga gtacgttcgc aagaatgaaa	900
	ctcaaaggaa ttgacgggga cccgcacaaa gcggtggagc atgtggttta attcgaaagc	960
	aaacgcgaag aaaccttacc tggctctgac atcccgatga cgagtgcagca aagtcacttt	1020
35	cccttcgggg caattggaga cagggtggtgc atgggttgtc gtcagctcgt gtcgtgagat	1080
	gttgggttaa gtcccgcac gagcgcaacc cctatttcca gtagccagca ggtagagctg	1140
	ggcactctgg agagactgcc cgggataacc gggaggaagg cggggatgac gtcaaatcat	1200
40	catgcccctt atgatcaggg ctacacacgt gctacaatgg cgtaaacaaa gggaagcgag	1260
	acggtgacgt taagcaaata ccaaaaataa cgtcccagtt cggattgtag tctgcaactc	1320
45	gattacatga agctggaata gctagtaata gcgaatcaga atgtcgcggt gaatacgttc	1380
	ccgggtcttg tacacaccgc ccgtcacacc atgggagtcg gaaatgcccg aagtcagtga	1440
	cctaaccgaa aggaaggagc tgccgaaggt ggagccggta actggggtga agtagataac	1500
50	aaggtagccg t	1511

<210> 41

<211> 1495

<212> DNA

<213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1495)

EP 2 575 835 B1

<223> 16S rRNA coding gene sequence of Clostridium strain 21
<400> 41

```

5      agagtttgat cctgcgctca ggacgaacgc tggcggcgcg cctaacacat gcaagtcgaa      60
      cgggactatt ttgggagaag ttttcggatg gatctcggga tagtttagtg gcggacgggt      120
      gagtaacgcg tgggcaacct gccttacaca gggggataac aattagaaat gattgctaata      180
10     accgcataag accacgggtac tgcattggtac agtggttaaaa actgaggtgg tgtaagatgg      240
      gcccgctct gattaggtag ttggtggggg agaagcctac caagccgacg atcagtagcc      300
      gacctgagag ggcgaccggc cacattggga ctgagacacg gcccactc ctacgggagg      360
15     cagcagtggg gaatatgca caatggggga aacctgatg cagcgacgcc gcgtgagtga      420
      ggaagtattt cggtatgtaa agctctatca gcagggaaga aaatgacggg acctgactaa      480
      gaagccccgg ctaactacgt gccagcagcc gcggtataac gtagggggca agcggtatcc      540
20     ggatttactg ggtgtaaagg gagcgtagac ggacttgcaa gtctgatgtg aaaatccggg      600
      ggcccaacct cggaactgca ttggaaactg tatacttaga gtgtcggaga ggcaagtgga      660
      atttcctggt gtagcgggtga aatgcgtaga tatcagagga acaccagtgg cgaaggcgct      720
25
      tgcctgacga tgactgacgt tgaagctcga aaagcgtggg tagcaaacag aattagatac      780
30     cctggtaagt caaccgggta aacgatgatt actaggtttt gggtggactg accccatccg      840
      tgccggagta acaccaataa gttatccaac ctgggaagta cggccggcag gttgaaactc      900
      aaaaggaaat gacggggggc cgcacaagca gttgaagtat gtgggttaat tcgacgcaaa      960
35     cgcaagaac cttaccaggt cttgacatcg agtgacggac atagagatat gtctttcctt      1020
      cgggacacga agacaggtgg tgcattggtt tcgtcagctc gtgtcgtgag atgttggtt      1080
40     aagtcgca acgagcgcaa cccttaccat tagttgctac gcaagagcac tctgatggga      1140
      ctgccgttga caaacgggag gaaggtgggg atgacgtcaa atcatcatgc cccttatgac      1200
      ctgggcgaca cacgtactac aatggcggtc aacagaggga ggcaaagccg cgaggcagag      1260
45     caaaccccta aaagcgtct cagttcggat tgcaggctgc aactcgctg catgaagtgc      1320
      gaattgctag taatcgcgga tcagcatgcc gcggtgaata cgttcccggg cttgtacac      1380
      accgcccgtc acaccatgag agccggtaac accggaagtc aatagtctaa ccgcaaggag      1440
50     gacattgccg aaggtgggat tggtaattgg ggtgaagtcg taacaaggta gccgt      1495

```

<210> 42

<211> 1491

<212> DNA

<213> Clostridium leptum

<220>

<221> rRNA

EP 2 575 835 B1

<222> (1)..(1491)

<223> 16S rRNA coding gene sequence of Clostridium strain 22

<400> 42

```

5      agagtttgat cctggctcag gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac      60
      gagaatccag tgaaggagtt ttcggacaac ggatctggag gaaagtggcg gacgggtgag      120
      taacgcgtga gcaatctgcc ttggagtggg gaataacggt tggaacagc cgctaatacc      180
10     gcatgatgcg tctgggagggc atctctctgg acgccaaaga tttatcgctc tgagatgagc      240
      tcgcgtctga ttagcttggt ggcggggtaa aggcccacca aggcgacgat cagtagccgg      300
      actgagaggt tggccggcca cattgggact gagacacggc ccagactcct acgggaggca      360
15     gcagtgggga atattgggca atgggcgcaa gcctgaccca gcaacccgc gtgaaggaag      420
      aaggctttcg ggttgtaaac ttcttttctg agggacgaag aaagtgacgg tacctcagga      480
20     ataagccacg gctaactacg tgccagcagc cgcggtaata cgtaggtggc aagcgttacc      540
      cggatttatt gggtgtaaag ggcgtgtagg cgggaaagca agtcagatgt gaaaactcag      600
      ggctcaaccc tgagcctgca tttgaaactg tttttcttga gtgctggaga ggcaatcggg      660
25     attccgtgtg tagcggtgaa atgcgtagat atacggagga caccagtggc gaagcggatt      720
      gctggacagt aactgacgct gaggcgcgaa gcgtggggag caaacaggat tagataccct      780
      ggtagtccac gccgtaaacg atggatacta ggtgtggggg gactgacccc ctccgtgccg      840
30
      cagctaacgc aataagtatc ccacctgggg agtacgatcg caaggttgaa actcaaagga      900
      attgacgggg gcccgacaaa gcggtggagt atgtggttta attcgaagca acgcgaagaa      960
35     ccttaccagg gcttgacatc ctgctaacga accagagatg gattaggtgc ccttcgggga      1020
      aagcagagac aggtggtgca tggttgtcgt cagctcgtgt cgtgagatgt tgggttaagt      1080
40     cccgcaacga gcgcaaccct tattgttagt tgctacgcaa gagcactcta gcgagactgc      1140
      cgttgacaaa acggaggaag gtggggacga cgtcaaatca tcatgccctt tacgtcctgg      1200
      gccacacacg tactacaatg gcggccaaca aagagaggca agaccgcgag gtggagcaaa      1260
45     tctcaaaaag cgtcccagt tcggatcgca ggctgcaacc cgcctgcgtg aagttggaat      1320
      cgctagtaat cgcggatcag catgccgcgg tgaatacgtt cccgggcctt gtacacaccg      1380
      cccgtcacac catgagagtc gggaacaccc gaagtccgta gcctaaccgc aaggggggcg      1440
50     cggccgaagg tgggttcgat aattgggggtg aagtcgtaac aaggtagccg t          1491

```

<210> 43

<211> 1495

<212> DNA

<213> Clostridium leptum

<220>

<221> rRNA

EP 2 575 835 B1

<222> (1)..(1495)

<223> 16S rRNA coding gene sequence of Clostridium strain 23

<400> 43

5	agagtttgat cctgtgcctc aggatgaacg ctggcggcgt gcttaacaca tgcaagtcga	60
	acgagaacca acggattgag gattcgtcca aatgaagttg gggaaagtgg cggacgggtg	120
	agtaacgcgt gagcaatctg ccttgaggatg ggggaataacg gttggaacaa gccgctaata	180
10	ccgcatgatg cgtctgggag gcatctctct ggacgcaaaa gatttatcgc tctgagatga	240
	gctcgcgtct gattagctag ttggcggggc aacggcccac caaggcgacg atcagtagcc	300
	ggactgagag gttggccggc cacattggga ctgagacacg gcccagactc ctacgggagg	360
15	cagcagtggg gaatatggg caatgggcgc aagcctgacc cagcaacgcc gcgtgaagga	420
	agaaggcttt cgggttgtaa acttctttta agggggacga acaaatgacg gtacccttg	480
	aataagccac ggctaactac gtgccagcag ccgcggtaat acgtagggtg caagcgttat	540
20	ccggatttat tgggtgtaaa ggcgtgtag gcgggaatgc aagtcagatg tgaaaaactat	600
	gggctcaacc catagcctgc atttgaaact gtatttcttg agtgctggag aggcaatcgg	660
	aattccgtgt gtagcgggtga aatgcgtaga tatacggagg aacaccagtg gcgaaggcgg	720
25	attgctggac agtaactgac gctgaggcgc gaaagcgtgg ggagcaaaca ggattagata	780
	ccctggtagt ccacgccgta aacgatggat actaagtgtg gggggactga cccctccgt	840
30	gccgcagcta acgcaataag tatccacct ggggagtacg atcgcaaggt tgaaactcaa	900
	aggaattgac gggggccgcg acaagcgggt gagtatgtgg ttaattcga agcaacgcga	960
	agaaccttac cagggttgta catcctgcta acgaaccaga gatggatcag gtgcccttcg	1020
35		
	gggaaagcag agacaggtgg tgcattggtt tcgtcagctc gtgtcgtgag atgttgggtt	1080
	aagtcccga acgagcgcaa cccctattgt tagttgctac gcaagagcac tctagcgaga	1140
40	ctgccgttga caaaacggag gaaggtgggg acgacgtcaa atcatcatgc cccttacgtc	1200
	ctgggccaca cacgtactac aatggcggcc aacaaagaga ggcaagaccg cgaggtggag	1260
	caaactctaa aaagccgtcc cagttcggat cgcaggctgc aaccgcctg cgtgaagttg	1320
45	gaatcgctag taatcgcgga tcagcatgcc gcggtgaata cgttcccggg ccttgtagac	1380
	accgccgtc acaccatgag agtcgggaac accggaagtc cgtagcctga ccgcaagggg	1440
50	ggcgcggccg aaggtgggtt cgataattgg ggtgaagtcg taacaaggta gccgt	1495

<210> 44

<211> 1440

<212> DNA

55 <213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1440)

EP 2 575 835 B1

<223> 16S rRNA coding gene sequence of Clostridium strain 24
<400> 44

5	agagtttgat cctggctcag gacgaacgct ggcggcacgc ctaacacatg caagtcgaac	60
	ggagtgaaga tgctcgcatc tgaacttagt ggcggaacgg tgagtaacac gtgagcaacc	120
	tgccctttcag agggggataa cgtttgaaaa cgaacgctaa taccgcataa aatatcggag	180
10	tcgcatggca ctgatatcaa aggagtaatc cgctgaaaga tgggctcgcg tccgattagg	240
	cagttggcgg ggtaacggcc caccaaaccg acaatcggta gccggactga gaggttgaac	300
	ggccacattg ggactgagac acggcceaaga ctctacggg aggcagcagt gggggatatt	360
15	gcacaatggg ggaaaccctg atgcagcgat gccgcgtgaa tgaagacggc cttcgggttg	420
	taaagttctg tcgcagggga cgaaaatgac ggtaccctgc aagaaagctc cggctaacta	480
	cgtgccagca gccgcggtaa tacgtaggga gcaagcgttg tccggaatta ctgggtgtaa	540
20	agggagcgta ggcgaggaga taagttgaat gtgaaatcta tgggctcaac ccatagttgc	600
	gttcaaaact gttcttcttg agtgaagtag aggcaggcgg aattcctagt gtagcggtag	660
	aatgcgtaga tattagagga acaccagtgg cgaagcggcc tgctgggctt ttactgacgc	720
25	tgagctcgaa agcgtgggta gcaacaggat tagataccct ggtagtccac gcggtaaacc	780
	atgattacta gtgtgggtgg actgacccat ccatgccgga gttaacacaa tagtaatcca	840
30	cctggggagt acgcgcagtg aactcaaagg attgacgggg cccgcacaag cagtgagtat	900
	gtggtttatt cgacgcacgc gagactacag tcttgacatc gatgacggac tagagatatg	960
	tctttctcgg acacgaagac aggtggtgca tggttgctgt cagctcgtgt cgtgagatgt	1020
35	tgggttaagt cccgcaacga gcgcaaccct taccattagt tgttacgcaa gagcactcta	1080
	atgggactgc cgttgacaaa acggaggaag gtggggatga cgtcaaatca tcatgccctt	1140
40	tatgacctgg gcgacacacg tactacaatg gcggtcaaca gagggaggca aagccgcgag	1200
	gcagagcaaa cccctaaaag ccgtctcagt tcggattgca ggctgcaact cgcctgcatg	1260
	aagtcggaat tgctagtaat cgcggatcag catgccgcgg tgaatacgtt cccgggcctt	1320
45	gtacacaccg cccgtcacac catgagagcc ggtaacaccc gaagtcaata gtctaaccgc	1380
	aaggaggaca ttgccgaagg tgggatggta attggggatga agtagtaaca aggtagccgt	1440

<210> 45

<211> 1495

<212> DNA

<213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1495)

<223> 16S rRNA coding gene sequence of Clostridium strain 25

<400> 45

EP 2 575 835 B1

	agagtttgat cctggctcag gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac	60
	gagaaccatt ggatcgagga ttcgtccaag tgaaggtggg gaaagtggcg gacgggtgag	120
5	taacgcgtga gcaatctgcc ttggagtggg gaataacggc tggaaacagc cgctaatacc	180
	gcatgataca gctgggagggc atctccctgg ctgtcaaaga tttatcgctc tgagatgagc	240
	tcgcgtctga ttagctagtt ggcggggtaa cgccccacca aggcgacgat cagtagccgg	300
10	actgagaggt tggccggcca cattgggact gagacacggc ccagactcct acgggaggga	360
	gcagtgggga atattgggca atgggcgcaa gcctgaccca gcaacgccgc gtgaagggaag	420
	aaggctttcg ggttgtaaac ttcttttgtc agggacgaag caagtgcgag tacctgacga	480
15	ataagccacg gctaactacg tgccagcagc cgcggttaata cgtagtggca agcgttatcc	540
	ggatttattg ggggtgtaaag ggcgtgtagg cggaatgca agtcagatgt gaaaactatg	600
	gggctcaacc catagcctgc atttgaaact gtatttcttg agtgctggag aggcattcga	660
20	attccgtgtg tagcgggtga aatgcgtaga tatacggagg aacaccagtg gcgaagcgga	720
	ttgctggaca agtaactgac gctgaggcgc gaaagcgtgg ggagcaaaca ggattagata	780
	ccctggtagt ccacgccgta aacgatggat actaggtgtg gggggactga cccctccgt	840
25	gccgcagcta acgcaataag tatccacct ggggagtacg atcgcaaggt tgaaactcaa	900
	aggaattgac gggggccgc acaagcgggt gagtatgtgg tttaattcga cgcaacgcga	960
30	agaaccttac cagggttga catcctacta acgaaccaga gatggattag gtgcccttcg	1020
	gggaaagtag agacaggtgg tgcattggtt tcgtcagctc gtgtcgtgag atgttgggtt	1080
	aagtcccgc aacgagcgcaa cccctattgt tagttgctac gcaagagcac tctagcgaga	1140
35	ctgccgttga caaaacggag gaaggtgggg acgacgtcaa atcatcatgc cccttacgtc	1200
	ctgggccaca cacgtactac aatggcggcc acaaaagaga ggcaaagccg cgaggtggag	1260
	caaactctca aaagccgtcc cagttcggat cgcaggctgc aaccgcctg cgtgaagttg	1320
40	gaatcgctag taatcgcgga tcagcatgcc gcgtgaata cgttcccggg ccttgtagac	1380
	accgcccgtc acaccatgag agtcgggaac acccgaagtc cgtagcctaa ccgcaagggg	1440
45	ggcgcgcccg aaggtgggtt cgataattgg ggtgaagtcg taacaaggta gccgt	1495

<210> 46

<211> 1495

<212> DNA

<213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1495)

<223> 16S rRNA coding gene sequence of Clostridium strain 26

<400> 46

EP 2 575 835 B1

	agagtttgat catggctcag gacgaacgct ggcggcgtgc ttaacacatg caagtcgaac	60
	ggagcacccc tgaaggagtt ttcggacaac ggatgggaat gcttagtggc ggactggtga	120
5	gtaacgcgtg aggaacctgc cttccagagg gggacaacag ttggaaacga ctgctaatac	180
	cgcatgatgc gttggagccg catgactccg acgtcaaaga tttatcgctg gaagatggcc	240
	tcgcgtctga ttagctagtt ggtgaggtaa cggcccacca aggcgacgat cagtagccgg	300
10	actgagaggt tggccggcca cattgggact gagatacggc ccagactcct acgggaggca	360
	gcagtgggga atattgggca atggacgcaa gtctgaccca gcaacgccgc gtgaagggaag	420
	aaggctttcg gggtgtaaac ttcttttaag ggggaagagc agaagacggg accccttgaa	480
15	taagccacgg ctaactacgt gccagcagcc gcgtaatac gtaggtggca agcgttgtcc	540
	ggatttactg ggtgtaaagg gcgtgcagcc ggagagacaa gtcagatgtg aaatccacgg	600
20	gctcaacccg tgaactgcat ttgaaactgt ttcccttgag tgtcggagag ggtaatcgga	660
	attcctttgt gtagcgtga aatgcgtaga tataagaaga acaccagtgg cgaaggcgga	720
	ttactggacg ataactgacg gtgaggcgcg aaagcgtggg ggagcaacag attaaatacc	780
25	ctggtagtcc acgctgttaa cgatcgatac taggtgtgcc gggactgacc ccctgcgtgc	840
	ccggaggtaa ccacaataag tatcgcacct ggggagtacg atcgcaaggt gaacttcaaa	900
	ggaattgacg ggggcccgc ccaagccgtg gattatgtgg ttaattcgaa gcaacgcgaa	960
30	gaacctaccc agggcttgac atcctgctaa cgaagtagag atacattagg tgccctttcg	1020
	gggaaagcag agacaggtgg tgcattggtt tcgtcagctc gtgtcgtgag atgttggggt	1080
	aagtcccgca acgagcgcaa cccctattgt tagttgctac gcaagagcac tctagcgaga	1140
35	ctgccgttga caaaacggag gaaggcgggg acgacgtcaa atcatcatgc cccttatgtc	1200
	ctgggctaca cacgtaatac aatggcgggt aacaaaggga tgcaaagccg cgaggcagag	1260
	cgaaccccaa aaagccgtcc cagttcggat cgcaggctgc aacccgcctg cgtgaagtcg	1320
40	gaatcgctag taatcgcgga tcagcatgcc gcggtgaata cgttcccggg ccttgtacac	1380
	accgccgctc acaccatgag agtcgggaac acccgaagtc cgtagcctaa ccgcaaggag	1440
45	ggcgcggccg aaggtggggt cgataattgg ggtgaagtcg taacaaggta gccgt	1495

<210> 47

<211> 1509

<212> DNA

<213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1509)

<223> 16S rRNA coding gene sequence of Clostridium strain 27

<400> 47

EP 2 575 835 B1

agagtttgat cctggctcag gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac 60
 ggagtacccc tgaaggagtt ttcggacaac tgatgggact acttagtggc ggacgggtga 120
 5 gtaacgcgtg agtaacctgc cttggagtgg ggaataacag ctggaaacag ctgctaatac 180
 cgcataatat gtctgtgtcg catggcactg gacatcaaag atttatcgct ctgagatgga 240
 ctcgctctg attagctagt tggcggggta acggcccacc aaggcgacga tcagtagccg 300
 10 gactgagagg ttggccggcc acattgggac tgagacacgg ccagactcc tacgggaggc 360
 agcagtgggg aatattgggc aatgggcgca agcctgacct agcaacgccg cgtgaaggaa 420
 gaaggctttc gggttgtaaa cttcttttaa gggggaagag cagaagacgg tacccttga 480
 15 ataagccacg gctaactacg tgccagcagc cgcggtataa cgtaggtggc aagcgttgtc 540
 cggatttact ggggtgtaaag ggcgtgcagc cggagagaca agtcagatgt gaaatccacg 600
 ggctcaaccc gtgaactgca tttgaaactg tttcctggag ttcggagggt atggaattct 660
 20 tgtagcgggt gaaatgctgt agatatggga gaaccaccag tgcgaggggg cttccgggac 720
 tgtacttgac tgtagaggtc tcaaagctgg gggagcaccg aggaatgaga taccgtgata 780
 gtcccacgcg gtaacggatg attactaggt gttgggggga ccaggtctt ttcgggtgccg 840
 25 ggcgcaaacc ctttaggaat tccacctggg gaattacgtt tggcaagaaa ggaacttcaa 900
 agaaattgaa cgggggaccc cccaaccgg tggaggcatg gtgttttatt tcggaggaac 960
 30 gggagaacc tttacctgt tctgacctc cggatgacga agtgagcaaa gtcaacttcc 1020
 cttcggggcc atggaggaca ggtggtggca tggttggtcg tcagctcgtg tcgtgagatg 1080
 ttgggttaag tcccgcacg agcgcaaccc ctatttccag tagccagcag gtagagctgg 1140
 35 gcactctgga gagactgccc gggataaccg ggaggaaggc ggggatgacg tcaaatacgc 1200
 atgcccctta tgatcagggc tacacacgtg ctacaatggc gtaaacaaag ggaagcgaga 1260
 cggtgacgtt aagcaaatcc caaaaataac gtcccagttc ggattgtagt ctgcaactcg 1320
 40 actacatgaa gctggaatcg ctagtaatcg cgaatcagaa tgtcgcggtg aatacgttcc 1380
 cgggtcttgt acacaccgcc cgtcacacca tgggagtcgg aaatgcccga agtcagtgc 1440
 ctaaccgaaa ggaaggagct gccgaagggt gagccggtaa ctggggtgaa gtcgtaacaa 1500
 45 ggtagccgt 1509

<210> 48

<211> 1583

50 <212> DNA

<213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1583)

55 <223> 16S rRNA coding gene sequence of Clostridium strain 28

<400> 48

EP 2 575 835 B1

	agagtttgat cctggctcag gacgaacgct ggcggcgcgc ctaacacatg caagtcgaac	60
	ggagcttata tttcagaagt tttcggatgg acgagagata agcttagtgg cggacgggtg	120
5	agtaacacgt gagcaacctg cctttcagag ggggataaca gttggaaacg actgctaata	180
	ccgcataacg ctgcgatggg gcatcccgat gcagccaaag gagcaatccg ctgaaagatg	240
	ggctcgcggc cgattagcta gttggtgggg caacggccca ccaaggcgac gatcggtagc	300
10	cggactgaga ggttgatcgg ccacattggg actgagacac ggcccagact cctacgggag	360
	gcagcagtgg gggatattgc acaatggagg aaactctgat gcagcgacgc cgcgtgaggg	420
	aagacggtct tcggattgta aacctctgtc tttggggaag aaaatgacgg taccctaaaga	480
15	ggaagctccg gctaactacg tgccagcagc cgcggttaata cgtaggggag cgagcgttgt	540
	ccggaattac tgggtgtaaa gggagcgtag cgggcgagaa agttgaatgt taaatctacc	600
20	ggcttaactg gtagctgcgt ccaaaacttc ttggtcttga gtgaaagtaa gaggccaggg	660
	cggaaaattct tagtgtaagc gggtgaaaat gcgttagata ttagggagga accaccaggt	720
	gggcgaaggg cggcttgctg ggctttaact ggacggctgg aggcttgga aaggcgtggg	780
25	gagagcaaac acagggaatt aagtataccc tggatatatgt cacacgcttg taaagagtat	840
	gattaactta ggggtggtgg ggaacttga ccctttcgtg tgccgcgcagg ttaacacaca	900
	tttagagtat atccaacttg gggagagtac ggccggcaaa gtttgaaact tcaaaaggga	960
30	aattgagacc ggggggcccg gccaccaagc acagtggaga gtatggtggg ttttaatttcg	1020
	agaagcaacc ggcggaagag aaactttacc agtccttgac atcgggtggcg gcataagccc	1080
	tagagattag gtgaagccct tcggggggccc caccagacag gtggtgcatg gttgtcgtca	1140
35	gctcgtgtcg tgagatgttg ggttaagtcc ccgcaaacga gcgcaaccct tattattagt	1200
	ttgctacgca agagcactct aatgagactg ccgttgacaa aacggaggaa ggtggggatg	1260
	acgtcaaata atcatgcccc ttatgacctg ggctacacac gtactacaat ggcactgaaa	1320
40	cagagggaag cgacatcgcg aggtgaagcg aatccccaaa aagtgtccca gttcggattg	1380
	caggctgcaa ctgccttga tgaagtcgga attgctagta atcgcggatc agcatgccgc	1440
45	ggtgaatacg ttcccgggcc ttgtacacac cgcccgtcac accatgggag tcggtaacac	1500
	ccgaagccag tagcctaacc gcaaggagg cgctgtcgaa ggtgggattg atgactgggg	1560
	tgaagtcgta acaaggtagc cgt	1583
50	<210> 49	
	<211> 1519	
	<212> DNA	
	<213> Clostridium coccoides	
	<220>	
55	<221> rRNA	
	<222> (1)..(1519)	
	<223> 16S rRNA coding gene sequence of Clostridium strain 29	
	<400> 49	

EP 2 575 835 B1

agagtttgat catggctcag gatgaacgct ggcggcgtgc ctaacacatg caagtcgaac 60
 ggggtgtacgg gaaggaaggc ttcggccgga aaacctgtgc atgagtggcg gacgggtgag 120
 5 taacgcgtgg gcaacctggc ctgtacaggg ggataacact tagaaatagg tgctaatacc 180
 gcataacggg ggaagccgca tggcttttcc ctgaaaactc cggtggtaca ggatgggccc 240
 gcgtctgatt agccagttgg cagggtaacg gcctaccaa gcgacgatca gtagccggcc 300
 10 tgagagggcg gacggccaca ctgggactga gacacggccc agactcctac gggaggcagc 360
 agtgggggat attgcacaat ggggggaacc ctgatgcagc gacgccgctg ggggtgaagaa 420
 gcgcctcggc gcgtaaagcc ctgtcagcag ggaaagaaaa tgacggtacc tgaagaagaa 480
 15 gccccgggct aactacgtgc cagcagccgg cggttaattac gtaggggggc aggcgttattc 540
 cggatttact gggtggtaaa ggggggcgca aacggcgatg gcaggccagg aatggaaagc 600
 ccggggggccc aaccccgga cttgctcttg ggaaactggc ttggctggga gtggcaggag 660
 20 gggcagcgcg aaattcctgg tggtagcggg ggaaaatggc taaaaatcaa gaagaaaaac 720
 cggtggggaa aggcggcctg gtgggactgc gaactgacgt tgaaggcccg aaagcgtggg 780
 gaacaaacag gatagattcc ctggtagttc cagccgtaa acgatgatta ctaggtgtcg 840
 gggagcagag actgcccggg gccgcagcca acgcattaag taatccacct ggggagtacg 900
 ttcgcaagaa tgaaactcaa aggaattgac ggggacccgc acaagcggtg gagcatgtgg 960
 30 ttttaattcga agcaacgcga agaaccttac ctggtcttga catcccgatg acgagtgagc 1020
 aaagtcactt tcccttcggg gcattggaga cagggtgtgc atggttgtcg tcagctcgtg 1080
 tcgtgagatg ttgggttaag tcccgcacg agcgcaaccc ctatttccag tagccagcag 1140
 35 gtagagctgg gcaactctga gagactgcc ggataaccg ggaggaaggc ggggatgacg 1200
 tcaaatcatc atgcccctta tgatcagggc tacacacgtg ctacaatggc gtaaacaaag 1260
 ggaagcgaga cggtgacgtt aagcaaattc caaaaataac gtcccagttc ggattgtagt 1320
 40 ctgcaactcg actacatgaa gctggaatcg ctagtaatcg cgaatcagaa tgtcgcggtg 1380
 aatacgttcc cgggtcttgt acacaccgcc cgtcacacca tgggagtcgg aaatgcccg 1440
 agtcagtac ctaaccgaaa ggaaggagct gccgaagggt gagccggtaa ctggggtgaa 1500
 45 gtcgtaacaa ggtagccgt 1519

<210> 50

<211> 1497

50 <212> DNA

<213> Clostridium coccoides

<220>

<221> rRNA

<222> (1)..(1497)

55 <223> 16S rRNA coding gene sequence of Clostridium strain 30

<400> 50

EP 2 575 835 B1

	agagtttgat cctggctcag gatgaacgct ggcggcgtgc ctaacacatg caagtcgaac	60
	ggggatatata agcggaaagt tacggatgga aggttatata cttagtggcg gacgggtgag	120
5	taacgcgtgg gcaacctgcc ccgtgccggg ggataccgcc tggaaacagg cgctaatacc	180
	gcataagcgc atacagccgc atgggtgtat gcggaaagct ccggcggcac gggatggggc	240
	cgcgcccgat tagccagttg gcggggtaac ggcccaccaa agcgacgacg ggtagccggc	300
10	ctgagagggc ggacggccac attgggactg agacacggcc caaactccta cgggaggcag	360
	cagtggggaa tattgcacaa tgggggaaac cctgatgcag caacgcccg tgggtgaagg	420
	agcgtttcgg cgcgtaaagc cctgtcagcg gggaagaaga aagacggtag ccgaccaaga	480
15	agccccggct aactacgtgc cagcagccgc ggtaatacgt agggggcgag cgttatccgg	540
	aattactggg tgtaaaggga gcgtagacgg cgaggtaagc ctgaagtgga agcccgggc	600
20	ccaaccgcgg aactgctttg ggaactgttt tgctggagta tgggaggggt aagcggaatt	660
	cctggtgtag cggtgaaatg cgtagatata aggaggaaca ccggtggcga aggcggctta	720
	ctggaccata actgacgttg aggctcgaaa gcgtggggag cgaacaggat tagataccct	780
25	ggtagtccac gcgtaaacga tgattaccag gtgtcgggtg tcgaaggacg gcccggtgcc	840
	gcagcgaacg cagtaagtaa tccacctggg gactacgttc gcaagaatga aactcaaagg	900
	aattgacggg gacccgcaca agcgggtggag catgtggttt aattcgaagc aacgcgaaga	960
30	accttaccgg gccttgacat cccctggaca gcatatgtaa tgtatgtttc cttcgggacc	1020
	agggagacag gtggtgcatg gttgtcgtca gctcgtgtcg tgagatgttg ggtcaagtcc	1080
	cgcaacgagc gcaacccttg cccccagtag ccagcattta agatgggcac tctgggggga	1140
35	ctgccgggga taaccgggag gaaggcgggg atgacgtcaa atcatcatgc cccttatggc	1200
	cggggctaca cacgtgtac aatggcgtaa acagagggag gcgagacagc gatgttaagc	1260
	gaacccccaaa aataacgtcc cagttcggat tgcagcctgc aactcggctg catgaagctg	1320
40	gaatcgctag taatcgcgga tcagaatgcc gcggtgaata cgttcccggg tcttgtagac	1380
	accgcccgtc acaccatggg agtcgggaac gcccgaaagcc ggtgaccgaa cccgaaaggg	1440
45	gaggagccgt cgaaggcggg cctggtgact ggggtgaagt cgtaacaagg tagccgt	1497

<210> 51

<211> 1475

<212> DNA

50 <213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1475)

<223> 16S rRNA coding gene sequence of Clostridium strain 31

55 <400> 51

EP 2 575 835 B1

gagtttgatc ctggctcagg ataaacgctg gcggcgacaca taagacatgc aagtcgaacg 60
aacttaatac cttgcttgca aggtaagcgg ttagtggcgg actggtgagt aacacgtaag 120
5 aaatctgcct atcagagggg aataacagtg agaaatcact gctaataccg catatgccat 180
agttatcgca tgataatagt gggaaagaag caattcgctg atagatgagc ttgcggctga 240
ttagctagtt ggtggggtaa cggcctacca aggcgacgat cagtagccgg cctgagaggg 300
10 tgaacggcca cattgggact gagacacggc ccaaactcct acgggaggca gcagtgggga 360
atattgcaca atgggggaaa ccctgatgca gcgacgccgc gtgagtgaag aagtatttcg 420
gtatgtaaag ctctatcagc agggaagaaa atgacggtac ctgactaaga aagccccggc 480
15 taactacgtg ccagcagccg cggtaatacg tagggggcaa gcgttatccg gatttactgg 540
tgtaaaggga gcgtagacgg cagcgcaagt ctgagtgaag tcccatggct taccatgaa 600
20 actgctttgg aaactgtgca gctggagtgc aggagaggtg agcggaatcc tagtgtagcg 660
gttgaaatgc gtagattatc agaaggaaca ccggtggccg aggcggcctg ctgggctttt 720
actgacgctg aggcctcgaag cgtgggtagc aaacaggatt agataccctg gtagtccacg 780
25 cggtaaacga tgattactag gtgtgggtgg actgacccca tccgtgccgg agttaacaca 840
ataagtaatc cacctgggga gtacggccgc aaggttgaag ctcaaaggaa ttgacggggg 900
cccgacaaag cagtggagta tgtggtttta ttcgacgcaa cgcgaagaac cttaccaggt 960
30 cttgacatcg agtgacggac atagagatat gtctttcctt cgggacacga agacaggtgg 1020
tgcatggttg tcgtcagctc gtgtcgtgag atgttgggtt aagtcgccga acgagcgcaa 1080
cccttaccat tagttgctac gcaagagcac tctaattgga ctgccgttga caaaacggag 1140
35 gaaggtgggg atgacgtcaa atcatcatgc cccttatgac ctgggcgaca cacgtactac 1200
aatggcggtc aacagaggga ggcaaagccg cgaggcagag caaacccta aaagccgtct 1260
cagttcggat tgcaggctgc aactcgctg catgaagtcg gaattgctag taatcgcgga 1320
40 tcagcatgcc gcggtgaata cgttcccggg ccttgtacac accgcccgtc acaccatgag 1380
agccggtaac acccgaagtc aatagtctaa ccgcaaggag gacattgccg aaggtgggat 1440
45 tggtaattgg ggtgaagtcg taacaaggta gccgt 1475
<210> 52
<211> 1491
<212> DNA
50 <213> Clostridium leptum
<220>
<221> rRNA
<222> (1)..(1491)
<223> 16S rRNA coding gene sequence of Clostridium strain 32
55 <400> 52

EP 2 575 835 B1

	agagtttgat cctggctcag gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac	60
	gagaatcagt ggattgagga ttcgtccaaa tgaaactgag gaaagtggcg gacgggtgag	120
5	taacgcgtga gcaatctgcc ttggagtggg gaataacggc tggaaacagc cgctaatacc	180
	gcatgataca gttgggaggc atctctctga ctgtcaaaga tttatcgctc tgagatgagc	240
10	tcgcgtctga ttagctagtt ggcggggtaa cgccccacca aggcgacgat cagtagccgg	300
	actgagaggt tggccggcca cattgggact gagacacggc ccagactcct acgggaggca	360
15	gcagtgggga atattgggca atgggcgcaa gcctgaccca gcaacgccgc gtgaaggaag	420
	aaggctttcg ggttgtaaac ttcttttctg ggggacgaac aaatgacggc accccaggaa	480
	taagccacgg ctaactacgt gccagcagcc gcgtaatac gtaggtggca agcgttatcc	540
20	ggatttattg ggtgtaaagg gcgtgtaggc gggaatgcaa gtcagatgtg aaaactatgg	600
	gctcaaccca tagcctgcat ttgaaactgt atttcttgag tgctggagag gcaatcggaa	660
	ttccgtgtgt agcggtgaaa tgcgtagata tacggaggaa caccagtggc gaagcggatt	720
25	gctggacagt aactgacgt gaggcgcgaa agcgtgggga gcaaacagga ttagataccc	780
	tggtagtcca cgccgtaacg atggatacta gtgtgggggg actgaccccc tccgtgccgc	840
	agctaacgca ataagtatcc ccacctgggg agtacgatcg caaggttgaa actcaaagga	900
30	attgacgggg gcccgcaaaa gcggtggagt atgtggttta attcgaagca acgcgaagaa	960
	ccttaccagg gcttgacatc ctgctaacga accagagatg gattaggtgc ccttcgggga	1020
	aagcagagac aggtggtgca tggttgtcgt cagctcgtgt cgtgagatgt tgggttaagt	1080
35	cccgcaacga gcgcaacccc tattgttagt tgctacgcaa gagcactcta gcgagactgc	1140
	cgttgacaaa acggaggaag gtggggacga cgtaaatca tcatgcccct tacgtcctgg	1200
40	gccacacacg tactacaatg gcggttaaca aagagaggca agaccgcgag gtggagcaaa	1260
	tctcaaaaag ccgtcccagt tcggatcgca ggctgcaacc cgctgcgtg aagttggaat	1320
	cgctagtaat cgcggatcag catgccgcgg tgaatacgtt cccgggcctt gtacacaccg	1380
45	cccgtcacac catgagagtc gggaacaccc gaagtccgta gcctaaccgc aagggggggcg	1440
	cggccgaagg tgggttcgat aattgggggtg aagtcgtaac aaggtagccg t	1491

<210> 53

<211> 1495

<212> DNA

<213> Clostridium coccooides

<220>

<221> rRNA

<222> (1)..(1495)

<223> 16S rRNA coding gene sequence of Clostridium strain 33

<400> 53

EP 2 575 835 B1

agagtttgat cctggctcag gatgaacgct ggcggcgtgc ctaacacatg caagtcgaac 60
 ggggtgtacgg ggaggaaggc ttcggccgga aaacctgtgc atgagtggcg gacgggtgag 120
 5 taacgcgtgg gcaacctggc ctgtacaggg ggataacact tagaaatagg tgctaatacc 180
 gcataacggg ggaagccgca tggcttttcc ctgaaaactc cgggtgtaca ggatgggccc 240
 gcgtctgatt agccagttag cagggtaacg gcctaccaa gcgacgatca gtagccggcc 300
 10 tgagagggcg gacggccaca ctgggactga gacacggccc agactcctac gggaggcagc 360
 agtgggggat attgcacaat ggggggaacc ctgatgcagc gacgccgcgt ggggtgaagaa 420
 15 gcgcctcggc gcgtaaagcc ctgtcagcag ggaagaaaat gacggtacct gaagaagaag 480
 ccccggttaa ctacgtgcc aacgcccgg taatacgtag ggggcaagcg ttatccggat 540
 ttactgggtg taaagggggc gcagacggcg atgcaagcca ggagtgaag cccggggccc 600
 20 aaccccgga ctgctcttgg aactgcgtgg ctggagtga ggaggggcag gcggaattcc 660
 tgggttagcg gtgaaatgc tagatatcag aggaacaccg gtggcgaaag cggcctgctg 720
 gactgcaact gacgttgagg cccgaaagcg gtgggagcaa acaggattag ataccctggt 780
 25 agtccacgcc gtaaacgatg attactaggt gtcggggagc agagactgcc cgggtgccga 840
 gcccaacgca ttaagtatcc acctggggag tacgttcgca agaataaac tcaaaggaat 900
 30 tgacggggac ccgcacaagc ggtggagcat gtggtttaat tcgaagcaac gcgaagaacc 960
 ttaccaggcc ttgacatccc cctggatggc ccgtaacggg gccagccctt tttgggcagg 1020
 ggagacaggt ggtgcatggt tgtcgtcagc tcgtgtcgtg agatgttggg ttaagtcccg 1080
 35 caacgagcgc aacccctgcc cgcagtagcc agcattttag atggggactc tgcggggact 1140
 gccggggaca acccgaggga aggcggggat gacgtcaaat catcatgccc cttatggcct 1200
 gggctacaca cgtgctacaa tggcgccgac agagggagga gaagcggcga cgcggagcga 1260
 40 acccaaaaaa cggcgtccca gttcggattg tagtctgcaa cccgactaca tgaagccgga 1320
 atcgctagta atcgcggatc agaataccgc ggtgaatacg ttcccgggtc ttgtacacac 1380
 cgcccgtcac accatgggag cggggaatgc ccgaagtctg tgaccgaacc cgtaagggga 1440
 45 ggggcagccg aaggcaggcc cgggtgactgg ggtgaagtcg taacaaggta gccgt 1495

<210> 54

<211> 1493

50 <212> DNA

<213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1493)

55 <223> 16S rRNA coding gene sequence of Clostridium strain 34

<400> 54

EP 2 575 835 B1

agagtttgat cctggctcag gacgaacgct ggcggcgtgc ttaacacatg caagtcgaac 60
 ggagcaccac tgaaggagtt ttcggacaac ggatgggaat gcttagtggtc ggactgggtga 120
 5 gtaacgcgtg aggaacctgc cttccagagg gggacaacag ttggaaacga ctgctaatac 180
 cgcattgatgc gttggagccg catgactccg acgtcaaaga tttatcgctg gaagatggcc 240
 tcgcgtctga tttgttagtt ggtgaggtaa cggcccacca aggcgacgat cagtagccgg 300
 10 actgagaggt tggccggcca cattgggact gagatacggc ccagactcct acgggaggga 360
 gcagtgggga atattgggca atggacgcaa gtctgaccca gcaacgccgc gtgaagggaag 420
 aaggctttcg ggttgtaaac ttcttttaag ggggaagagc agaagacggt accccttgaa 480
 15 taagccacgg ctaactacgt gccagcagcc gcggtaatat gtaggtggca agcgttggtcc 540
 ggatttactg ggtgtaaagg gcgtgcagcc ggagagacaa gtcagatgtg aaatccacgg 600
 gctcaaccac tgaactgcat ttgaaactgt ttcccttgag tgcggagag gtaatcggaa 660
 ttccttggtg agcggtgaaa tgcgtagata taaggaaaga caccagtggc gaaggcggat 720
 25 tactggacga taactgacgg tgaggcgcca aagcgtggg agcaaacagg attagatacc 780
 ctggtagtcc acgctgtaaa cgatcgatac taggtgtgctg gggactgacc cctgctgtgc 840
 cggagttaac acaataagta tcgcacctgg ggagtacgat cgcaagggtg aaactcaaag 900
 30 gaattgacgg gggcccgcac aagcggtgga ttatgtggtt taattcgaag caacgcgaag 960
 aaccttacca gggcttgaca tcctgctaac gaagtagaga tacattaggt gcccttcggg 1020
 gaaagcagag acagggtggt catggttctg gtcagctcgt gtcgtgagat gttgggttaa 1080
 35 gtcccgcaac gagcgcaacc cctattgtta gttgctacgc aagagcactc tagcgagact 1140
 gccgttgaca aaacggagga aggcggggac gacgtcaaat catcatgccc cttatgtcct 1200
 gggctacaca cgtaatacaa tggcggttaa caaagggatg caaagccgcg aggcagagcg 1260
 aaccccaaaa agccgtccca gttcggatcg caggctgcaa cccgcctgctg tgaagtcgga 1320
 atcgctagta atcgcggatc agcatgccgc ggtgaatacg ttcccgggac ttgtacacac 1380
 45 cgcccgtcac accatgagag tcgggaacac ccgaagtccg tagcctaacc gcaaggaggg 1440
 cgcgcccgaa ggtgggttcg ataattgggg tgaagtcgta acaaggtagc cgt 1493

<210> 55

<211> 1498

<212> DNA

<213> Clostridium coccooides

<220>

<221> rRNA

<222> (1)..(1498)

<223> 16S rRNA coding gene sequence of Clostridium strain 35

<400> 55

EP 2 575 835 B1

```

agagtttgat cctggctcag gatgaacgct ggcggcgtgc ctaacacatg caagtccaac      60
gggtgtacag aaggggaagat tacggtcgga aggtctgtgc atgagtggcg gacgggtgag      120
5 taacgcgtgg gcaacctggc ctgtacaggg ggataaact tagaaatagg tgctaatacc      180
gcataacggg ggaagccgca tggcttttcc ctgaaaactc cggtggtaca ggatgggccc      240
gcgtctgatt attttttttg tcagggtaac ggcctaccaa agcgacgatc agtagccggc      300
10 ctgagagggc ggacggccac actgggactg agacacggcc cagactccta cgggaggcag      360
cagtggggga tattgcacaa tggggggaac cctgatgcag cgacgcccgcg tgggtgaaga      420
agcgccctcg cgcgtaaagc cctgtcagca gggaagaaaa tgacgggtacc tgaagaagaa      480
15 gccccggcta actacgtgcc agcagcccgcg gtaatacgta aggggcaagc gttatccgga      540
tttactgggt gtaaaggggg cgcgacggc gatgcaagcc aggagtgaag gccccgggccc      600
20 caaccccggg actgctcttg ggaactgcgg tggctggagt gcaggagggg caggccggaa      660
ttcctggtgt agcggtgaaa tgcgtagata tcaggaggaa caccggtggc gaaggcgggc      720

tgctggactg caactgacgt tgaggcccga aagcgtgggg agcaaacagg attagatacc      780
25 ctggtagtca cgccgtaaac gatgattact aggtgtcggg gacgagagac tgcccggtgc      840
cgcgccaac gcattaagta atccacctgg ggagtacgtt cgcaagaatg aaactcaaag      900
30 gaattgacgg ggaccgcac aagcggtgga gcatgtggtt taattcgaag caacgcgaag      960
aaccttacca ggccttgaca tccccctgga tggcccgtaa cggggtcagc ctttcggggc      1020
aggggagaca ggtggtgcat ggttgctcgc agctcgtgtc gtgagatggt gggttaagtc      1080
35 ccgcaacgag cgcaaccctt gcccgcagta gccagcattt tagatgggga ctctgcgggg      1140
actgccgggg acaaccgga ggaaggcggg gatgacgtca aatcatcatg ccccttatgg      1200
cctgggctac acacgtgcta caatggcgcc gacagaggga ggcgaagcgg cgacgcggag      1260
40 cgaaccccaa aaacggcgtc ccagttcgga ttgtagtctg caaccgact acatgaagcc      1320
ggaatcgcta gtaatcgcg atcagaatgc cgcggtgaat acgttcccg gtcttgata      1380
caccgcccgt cacaccatgg gagccgggaa tgcccgaagt ctgtgaccga acccgtaagg      1440
45 ggaggggcag ccgaaggcag gcccggtgac tggggtgaag tcgtaacaag gtagccgt      1498

<210> 56
<211> 1491
50 <212> DNA
<213> Clostridium leptum
<220>
<221> rRNA
<222> (1)..(1491)
55 <223> 16S rRNA coding gene sequence of Clostridium strain 36
<400> 56

```

EP 2 575 835 B1

	agagtttgat catggctcag gacgaacgct ggcggcaagc ttaacacatg caagtcgaac	60
	ggagcgccta tgaaggagat ttcgggtcaac ggaataggct gcttagtggc tgacgggtga	120
5	gtaacgcgtg aggaacctgc ctttcagagg gggacaacag ttggaaacga ctgctaatac	180
	cgcataacac ataggtgtcg catggcattt atgtcaaaga tttatcgctg aaagatggcc	240
	tcgctgtctga ttagctagtt ggtgaggtaa cggctcacca aggcgacgat cagtagccgg	300
10	actgagaggt tagccggcca cattgggact gagatacggc ccagactcct acgggaggca	360
	gcagtgggga atattgggca atggacgcaa gtctgaccca gcaacgccgc gtgaagggaag	420
	aaggctttcg ggttgtaaac ttcttttaag agggaagagc agaagacggt acctcttgaa	480
15	taagccacgg ctaactacgt gccagcagcc gcggtaatag gtagtggcaa gcgttggtccg	540
	gatttactgg gtgtaaagggt cgtgtagccg ggctgacagt cagatgtgaa attccggggc	600
20	tcaacccccg acctgcattt gaaactgttg gtcttgagta tcggagaggc aggcggaatt	660
	cctagtgtag cggtgaaatg cgtagatatt aggaggaaca ccagtggcga aggcggcctg	720
	ctggacgaca actgacgggtg aggcgcgaaa gcgtggggag caaacaggat tagataccct	780
25	ggtagtccac gctgtaaacg atggatacta ggtgtgcggg gactgacccc ctgcgtgccg	840
30	cagttaacac aataagtatc ccacctgggg agtacgatcg caagggtgaa actcaaagga	900
	attgacgggg gcccgcacaa gcggtggatt atgtggttta attcgatgca acgcgaagaa	960
	ccttaccagg gcttgacatc ctgctaacga ggtagagata cgtcagggtgc ccttcgggga	1020
35	aagcagagac aggtggtgca tgggtgtcgt cagctcgtgt cgtgagatgt tgggttaagt	1080
	cccgaacga gcgcaaccct tattgttagt tgctacgcaa gagcactcta gcgagactgc	1140
	cgttgacaaa acggaggaag gtggggacga cgtcaaatca tcatgcccct tatgtcctgg	1200
40	gctacacacg taatacaatg gcggtaaaca gagggatgca atactgcgaa gtggagcgaa	1260
	cccctaaaag ccgtcccagt tcagattgca gtctgcaact cgactgcatg aagtcggaat	1320
	cgctagtaat cgcggatcag catgccgcgg tgaatacgtt cccgggcctt gtacacaccg	1380
45	cccgtcacac catgagagtc gggaacaccc gaagtccgta gcctaaccgc aaggagggcg	1440
	cggccgaagg tgggttcgat aattgggggtg aagtcgtaac aaggtagccg t	1491
50	<210> 57	
	<211> 1493	
	<212> DNA	
	<213> Clostridium coccooides	
	<220>	
55	<221> rRNA	
	<222> (1)..(1493)	
	<223> 16S rRNA coding gene sequence of Clostridium strain 37	
	<400> 57	

EP 2 575 835 B1

	agagtttgat cctggctcag gatgaacgct ggcggcgtgc ctaacacatg caagtcgaac	60
	gggtgtacgg ggaggaaggc ttcggccgga aaacctgtgc atgagtggcg gacgggtgag	120
5	taacgcgtgg gcaacctggc ctgtacaggg ggataacact tagaaatagg tgctaatacc	180
	gcataacggg ggaagccgca tggcttttcc ctgaaaactc cggtggtaca ggatgggccc	240
	gcgtctgatt agccagttgg cagggtaacg gcctaccaa gcgacgatca gtagccggcc	300
10	tgagagggcg gacggccaca ctgggactga gacacggccc agactcctac gggaggcagc	360
	agtgggggat attgcacaat ggggggaaac cctgatgcag cgacgcccg tgagtgaaga	420
	agtatttcgg tatgtaaagc tctatcagca gggaagaaaa tgacgggtacc tgactaagaa	480
15	gccccggcta actacgtgcc agcagcccg gtaatacgta gggggcaagc gttatccgga	540
	tttactgggt gtaaaggag cgtagacggc agcgcaagtc tgaagtgaaa tcccatggct	600
20	taaccatgga actgctttgg aaactgtgca gctggagtgc aggagaggta agcgggaattc	660
	ctagtgtagc ggtgaaatgc gtagatatta ggaggaacac cagtggcgaa ggcggcttac	720
	tggactgtac tgacgttgag gctcgaaagc gtggggagca aacaggatta gataccctgg	780
25	tagtccacgc cgtaaacgat gattactagg tgttggggga ccaaggctct cggtgccggc	840
	gcaaacgcat taagtaatcc acctggggag tacgttcgca agaataaaac tcaaaggaat	900
	tgacggggac ccgcacaagc ggtggagcat gtggtttaat tcgaagcaac gcgaagaacc	960
30	ttacctggtc ttgacatccc gatgacgagt gagcaaagtc actttccctt cggggcattg	1020
	gagacagggtg gtgcatgggt gtcgtcagct cgtgtcgtga gatgttgggt taagtccgc	1080
35	aacgagcgca acccctatct ccagtagcca gcaggtagag ctgggcactc tggagagact	1140
	gccccgggata accgggagga aggcggggat gacgtcaaact catcatgccc cttatgatca	1200
	gggctacaca cgtgctacaa tggcgtaaac aaagggaagc gagacgggtga cgttgagcaa	1260
40	atccccaaaa taacgtccca gttcggattg tagtctgcaa ctcgactaca tgaagctgga	1320
	atcgctagta atcgcgaaac agaattgtcg ggtgaataacg ttcccgggtc ttgtacacac	1380
45	cgccccgtcac accatgggag tcggaaatgc ccgaagtcag tgacctaac gaaaggaagg	1440
	agctgccgaa ggtggagccg gtaactgggg tgaagtcgta acaaggtagc cgt	1493

<210> 58

<211> 1493

<212> DNA

<213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1493)

<223> 16S rRNA coding gene sequence of Clostridium strain 38

<400> 58

EP 2 575 835 B1

	aaagtttgat cctggctcag gacgaacgct ggcggcgtgc ttaacacatg caagtcgaac	60
	ggagcacccc tgaaggagtt ttcggacaac ggatgggaat gcttagtggc ggactggtga	120
5	gtaacgcgtg aggaacctgc cttccagagg gggacaacag ttggaaacga ctgctaatac	180
	cgcgatgatgc gttggagccg catgactccg acgtcaaaga tttatcgctg gaagatggcc	240
	tcgcgtctga ttagctagtt ggtgaggtaa cggcccacca aggcgacgat cagtagccgg	300
10	actgagaggt tggccggcca cattgggact gagatacggc ccagactcct acgggaggca	360
	gcagtgggga atattgggca atggacgcaa gtctgaccca gcaacgcgcg gtgaaggaag	420
	aaggctttcg gggtgtaaac ttcttttaag ggggaagagc agaagacggt accccttgaa	480
15	taagccacgg ctaactacgt gccagcagcc gcgtaatac gtagtggcaa gcgttgtcg	540
	gatttactgg gtgtaaaggg cgtgcagccg gagagacaag tcagatgtga aatccacggg	600
	ctcaaccggt gaactgcatt tgaaactgtt tcccttgagt gtcggagagg taatcggaat	660
20	tccttggtga gcggtgaaat gcgtagatat aaggaagaac accagtggcg aaggcggatt	720
	actggacgat aaactgacgg tgaggcgcg aagcgtgggg agcaaacagg attagatacc	780
	ctggtagtcc acgctgtaaa cgatcgatac taggtgtgcg gggactgacc ccctgcgtgc	840
	cggagttaac acaataagta tcgcacctgg ggagtacgat cgcaagggtg aaactcaaag	900
	gaattgacgg gggcccgcac aagcggtgga ttatgtggtt taattcgaag caacgcgaag	960
30	aaccttacca gggcttgaca tcctgctaac gaagtagaga tacattaggt gcccttcggg	1020
	gaaagtagag acaggtggtg catggtgtgc gtcagctcgt gtcgtgagat gttgggttaa	1080
	gtcccgaac gagcgcaacc cctattgtta gttgctacgc aagagcactc tagcgagact	1140
35		
	gccgttgaca aaacggagga aggcggggac gacgtcaa at catcatgccc cttatgtcct	1200
	gggctacaca cgtaatacaa tggcgggttaa caaagggatg caaagccgcg aggcagagcg	1260
40	aacccccaaa agccgtccca gttcggatcg caggctgcaa cccgcctgcg tgaagtcgga	1320
	atcgctagta atcgcggatc agcatgccgc ggtgaatacg ttcccgggccc ttgtacacac	1380
	cgcccgtcac accatgagag tcgggaacac ccgaagtccg tagcctaacc gcaaggaggg	1440
45	cgcgccgcaa ggtgggttcg ataattgggg tgaagtcgta acaaggtagc cgt	1493

<210> 59

<211> 1511

50 <212> DNA

<213> Clostridium leptum

<220>

<221> rRNA

<222> (1)..(1511)

55 <223> 16S rRNA coding gene sequence of Clostridium strain 39

<400> 59

EP 2 575 835 B1

	agagtttgat cctggctcag gacgaacgct ggcggcgtgc ttaacacatg caagtcgaac	60
	ggagcacccc tgaaggagtt ttcggacaac ggatgggaat gcttagtggc ggactggtga	120
5	gtaacgcgtg aggaacctgc cttccagagg gggacaacag ttggaaacga ctgctaatac	180
	cgcatgatgc gttggagccg catgactccg acgtcaaaga tttatcgctg gaagatggcc	240
	tcgcgtctga ttagctagtt ggtgaggtaa cggcccacca aggcgacgat cagtagccgg	300
10	actgagaggt tggccggcca cattgggact gagatacggc ccagactcct acgggaggca	360
	gcagtgggga atattgggca atggacgcaa gtctgacca gcaacgccgc gtgaaggaa	420
	aaggctttcg ggttgtaaac ttcttttaag ggggaagagc agaagacggt accccttgaa	480
15	taagccacgg ctaactacgt gccagcagcc gcgtaatac gtaggtggca agcgttgtcc	540
	ggatttactg ggtgtaaagg gcgtgcagcc ggagagacaa gtcagatgtg aaatccacgg	600
	gctcaacccg tgaactgcat ttgaaactgt ttcccttgag tgtcggagag gtaatcggaa	660
20	ttccttgtgt agcggtgaaa tgcgtagata taaggaagac accagtggcg aagcggatta	720
	ctggacgata actgacggtg aggcgcgaaa gcgtggggag caaacaggat tagatacctg	780
	ggtagtcaac gctgtaaacg atcgatacta ggtggtgcgg gggacttgac cccctgccgt	840
25	tgccggagtt aacaccaata aagtattcgg caccctgggg agtacgatcg caaagggtga	900
	aaactcaaaa gaaatggacg gggggccccc ccccaagcgg gtgggattat gttggtttat	960
30	ttcgaaagca acgcgaagaa ccctaacagg gcttgacatc ctgctaacga agtagagata	1020
	cattaggtgc ccttcgggga aagtagagac aggtggtgca tggttgtcgt cagctcgtgt	1080
	cgtgagatgt tgggttaagt cccgcaacga gcgcaacccc tattgttagt tgctacgcaa	1140
35	gagcactcta gcgagactgc cgttgacaaa acggaggaag gcggggacga cgtcaaatca	1200
	tcatgccctt tatgtcctgg gctacacacg taatacaatg gcggttaaca aagggatgca	1260
	aagccgcgag gcagagcgaa ccccaaaaag ccgtcccagt tcggatcgca ggctgcaacc	1320
40		
	cgctgcgtg aagtcggaat cgctagtaat cgcggatcag catgccgcgg tgaatacgtt	1380
	cccgggcctt gtacacaccg cccgtcacac catgagagtc gggaacaccc gaagtcgcta	1440
45	gcctaaccgc aaggagggcg cggccgaagg tgggttcgat aattgggggtg aagtcgtaac	1500
	aaggtagccg t	1511

50	<210> 60
	<211> 1499
	<212> DNA
	<213> Clostridium leptum
	<220>
55	<221> rRNA
	<222> (1)..(1499)
	<223> 16S rRNA coding gene sequence of Clostridium strain 40
	<400> 60

EP 2 575 835 B1

agagttttgat cctggctcag gataaacgct ggcggcatgc ctaacacatg caagtcgaac 60
 ggagcgctt ggaaggagac ttcgggtcaac ggaagaggag gcttagtggc ggacgggtga 120
 5 gtaacgcgtg aggaacctgc ctgagagagg gggataacac accgaaaggt gtgctaatac 180
 cgcataacat atgagagggg catccctttc atatcaaaga ttatttgctt tgagatggcc 240
 tcgctgcca ttagctagtt ggtgaggtaa cggcccacca aggcgacgat tggtagccgg 300
 10 actgagaggt tgaacggcca cattgggact gagacacggc ccagactcct acgggaggca 360
 gcagtgggga atattgcaca atggggggaa ccctgatgca gcaatgccgc gtgaaggatg 420
 aaggttttcg gattgtaaac ttcttttgta cgggacgaag aaagtgacgg taccgtaaga 480
 15 ataagccacg gctaactacg tgccagcagc cgcggtaata cgtaggtggc aagcgttatc 540
 cggatttact ggggtgtaaag ggcgagtagg cgggattgca agtcagatgt gaaaactatg 600
 ggctcaaccg atagagtgca ttgaaactg cagttcttga gtgatggaga ggcaggcgga 660
 20 attcccggtg tagcgggtgga atgcgtagat atcgggaggg aacaccagtg gcgaaggcgg 720
 cctgctggac attaactgac gctgatgccc gaaagcgtgg ggagcaaaca ggattagata 780
 ccctggtagt cacgctgtaa acgatgatta ctaggtgtgg ggggtactga ccccttccc 840
 25 gtgccggagt taacacaata agtaatccac ctggggagta cggccgcaag gttgaaactc 900
 aaaggaattg acggggggccc gcacaagcag tggagtatgt ggttttaatt cgaagcaacg 960
 30 cgaagaacct taccagggtc tgacatgggg atgaccgctt tagagataga gctttctctt 1020
 cggagacatc ccacacaggt ggtgcatggt tgctcgcagc tcgtgtcgtg agatgttggg 1080
 ttaagtcccg caacgagcgc aacccttatt gttagttgct acgcaagagc actctagcga 1140
 35 gactgccgtt gacaaaacgg aggaagggtg ggacgacgtc aaatcatcat gccctttatg 1200
 tcctgggcta cacacgtact acaatggcgg acatacagag ggaagcaaga cagcgatgtg 1260
 gagcaaatcc ctaaaagccg tctcagttca gattgcaggc tgcaaccgc ctgcatgaag 1320
 40 tcggaattgc tagtaatcgc ggatcagcat gccgcggtga atacgttccc gggccttgta 1380
 cacaccgccc gtcacacat gagagtcgga aacacccgaa gcctgtagcc caaccgcaag 1440
 45 gggggcgcag tcgaagggtg gtctgataat tgggggtgaag tcgtaacaaa ggtagccgt 1499

50 <210> 61
 <211> 1512
 <212> DNA
 <213> Clostridium coccooides
 <220>
 <221> rRNA
 55 <222> (1)..(1512)
 <223> 16S rRNA coding gene sequence of Clostridium strain 41
 <400> 61

EP 2 575 835 B1


agagtttgat cctggctcag gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac 60
 ggagatatca ttttcgaagc gattagttta ctaagagcgg agatgttgct atcttagtgg 120
 5 cggacgggtg agtaacgcgt gggtaacctg ccttgactg ggggataaca cttagaaata 180
 ggtgctaata ccgcataaca gtaggagacg catgtctttt acttgaaaac tccggtggtg 240
 taagatggac ccgcgtctga ttagcttgtt ggcggggtaa cggcccacca aggcaacgat 300
 10 cagtagccgg cctgagaggg tgaacggcca cattgggact gagacacggc ccaaactcct 360
 acgggaggga gcagtgggga atattggaca atggggggaa ccctgatcca gcgacgccgc 420
 gtgagtgaag aagtatttcg gtatgtaaag ctctatcagc agggaagaaa gaaatgacgg 480
 15 tacctgacta agaagccccg gctaactacg tgccagcagc cgcgtaata cgtagggggc 540
 aagcgttata cggatttact ggggtgtaaag ggagcgtaga cggcgatgca agtctgaagt 600
 gaaaggcggg ggcccaaccc ccggactgct ttggaaactg tatggctgga gtgcaggaga 660
 20 ggtaagtgga attcctagtg tagcggtgaa atgcgtagat attaggagga acaccagtgg 720
 cgaaagcggc ttactggact gtaactgacg ttgaggctcg aaagcgtggg gagcaaacaa 780
 gattagatac ctggtagtca cgccgtaaac gatgatcacc ggtttcggtg ggttatggac 840
 25 ccatcggttg cgcagcaaac gcagtagtga tccacctggg gagtaacgtt cgcaagaatg 900
 aaacttcaaa ggaaatgacg ggggacccgg cacaagcggg ggaggcatgt gtttaattcg 960
 30 aagcaacgcg aagaacctta cccaagtctt gacatcccggt gacgagttag taacgtcact 1020
 ttcccttcgg ggcagcggag acagggtggg catgggtgtc gtcagctcgt gtcgtgagat 1080
 gttgggttaa gtcccgaac gagcgcaacc cctatcctta gtagccagcg agttaggctg 1140
 35 ggcactctag ggagactgcc ggggacaacc cggaggaagg tggggatgac gtcaaatcat 1200
 catgcccctt atgatttggg ctacacacgt gctacaatgg cgtaaacaaa ggggaagcgag 1260
 cctgtgaagg taagcgaatc ccagaaataa cgtctcagtt cggattgtag tctgcaactc 1320
 40 gactacatga agctggaatc gctagtaatc gcggatcaga atgccgcggg gaatacgttc 1380
 ccgggtcttg tacacaccgc ccgtcacacc atgggagtcg gaaatgcccg aagtctgtga 1440
 45 cccaacctga gaaggaggga gcagccgaag gcaggtcgga tgactggggg gaagtcgtaa 1500
 caaggtagcc gt 1512

50 <210> 62
 <211> 17
 <212> DNA
 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 55 <400> 62
 ggtgaatacg ttcccgg 17
 <210> 63
 <211> 22


EP 2 575 835 B1

<212> DNA
 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 5 <400> 63
 tacggctacc ttgttacgac tt 22
 <210> 64
 <211> 20
 <212> DNA
 10 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 <400> 64
 aaatgacggg acctgactaa 20
 15 <210> 65
 <211> 22
 <212> DNA
 <213> Artificial
 <220>
 20 <223> Artificially synthesized primer sequence
 <400> 65
 ctttgagttt cattcttgcg aa 22
 <210> 66
 <211> 16
 25 <212> DNA
 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 <400> 66
 30 gcacaagcag tggagt 16
 <210> 67
 <211> 18
 <212> DNA
 <213> Artificial
 35 <220>
 <223> Artificially synthesized primer sequence
 <400> 67
 ctctctcgt ttgtcaa 18
 <210> 68
 40 <211> 18
 <212> DNA
 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 45 <400> 68
 gagaggaagg tccccac 18
 <210> 69
 <211> 19
 <212> DNA
 50 <213> Artificial
 <220>
 <223> Artificially synthesized primer sequence
 <400> 69
 cgctacttgg ctggttcag 19
 55


[Fig. 1]




[Fig. 2]




[Fig. 3]




[Fig. 4]




[Fig. 5]




[Fig. 6]




[Fig. 7]




[Fig. 8]




[Fig. 9]




[Fig. 10]




[Fig. 11]




[Fig. 12]




[Fig. 13]




[Fig. 14]




[Fig. 15]




[Fig. 16]




[Fig. 17]




[Fig. 18]




[Fig. 19]




[Fig. 20]




[Fig. 21]




[Fig. 22]




[Fig. 23]




[Fig. 24]




[Fig. 25]




[Fig. 26]




[Fig. 27]




[Fig. 28]




[Fig. 29]




[Fig. 30]




[Fig. 31]




[Fig. 32].




[Fig. 33]




[Fig. 34]




[Fig. 35]




[Fig. 36]




[Fig. 37]




[Fig. 38]




[Fig. 39]




[Fig. 40]




[Fig. 41]




[Fig. 42]




[Fig. 43]




[Fig. 44]




[Fig. 45]




[Fig. 46]




[Fig. 47]




[Fig. 48]




[Fig. 49]




[Fig. 50]



[Fig. 51]



[Fig. 52]



[Fig. 53]

